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Scope of this thesis
The cellular and humoral immune response
The immune system protects our body against invading pathogens (bacteria, fungi 
and viruses) and plays an important role in the fight against cancer. The first line of 
defense against invaders is the innate immune system, which is rapidly activated, 
but gives a non-specific immune response. Next, the adaptive immune system is 
triggered in which antigen-presenting cells (APCs), including dendritic cells (DCs), 
macrophages and B cells, specifically recognize pathogens and stimulate T cells to 
eliminate those1. The adaptive immune response consists of two components: the 
humoral immune response driven by antibody-producing B cells, and the cellular 
immune response in which DCs stimulate T cells to fight the infection. When DCs 
encounter an antigen (i.e. small part of bacterium, virus or tumor cell), they internalize 
this antigen and present it on major histocompatibility complex class I or II (MHC-I or 
MHC-II). The antigen-activated DCs migrate through the lymphatic vessels to reach 
the T cell zone in the lymph node. During this journey DCs interact with lymph node 
stromal cells, like lymphatic endothelial cells (LECs) and fibroblastic reticular cells 
(FRCs) that express podoplanin (PDPN). The interaction between PDPN and C-type 
lectin-like receptor 2 (CLEC-2; expressed by DCs) is essential for DC migration 
towards and within the lymph node2. In addition, this interaction initiates activation 
and elongation of FRCs resulting in lymph node expansion and subsequent infiltration 
and proliferation of T cells3,4. In the T cell zone, the MHC-antigen complex on DCs is 
recognized by the T-cell receptor (TCR) leading to subsequent activation of CD8+ 
or CD4+ T cells, respectively. Activated CD8+ cytotoxic T cells can kill tumor cells 
and virus-infected cells, whereas CD4+ T helper cells further enhance the adaptive 
immune response by activation of other immune cells, like B cells. 
 B cells are central players in the humoral immune response by their capacity to 
produce immunoglobulins (antibodies) that recognize invaders5. B cells bind antigens 
via the B-cell receptor (BCR) complex and after internalization present these on 
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MHC-II molecules. When these specific MHC-antigen complexes are recognized by 
CD4+ T helper cells, they will deliver signals to initiate B-cell proliferation resulting 
in the formation of germinal center (GC) structures. GCs are temporary and dynamic 
structures within secondary lymphoid organs (lymph nodes and spleen) that consist 
of a dark and a light zone. Within the GC, B cells undergo several rounds of selection 
to improve the BCR affinity for its specific antigen. In the dark zone, B cells are 
clonally expanded and undergo somatic hypermutation (SHM) in which random point 
mutations in the variable region of the immunoglobulin gene result in a higher affinity 
BCR. Next, B cells move to the light zone where the BCR is selected for improved 
binding upon interactions with antigen-expressing T cells and follicular DCs that 
provide B-cell survival signals. B cells expressing a low-affinity BCR will be neglected 
and undergo apoptosis, whereas B cells with high affinity BCRs will be stimulated to 
expand. These selected B cells can be subject to class-switch recombination (CSR) in 
which genomic changes in the constant region of the immunoglobulin heavy chain 
cause isotype switching of the immunoglobulin class produced by the B cell (e.g. 
from IgM to IgG or IgA). Eventually, B cells with a high affinity BCR will be selected 
to differentiate into memory B cells or antibody-producing plasma cells. 
 During the selection rounds in the GC, B cells are constantly undergoing genomic 
changes during SHM and CSR, which are error-prone mechanisms that can lead 
to malignant transformation. Therefore, the majority of B-cell non-Hodgkin 
lymphomas (B-NHL) originate from GC-derived B cells, including Burkitt lymphoma, 
follicular lymphoma and diffuse large B-cell lymphoma (DLBCL)6. The latter is 
divided in two subtypes: germinal center B-cell-like (GCB-)DLBCL, which originates 
from B cells in the light zone, and activated B-cell-like (ABC-)DLBCL, which develops 
from differentiating post-GC B cells (plasma blasts). Most B-NHL types are driven 
by chromosomal translocations of proto-oncogenes under the promoter of the 
immunoglobulin heavy chain, resulting in continuous BCR signaling and lymphoma 
cell survival7. Currently, B-NHL patients are treated with immuno-chemotherapy 
(e.g. R-CHOP), but disease relapse commonly occurs8. A better understanding of the 
molecular mechanisms underlying B-NHL development is needed to improve and 
develop novel therapeutic strategies for patients with B-cell lymphoma.
Tetraspanin CD37 in the immune system
Essential for effective initiation of humoral and cellular immune responses is the 
communication between immune cells. Interaction between receptors on the cell 
membrane mediates cell adhesion and initiates activation of intracellular signaling 
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pathways. These processes are facilitated by membrane-organizing proteins, 
which recruit and stabilize specific receptors at the cell surface. Tetraspanins are 
a superfamily of four-transmembrane proteins that interact with each other and 
partner proteins (i.e. receptors, signaling molecules) on the same cell leading to the 
formation of signaling platforms, called tetraspanin-enriched microdomains (TEMs) 
or the tetraspanin web9–11. Tetraspanins have four transmembrane domains, a small 
(EC1) and a large extracellular loop (EC2), a small intracellular loop and two short 
cytoplasmic tails12. In mammals, 33 different tetraspanin proteins are known, which 
are expressed on all cell types and contain a conserved CCG sequence in the EC2. 
Variety between different tetraspanin proteins is mainly determined by the structure 
of the EC2, which varies in length, amino acid sequence and number of cysteine 
residues which form disulfide bridges13. In addition, some tetraspanins undergo post-
translational modifications like glycosylation and palmitoylation. Whereas many 
tetraspanins are broadly expressed, the expression of tetraspanins CD37 and CD53 
is restricted to immune cells. However, the exact expression pattern and function of 
both CD37 and CD53 in the human immune system is currently unclear.
 In the past decade, the function of CD37 in the immune system has been extensively 
studied using a Cd37-deficient (Cd37-/-) mouse model14. Cd37-/- mice exhibit normal 
development of the immune system, but show aberrant cellular and humoral immune 
responses. Cd37-/- mice have decreased IgG1 levels14,15, but produce more IgA, which 
protects them from fungal infections15. Furthermore, expression and membrane 
stabilization of the fungal C-type lectin receptor Dectin-1 is decreased in absence 
of CD37 leading to increased IL-6 production upon fungal stimulation16. On T cells, 
Cd37-deficiency results in increased TCR signaling and IL-2 production leading to T 
cell hyperproliferation17. Furthermore, Cd37-/- DCs are hyperstimulatory for T cells 
in vitro, since Cd37-deficiency increased antigen presentation via MHC18, a reported 
interaction partner of CD3719. Besides MHC-II, CD37 has been reported to interact 
with several tetraspanins (CD53, CD81, CD82), Dectin-116, and the BCR co-receptors 
CD19 and CD2119, although CD37 was not required for surface expression of MHC-
II, CD81 and CD1914. DCs lacking CD37 showed impaired adhesion and migration 
capacity20, but the underlying mechanism remained to be elucidated. Crucial in 
DC migration is the C-type lectin protein CLEC-22, which is highly related to the 
CD37-interacting protein Dectin-121. Therefore, I hypothesized that CD37 regulates 
CLEC-2-dependent DC migration. Identifying (novel) interaction partners of CD37 
and unraveling the composition of CD37 microdomains will aid in understanding DC 
function.
 On B cells, CD37 is shown to be important for IgG plasma cell survival by controlling 
the α4β1 integrin-Akt signaling pathway22. Furthermore, CD37 contains an inhibiting 
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(ITIM-like) and activating (ITAM-like) motif in its cytoplasmic tails which are involved 
in B-cell apoptosis and survival, respectively23. Already in the 1980’s, CD37 was 
found to be highly expressed on lymphoma B cells24. Therefore, targeting of CD37 
was explored as B-cell lymphoma therapy25, but only recently regained interest as 
therapeutic target and is currently studied in clinical trials26. The importance of CD37 
in B-cell survival and high CD37 expression in B-NHL prompted me to investigate the 
effect of Cd37-deficiency on B-cell lymphoma development.
Outline of this thesis
The aim of this thesis is to decipher the immunoregulatory function of CD37 
to gain better insight into DC and B cell function in health and disease. In Chapter 1, 
I reviewed different types of plasma membrane microdomains, including 
tetraspanin microdomains, and discussed how these control signal transduction 
in antigen-presenting cells. Furthermore, I described the role of microdomains in 
immune-related diseases and their use as targeted therapy. In Chapter 2 the normal 
expression and tissue distribution of tetraspanins CD37 and CD53 in the human 
immune system is investigated using a novel multispectral imaging technique. 
In Chapter 3, I discovered that CD37 is important for CLEC-2 recruitment in the 
DC plasma membrane in response to PDPN. In addition, I showed that CD37 
inhibits signaling downstream of CLEC-2 and its related family member Dectin-1. 
In Chapter 4, Cd37-/- mice are shown to spontaneously develop GC-derived B-cell 
lymphoma. The underlying molecular mechanism is identified as enhanced IL-6 
signaling in absence of CD37. Moreover, the results of this study are extrapolated 
to human B-cell lymphoma, which is further investigated in Chapter 5. Here, the 
nature and functional consequences of two genomic CD37 mutations in CD37-
negative DLBCL are reported. Current developments in membrane-targeted 
therapies for B-cell lymphoma are reviewed in Chapter 6, and based on my findings 
I present a new concept of cell surface protein organization in lymphoma B cells and 
implications for membrane-targeted therapy.
Scope of this thesis
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Chapter 1
Microdomains in the membrane 
landscape shape antigen-presenting 
cell function
Malou Zuidscherwoude, Charlotte M de Winde, Alessandra Cambi,
Annemiek B van Spriel
Journal of Leukocyte Biology, 2014, 95:251-63
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Membrane landscape shapes APC function
Abstract
The plasma membrane of immune cells is a highly organized cell structure that is 
key to the initiation and regulation of innate and adaptive immune responses. It is 
well-established that immunoreceptors embedded in the plasma membrane have 
a non-random spatial distribution which is important for coupling to components 
of intracellular signaling cascades. In the last two decades, specialized membrane 
microdomains, including lipid rafts and tetraspanin-enriched microdomains have 
been identified. These domains are preformed structures (‘physical entities’) that 
compartmentalize proteins, lipids and signaling molecules into multi-molecular 
assemblies. In antigen-presenting cells, different microdomains containing 
immunoreceptors (major histocompatibility complex proteins, pattern-recognition 
receptors, integrins, among others) have been reported that are imperative for 
efficient pathogen recognition, the formation of the immunological synapse and 
subsequent T cell activation. In addition, recent work has demonstrated that both 
tetraspanin microdomains and lipid rafts are involved in B cell receptor signaling and 
B cell activation. Research into the molecular mechanisms underlying membrane 
domain formation is fundamental to a comprehensive understanding of membrane-
proximal signaling and antigen-presenting cell function. This review will also discuss 
the advances in the microscopy field for the visualization of the plasma membrane as 
well as the recent progress in targeting microdomains as novel therapeutic approach 
for infectious and malignant diseases.
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Membrane microdomains
The plasma membrane is essential for cell function due to its unique role in the 
communication between the inside and outside of the cell. Immune cells rely on the 
activation and collaboration of multiple different receptors in the plasma membrane 
that are central to leukocyte function including antigen recognition and presentation, 
cell adhesion, and cytokine production. A contemporary goal of researchers has 
been to uncover how immune cells physically organize and compartmentalize 
receptors and signaling molecules into efficient, regulated membrane-proximal 
signaling complexes. Whereas many studies have been performed on investigating 
the plasma membrane of T lymphocytes, this review focuses on new insights into the 
immunological relevance of microdomains in the membrane of antigen-presenting 
cells (APCs). 
 In 1972, Singer and Nicolson presented their classical view of membrane 
structures in which monomeric and amphiphilic membrane proteins diffuse in a 
two-dimensional fluid lipid bilayer1. The identification of specialized membrane 
domains including lipid rafts, tetraspanin-enriched microdomains, and caveolae 
has been a major breakthrough in cell biology and has changed the classical fluid 
mosaic model. Although different in size and composition we define them as 
membrane microdomains throughout this review. Lipid rafts are microdomains 
with an estimated size of 10-200nm present in the plasma membrane of all 
eukaryotic cells2. The outer leaflet of lipid rafts consists of cholesterol which binds 
to glycosphingolipids and promotes formation of a liquid ordered phase within the 
disordered glycerophospholipid bilayer of the plasma membrane (Figure 1). The 
inner leaflet of lipid rafts is composed of saturated phospholipids3,4. Inside the cell, 
the concentration of cholesterol is increased from the endoplasmatic reticulum to 
the Golgi, which may underlie the important role of cholesterol in the trafficking 
of transmembrane proteins to the plasma membrane5. Typical raft constituents 
within the outer leaflet are glycosylphosphatidylinositol (GPI)-anchored proteins6, 
which partition to the lipid rafts in virtue of their glycolipid anchor. Different models 
have been proposed that underlie plasma membrane compartmentalization. 
Simons refers to lipid rafts as a membrane-organizing principle in which rafts 
allow lateral segregation of proteins in the plasma membrane and recruitment 
of signaling molecules in order to compartmentalize cellular events, including 
signal transduction, membrane traffic and endocytosis. Upon cross-linking of raft-
associated receptors, two or more rafts may coalesce into larger domains where 
more sustained signaling can occur and anchoring to the actin cytoskeleton can take 
place (reviewed in [7]). Kusumi proposes a major role for the actin cytoskeleton in 
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his ‘picket-fence’ model that is described by a hierarchical three-tiered mesoscale-
domain architecture present in the plasma membrane (reviewed in [8]). Mesoscale 
refers to a size greater than a nanometer and smaller than a micron. The first 
hierarchy are membrane compartments of 40-300nm formed by a fence of actin-
based membrane cytoskeleton and pickets of transmembrane proteins anchored 
to this fence. The second-tier are raft domains of 2-20nm consisting of cholesterol, 
glycosphingolipids and GPI-anchored proteins. The third-tier are dynamic protein 
complexes of 3-10nm containing membrane-associated and integral membrane 
proteins. In this ‘picket-fence’ model, transmembrane proteins and phospholipids 
can undergo hop diffusion between membrane compartments, whereas they can 
move freely within a compartment emphasizing the important role of the actin 
cytoskeleton8 versus the more classical model of lipid raft compartmentalization 
described by Simons and others5. The nanoscale size of rafts is also consistent with 
the ‘lipid shell’ model which proposes that each protein is surrounded by a ring of 
laterally organized lipids9.
 Sixty years ago, small (60-80nm) microdomains, called caveolae, present on 
specific cell types were first identified using electron microscopy10,11. Caveolae are 
cholesterol-enriched membrane invaginations consisting of caveolin proteins and 
cavin proteins. These proteins interact with each other in order to regulate signal 
transduction, endocytosis, and transport of free cholesterol (reviewed in [12,13]). 
Like lipid rafts, caveolae can cluster together and form extensive networks14. In the 
immune system, they are found in certain myeloid15 and lymphoid13 cell lineages 
depending on the activation and maturation state of the cell. Studies on murine 
macrophages revealed that caveolae structural proteins are important regulators 
of macrophage number and phenotype in the lung16, and caveolin proteins may 
promote differentiation of monocytes into macrophages17. The role of caveolae in 
other APCs is not well established and will therefore not be the focus in the remainder 
of this review. 
 During the nineties, a novel type of membrane microdomain was identified: 
the tetraspanin-enriched microdomain (TEM)18. Tetraspanins are a family of four 
transmembrane proteins present on the plasma membrane and on intracellular 
vesicles of virtually all mammalian cell types. Their structure is characterized by 
four transmembrane domains, a small and a large extracellular loop and 2 short 
cytoplasmic tails19. The size of a TEM varies between cell types and diameter 
sizes between 100-300nm have been reported (Table 1). The assembly of TEMs is 
dependent on tetraspanin-tetraspanin interactions and tetraspanin interactions 
with transmembrane receptors, enzymes, adhesion molecules (integrins and others) 
and signaling molecules (reviewed in [20,21]). These interactions can be divided into 
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three levels22,23. Level 1 refers to very robust and direct interactions that are stable 
in strong detergents (i.e. Triton X-100). Level 2 interactions are less robust and are 
disrupted by strong detergents, but are stable in hydrophobic detergents (i.e. Brij 
96 or Brij 97). Level 3 consists of weaker indirect interactions only detected in mild, 
less hydrophobic, detergents (i.e. Brij 99 or CHAPS). These different interaction 
levels reveal the concept of a tetraspanin web, in which tetraspanins are organizers 
of multi-molecular complexes on the plasma membrane. Each tetraspanin 
molecule recruits specifically one or more partner molecules, following interaction 
with another tetraspanin molecule to form larger complexes23 (Figure 1). The 
composition of TEMs is highly dependent on the specific cell type studied, and it has 
been shown that different TEMs exist within one particular cell type24. In the Golgi 
complex tetraspanin proteins can be palmitoylated, which allows dynamic homo- or 
heterodimerization with another tetraspanin molecule or with associated proteins 
in the plasma membrane. Palmitoylation is the covalent attachment of fatty acids, 
such as palmitic acid, to cysteine residues of membrane proteins, which promotes 
protein-protein interactions in the lipid environment. This post-translational 
modification was shown to be important for the assembly of TEMs, as previously 
Table 1. Characteristics of tetraspanin-enriched microdomains and lipid rafts 
Although TEMs and conventional lipid rafts display some similarities (both enriched in cholesterol 
and partition into low-density fractions of sucrose gradients), there are a number of critical 
differences that distinguish these two microdomains.
TEM Lipid raft
Estimated diameter size 100-300nm24 10-200nm2
Content/ characterization Enriched in tetraspanins, tetraspanin-partner 
proteins, cholesterol.
Enriched in cholesterol, sphingomyelin, lipids  
with saturated acyl chains, raft-a-like proteins  
(GPI-anchored, caveolin, other).
Biochemical features Partition into low-density fractions of sucrose 
gradients. Resistant to mild detergents (Brij 97) 
at 37°Ca. Partially dependent on cholesterolb.
Partition into low-density fractions of sucrose 
gradients. Resistant to non-ionic detergents (Tx-100) 
at 4°C. Dependent on cholesterolb.
Signaling molecules PKC, PI4K, phosphatases, Rac, other. Src kinases, H-Ras, PI3K/Akt , 
B and T cell receptor associated signaling effectors.
a  Tetraspanin–protein interactions have been classified into three categories based on their 
stringency in different detergents (see text for more details). This concept is also relevant for lipid 
rafts since the protein content of DRMs differs depending on the detergent utilized. 
b  Although direct interactions between tetraspanins and their partners are resistant to cholesterol 
depletion22, signal transduction downstream of TEMs is affected by MCD treatment36. 
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described for tetraspanins CD925 and CD15126. These protein-protein interactions in 
the plasma membrane have an important role in intercellular (adhesion, migration, 
synapse formation) and intracellular (organizers of membrane-signaling complexes) 
interactions as well as intracellular protein transport and endo- and exocytosis. 
TEMs are not static entities, instead there is now prevailing evidence from studies 
in living cells that both their localization and composition are dynamic25,27. There is 
constant diffusion of individual tetraspanins and partner proteins between specific 
^ Figure 1. Schematic representation of a lipid raft and a tetraspanin-enriched microdomain. 
(A) Lipid raft. Lipid rafts are enriched in sphingolipids, cholesterol, and GPI-anchored proteins. 
Certain transmembrane (TM) proteins are specifically associating with lipid rafts, whereas other 
proteins are excluded. (B) Tetraspanin-enriched microdomain. Tetraspanin proteins specifically 
recruit one or more partner molecules (including (immuno-)receptors and signaling molecules) 
whereby they induce the formation of multi-molecular complexes in the membrane. These 
protein-protein interactions can be direct or indirect (via other members of the tetraspanin 
family) forming so-called tetraspanin-enriched microdomains, or the ‘tetraspanin-web’ (see text 
for details). Molecules depicted in this schematic representation of membrane microdomains are 
not drawn to scale.
Lipid raft Non raft membrane 
GPI-anchored 
protein
Cholesterol
Non-raft 
TM protein
Raft associated
TM protein
Sphingolipid
Tetraspanin
Tetraspanin
partners
A
B
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microdomains, which may induce clustering of two or more TEMs in order to enhance 
the strength of a response. Furthermore, the diffusion dynamics of the different 
molecules present in the microdomain can be influenced by ligation of a receptor 
within the TEM.
 Despite the different biochemical principles regulating rafts and TEMs, these 
microdomains are dynamic in time and space, and their molecular constituents 
may exchange between different types of microdomains22,25,28. In the remainder 
of this review, we will focus on the characterization and function of lipid rafts and 
tetraspanin-enriched microdomains in APCs.
Approaches to characterize microdomains
The formation of membrane microdomains depends on lipid-lipid, lipid-protein and 
protein-protein interactions, indicating the existence of a variety of biochemical 
principles that allow these interactions to occur at the molecular level. Strong 
interactions between cholesterol and sphingolipids promote their co-segregation in 
raft domains, which in turn can sequester specific signaling proteins allowing the 
formation of large signaling complexes. In the past, the nanoscale size and dynamic 
nature of lipid rafts have posed technical challenges for their identification and the 
study of their composition. A solution to this problem came with the discovery that 
segregation of certain proteins into lipid rafts was determined by their capacity 
to reside in a specific fraction of membrane-derived material that appeared to 
resist detergent treatments29,30. These so-called detergent resistant membranes 
(DRMs) were initially isolated after cell lysis in the presence of the detergent Triton 
X-100 and subsequent ultracentrifugation on sucrose gradient where the floating 
fraction was found to contain DRMs (for a detailed description of the most widely 
used protocols see [31]). Another frequently used technique to study lipid rafts is 
methyl-β-cyclodextrin (MCD) treatment, which depletes cholesterol, an essential 
constituent of lipid rafts, from the plasma membrane.
 It should be noted that DRM extraction has been primarily used to determine the 
association of membrane proteins with lipid rafts. In fact, although localization of 
TEMs in DRMs has been documented32,33, seminal work from the Hemler laboratory 
has demonstrated that TEMs are discrete units that are distinct from lipid rafts but 
can occasionally interact with them22,34 (Table 1). In addition, proteomics approaches 
have demonstrated that the composition of TEMs is specifically distinct from that of 
lipid rafts as different sets of proteins were detected in lipid rafts and TEMs (reviewed 
in [35]). Part of the controversy was caused by the sensitivity of both DRMs and 
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TEMs to cholesterol depletion by MCD, although for the integrity of TEMs the effects 
of cholesterol depletion were reported to be milder36. MCD has been widely, and 
sometimes without including basic controls of cell viability or residual cholesterol 
levels, used to determine the association of membrane proteins with lipid rafts. 
Lack of receptor functionality upon MCD treatment has often been attributed to 
impaired colocalization with lipid rafts. However, one should consider that MCD has 
been shown to exert pleiotropic effects among which destruction of clathrin-coated 
pits37,38 and rearrangement of the cytoskeleton28,39. 
 Despite the slightly artifactual nature of both DRMs and MCD treatment, one 
should acknowledge that these approaches have been instrumental to the original 
identification of the potential raftophilic/raftophobic nature of a large variety of 
proteins. However, it is increasingly recognized that protein-protein and protein-
lipid interactions that mediate the formation of specific membrane compartments 
or scaffolds are often transient and highly dynamic. Therefore, although DRMs give 
a broad view of domain composition, they represent a bulk snapshot of a specific 
situation and cannot provide information on the spatiotemporal variations of the 
membrane domains. Moreover, while the use of the detergent Triton has been 
shown to induce formation of DRMs40, different detergents have different ability 
to selectively solubilize membrane proteins or enrich glycosphingolipids and 
cholesterol41, emphasizing the notion that DRMs might not be fully representative 
of lipid rafts. Fast developments in fluorescence microscopy techniques have now 
made it possible to measure protein aggregation state, dynamics, and interactions 
in living cells, facilitating in situ measurements of biochemical parameters and 
revealing novel aspects of membrane microdomain organization and function.
 Although a detailed overview of all the state of the art microscopy techniques 
that can image membrane domains falls outside the scope of this review, it is worth 
to highlight the increasing application of novel imaging techniques that are perfectly 
suited to visualize the nanoscale organization of the plasma membrane, including 
lipid rafts and TEMs. Images of membrane domains were initially obtained by using 
immunogold labeling and transmission electron microcopy on either membrane 
sheets or intact cells42-45. With the advent of super-resolution microscopy techniques 
in the past decade, techniques such as Near-field Scanning Optical Microscopy 
(NSOM), Stimulated Emission Depletion (STED) and localization microscopy were 
shown to be capable of directly mapping out the nanoscale landscape of the cell 
surface46-48 (Figure 2). Nanoscale proximity of raft components and transmembrane 
adhesion receptors has been revealed by NSOM imaging of the cell surface of 
human monocytes49,50, while pioneering measurements of STED combined with 
Fluorescence Correlation Spectroscopy (STED-FCS) have been able to determine 
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fast diffusion of phospholipids and sphingolipids in living cells51,52. More recently, 
photoactivated localization microscopy (PALM) in combination with pair-correlation 
analysis has been shown to be a promising tool to analyze complex organization 
patterns of membrane proteins enabling quantification of protein cluster size, 
density and abundance in the cell membrane53.
 Single molecule imaging, such as Förster Resonance Energy Transfer and 
Fluorescence Lifetime Microscopy (FRET-FLIM) and multi-color single particle 
^ Figure 2. Model illustrating microdomains in the plasma membrane which can facilitate 
immunoreceptor clustering, cross-talk, and immune cell signaling. (1) Clustering. 
Immunoreceptors can be clustered within membrane microdomains leading to an increase of 
receptor avidity. (2) Cross-talk. Membrane microdomains provide a local environment which 
facilitates cross-talk between different immunoreceptors and their co-receptors resulting 
in enhancement (or dampening) of their function. In addition, regulators of signaling can 
be excluded. (3) Signaling. Signaling molecules are specifically recruited toward membrane 
domains, where stable signaling complexes are being created. It should be noted that the plasma 
membrane is much more crowded with proteins than depicted in this model adding an extra level 
of complexity. An example of visualization of membrane microdomains is given in the upper right 
corner: confocal and super-resolution microscopy (STED) of tetraspanin microdomains in the 
plasma membrane of human B cells, demonstrating the need for advanced imaging techniques 
to investigate single membrane microdomains and their constituents. The diameter size of a 
TEM in B cells is estimated to be around 100nm. Scale bars indicate 2mm.
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tracking (SPT), can provide a view of protein dynamic behavior at the molecular level54. 
Elegant FRET-FLIM studies from the Sanchez-Madrid group have demonstrated 
the existence of specialized preformed tetraspanin-enriched adhesive platforms at 
the plasma membrane of endothelial cells containing VCAM-1 or ICAM-1, ligands 
for the leukocyte integrins VLA-4 (a4β1) and LFA-1, as well as the tetraspanins 
CD151 and CD9, respectively27. This study shows that also the spatial organization 
of membrane receptors in non-immune cells affects immune cell function during 
cell-cell interactions, such as adhesion and transmigration. Despite the numerous 
interactions discovered between tetraspanins and immune receptors, only few 
similar studies have been performed on immune cells55.
 While FRET-FLIM generally provides averaged values of ensemble measurements, 
SPT offers the opportunity to distinguish fractions of proteins exhibiting different 
dynamic behavior. An excellent example was provided by Jaqaman and colleagues 
who used SPT to investigate the dynamics and signaling of the scavenger receptor 
CD36 at the plasma membrane of macrophages which was controlled by the 
cortical cytoskeleton56. Recent work from our laboratory also demonstrated the 
power of SPT to study immune receptor nanoscale organization and function. 
On monocyte-derived dendritic cells (DCs), we followed single molecules of the 
pathogen-recognition receptor DC-SIGN and demonstrated a direct relationship 
between spatial nanopatterning and lateral diffusion to provide DC-SIGN with 
the exquisite ability to bind many different viruses57. On the cell surface of human 
monocytes, where the integrin LFA-1 is organized in nanometer-sized domains45,49, 
we unraveled the intricate coupling between conformation and lateral diffusion of 
LFA-1 microdomains. Domain mobility was crucial for the formation of stable and 
large clusters that initiate LFA-1 mediated leukocyte adhesion58. In addition, these 
novel imaging techniques have now provided compelling evidence that tetraspanins 
regulate the mobility of integrin molecules in the plasma membrane. The physical 
association of the laminin-binding α6 integrin with tetraspanin CD151 was 
demonstrated to promote random-confined diffusion of the integrin in mammary 
cells, which may regulate its interaction with the cytoskeletal protein talin59. In B 
lymphocytes, we have shown that the tetraspanin CD37 is required for the mobility 
and clustering of α4β1 integrin molecules in the plasma membrane, which is 
important for plasma cell survival and antibody production60. These studies provide 
novel mechanistic insights into the contribution of TEMs to integrin lateral motility 
and adhesive properties. Still, studies addressing the mechanisms underlying TEM 
dynamics and interactions in the plasma membrane are scarce, in particular in 
immune cells. The elegant study on the mobility of single molecules of tetraspanin 
CD9 in prostate carcinoma cells revealed that CD9 mostly exhibits Brownian 
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diffusion at the plasma membrane, but is transiently confined to platforms that are 
enriched in CD9 and its interaction partners25 again highlighting the importance to 
investigate TEMs in living cells. Although no single technique is able to unravel the 
concept of membrane receptor compartmentalization and function, we believe that 
the best approach toward understanding the principles of membrane microdomains 
is to compare and contrast results obtained with the existent methods as well as 
exploring new techniques as they are developed and improved. The advantages and 
limitations of the discussed microscopy techniques, that are able to image all types 
of microdomains, are nicely reviewed elsewhere61. A major current challenge in the 
field is to increase insight into the molecular mechanisms underlying the regulation 
of membrane-proximal signaling by membrane microdomains in immune cells.
Signal transduction regulated by plasma membrane 
microdomains 
It is well-established that signaling transduction efficiency is dependent on the 
selective concentration of signaling proteins into discrete clusters in the plasma 
membrane (reviewed in [62,63]), including their recruitment into specialized 
microdomains such as rafts and TEMs64,65. Whereas some proteins constitutively 
reside in rafts, like most Src family kinases, other proteins become only transiently 
associated with rafts, for example upon activation. Similarly, protein kinase C (PKC) 
recruitment to TEMs and subsequent activation is an inducible process that depends 
on integrin activation66. Thus, microdomains can serve as ‘scaffolds’ to localize and 
transiently concentrate specific signaling molecules67. The time a protein resides 
within a microdomain can be altered upon oligomerization of the protein after for 
example multivalent ligand binding. In addition, activated receptors can induce 
coalescence of rafts with a different composition resulting in large and stable 
structures on the plasma membrane64,68 again underscoring the dynamic nature of 
the signaling capacity of membrane microdomains. 
 Within the microdomain environment, receptors can be modified by local kinases, 
leading to further downstream signaling. Indeed proteomics data demonstrate 
an enrichment of specific signaling molecules in rafts fractions compared to total 
membrane fractions69 (Table 1). Although the exact mechanisms underlying this 
enrichment need to be identified, it is apparent that special domains or motifs in the 
molecular structure of signaling proteins determines their localization to the plasma 
membrane62. This concept is nicely illustrated by members of the ubiquitously 
expressed proteins of the Ras family of GTPases. The importance of Ras for APC 
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biology is illustrated by R-Ras-deficient murine DCs that show impaired maturation 
and T lymphocyte priming, which is linked to defective LPS signaling70. H-Ras and 
K-Ras are highly homologous proteins, still they generate very distinct signaling 
outputs, due to their different lipid anchors interacting with different regions of the 
plasma membrane. H-Ras, which is palmitoylated, has transient interactions with 
lipid rafts, whereas K-Ras clusters in non-raft areas of the plasma membrane42. 
Palmitoylation by itself is not a prerequisite for raft localization since this modification 
has also been shown essential for tetraspanin-tetraspanin interactions, the stability 
of TEMs, and its signaling capacity71,72. Several tetraspanins have been reported 
to interact with G protein subunits, phosphatidylinositol 4-kinase, and activated 
PKC isoforms in many different cell types including APCs (reviewed in [21,65,73]). 
Whether these signaling proteins interact directly to tetraspanins is unclear, but the 
intracellular or the transmembrane regions of tetraspanins have been implicated in 
their interaction with PKC66,74,75. Interestingly, some tetraspanins contain a PDZ motif 
in their C-terminal tail, which facilitates the anchoring of transmembrane proteins to 
the cytoskeleton and hold together signaling complexes, thus providing a direct way 
to sequester components of a signaling cascade to TEMs21,76. Furthermore, several 
studies have demonstrated that TEMs are implicated in regulation of the JNK and 
Akt signaling pathways60,77-79. In B cells, we have recently shown the requirement of 
tetraspanin CD37 for proper α4β1 integrin mobility and clustering, which is essential 
for Akt signaling and survival of IgG1-producing plasma cells60. Many studies support 
the concept that tetraspanins act as linker molecules to recruit kinases in the proximity 
of integrins66,72,80. Strikingly, it was shown that tetraspanin CD37 is able to signal by 
itself, as it contains predicted ITAM-like and ITIM-like motifs in its two intracellular 
tails81. Antibody cross-linking of CD37 on B cells resulted in recruitment of Lyn and 
SHP1 via its ITIM-like domain, leading to cell death, whereas its ITAM-like domain 
recruited PI3K and Akt leading to cell survival. Thus, upon antibody ligation of CD37, 
two opposing stimuli act simultaneously on the Akt signaling pathway, although the 
involvement of Fc receptors cannot be completely excluded in this study. Different 
groups have demonstrated that TEMs can also inhibit signal transduction pathways 
by the recruitment of phosphatases82,83, or alternatively by the sequestering of 
kinases away from their site of action84,85. Recently, the C-terminal cytoplasmic 
domain of tetraspanin CD81 was shown to directly interact with the GTPase Rac and 
to inhibit Rac activation86. 
 Taken together, microdomains are implicated in enhancing or dampening 
signaling from immune receptors by serving as platforms for the dynamic assembly 
of signaling complexes. Considering the complexity of TEMs and lipid rafts, it not 
surprising that they regulate many different signaling pathways by their capacity 
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to not only include but also exclude proteins from microdomains. For instance, 
phosphatase CD45, a negative regulator of receptor signaling, is well-known to be 
excluded from lipid rafts87. Another example is the interaction of tetraspanins (CD81, 
CD82) with CD4 and CD8 co-receptors, that can sequester these proteins away from 
the T cell receptor signaling complex in the plasma membrane84. Next to regulating 
the recruitment of signaling molecules and activation of immune receptors on the 
plasma membrane, microdomains can also promote cross-talk between different 
receptors (Figure 2). These fascinating processes will be discussed below, taking 
pattern-recognition receptors (PRRs), major histocompatibility complex (MHC) class 
II and the B cell antigen receptor (BCR) as classical examples of immune receptors 
regulated by membrane microdomains during the course of an immune response. 
Pattern-recognition receptors
APCs are equipped with a broad panel of specific PRRs that are essential for the 
recognition and uptake of pathogens. APCs bind pathogens by means of complex 
multi-molecular interactions between different PRRs and a wide variety of microbial 
structures called pathogen-associated molecular patterns (PAMPs). Efficient 
pathogen recognition and uptake is dependent on a high level of organization 
of PRRs in the plasma membrane of APCs. There is now increasing evidence that 
specialized microdomains can serve as organizing platforms that facilitate PRR 
multimerization and clustering; cross-talk between different PRRs; and integration 
of downstream signal transduction pathways. The two main PRR subclasses that are 
expressed on the plasma membrane of APCs include C-type lectin receptors (CLRs) 
and Toll-like receptors (TLRs). 
 Receptor multimerization is a well-defined mechanism that increases receptor 
avidity and ligand engagement. A classical example is the CLR DC-SIGN which exists 
as tetramers in the plasma membrane, and is clustered into microdomains during 
DC differentiation44,88. A direct structural relationship between tetramer stability 
and nanoclustering formation sustained by the neck region of DC-SIGN has recently 
been reported57. This provides DC-SIGN with the ability to bind nanoscale pathogens 
(viruses) of different sizes highlighting a physiological role for nanoclustering. 
Another CLR, Dectin-1, has been found to cluster in a ‘phagocytic synapse’ 
(a structure reminiscent of the immunological synapse formed between APCs and 
T cells) in myeloid cells which is crucial for triggering phagocytosis and full anti-fungal 
activity89. Different studies have shown that Dectin-1 interacts with tetraspanin 
proteins (CD63 and CD37) on the cell surface of APCs which may facilitate Dectin-1 
clustering90,91. CD37-deficiency leads to impaired stabilization of Dectin-1 molecules 
in the membrane of APCs due to increased internalization. The Dectin-1-CD37 
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interaction has also functional consequences since Dectin-1-mediated interleukin-6 
production by APCs is inhibited by CD37.
 TLRs have also been reported to dimerize into homodimers and/or heterodimers 
which facilitates recruitment of intracellular signaling adapters and kinases. Dimer 
formation of TLRs occurs at both the extracellular Leucin-rich repeat domain and 
the cytosolic TIR domain. TLR localization into microdomains may further induce 
receptor clustering. TLR2 and TLR4-CD14 recruitment to lipid rafts has been 
described92-94, although other studies documented TLR4 association with tetraspanin 
microdomains in macrophages95. It is not unlikely that different pools of TLRs exist 
in the membrane that are localized to different microdomains. Regulation of these 
receptor pools may be linked to ligand-specific cellular responses and/or depend on 
the activation status of the cell. This hypothesis may be resolved by investigating 
TLR clustering and localization in living APCs using high resolution microscopy 
(such as multi-color SPT). Recently, the scavenger receptor CD36 has been found 
in multi-molecular complexes composed of tetraspanin CD9, CD81, integrins, 
and Syk kinase96. Although not a classical PRR, CD36 can recognize Plasmodium 
falciparum and bacterial diacylglycerides. Similarly, the scavenger receptor CD5 that 
recognizes β-glucan in fungal cell wall was reported to interact with the tetraspanin 
CD9 although functional implications of this interaction have not been reported97. 
Thus, assembly of PRRs in membrane microdomains may underlie the mechanism 
of receptor multimerization (reviewed in [98-100]). It is important to note that 
besides the presence of PRRs in preassembled clusters, pathogen binding itself will 
further induce PRR clustering, possibly altering PRR-induced signaling intensity and 
duration.
 Receptor cross-talk refers to the collaborative induction of a response by 
different receptors that is distinct from the response elicited by individual receptors. 
Microdomains are believed to provide a platform for efficient receptor cross-talk 
in the plasma membrane. For example, mutual signaling from TLR2 and Dectin-1 
is documented to be required for pro-inflammatory cytokine production by APCs 
upon β-glucan binding101. Besides synergistic responses, the outcome of PRR 
cross-talk may also dampen unwarranted immune responses when receptors act 
antagonistically. For example, there is now evidence of existing inhibitory interactions 
between different TLRs in the membrane of human PBMCs102. A consequence of 
such receptor cross-talk is the integration of different signal transduction pathways 
which eventually determines the outcome of the immune response aimed to 
eradicate the pathogen (reviewed in [100]). However, less well-known is the 
existence of cross-talk between different signaling molecules already at the level 
of the plasma membrane62. In this context signaling molecules that contain specific 
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protein or lipid binding specificity can dock at the plasma membrane which often 
directly coincides with their activation. For example, the kinase Syk gets recruited 
to the phosphorylated ITAM-like motif in the intracellular tail of Dectin-1 upon yeast 
binding103. Although the precise role of lipid rafts and TEMs in PRR cross-talk needs 
to be established, evidence is accumulating that membrane microdomains are 
important for the formation of multi-molecular signaling complexes by providing a 
local environment that allows for efficient physical interactions between signaling 
molecules and PRRs98. 
MHC class II
APCs utilize MHC class II molecules to present non-self peptides to CD4+ T cells. 
As the abundance of relevant MHC class II-peptide complexes is rather low, it is 
necessary to organize and cluster MHC on the APC surface for efficient antigen-
specific T cell activation. Early crystallography studies of MHC class II molecules 
revealed a structure described as a dimer of heterodimers104 that supported a model 
in which superdimers of MHC II molecules may facilitate the activation of T cells 
by cross-linking T cell receptors105. However, this could not explain how sufficient 
numbers of agonistic MHC-peptide complexes from all over the cell surface could be 
concentrated in the centre of a synapse to activate T cells. It is now widely accepted 
that MHC molecules cluster in the plasma membrane of APC106. MHC class II-peptide 
complexes in mature DC are collectively transported to the plasma membrane 
where they remain pre-clustered at the cell surface107,108. This has led to the concept 
that MHC-peptide complexes cluster into specialized microdomains in APC prior to 
the formation of the immunological synapse109. This concept has been supported 
by different studies that provide evidence for a functional association of MHC 
class II molecules with lipid rafts. Disrupting raft integrity on B cells indeed results 
in inhibition of MHC class II antigen presentation at low antigen concentration. 
Since the surface expression of MHC class II and the peptide binding to MHC class 
II were unaltered after raft disruption, a model was postulated in which lipid rafts 
locally concentrate MHC class II-peptide complexes, crucial for efficient antigen 
presentation at low doses of antigen110. However, there is also compelling evidence 
that MHC class II molecules interact with tetraspanins (CD9, CD63, CD37, CD53, 
CD81, CD82) demonstrated by immunoprecipitation studies18,111, FRET microscopy55, 
and electron microscopy112,113. These studies revealed that tetraspanins are enriched 
on the internal membranes of MHC II enriched compartments (MIICs) in B cells where 
they can interact with MHC class II, HLA-DM and HLA-DO112,113. In immature DCs 
however, CD63 was found exclusively in MIICs, whereas CD9, CD53 and CD81 mainly 
interact with MHC class II at the plasma membrane114, indicating that individual 
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tetraspanins can selectively interact with MHC class II in different compartments. 
Selective enrichment of tetraspanin molecules in the central supramolecular 
activation complex formed between APCs and T cells has also been demonstrated115. 
In addition, co-clustering of murine MHC class II molecules I-A and I-E has been 
reported to depend on TEMs. In CD9-deficient DCs, MHC I-E failed to co-cap with 
I-A molecules and exogenous expression of CD9 in CD9-negative B cells enhanced 
I-A/I-E interaction116. This model was challenged in a study in which cholesterol 
depletion, but not absence of CD9, did affect I-A/I-E interaction117. This controversy 
may be explained by sensitivity of both DRMs and TEMs to cholesterol depletion by 
MCD, favoring a model where both microdomains are involved in MHC clustering. 
The mobility of MHC class II molecules in the plasma membrane is also dependent 
on cholesterol118. Furthermore, single molecule tracking revealed that MHC class II 
molecules undergo hop diffusion between membrane compartments119, providing a 
possible explanation for the molecular exchange between microdomains. 
 Interestingly, some studies reported that tetraspanins associate predominately with 
peptide-loaded MHC class II complexes114,120. Tetraspanins were found in complexes 
with multimerized MHC class II molecules as shown by immunoprecipitations with 
the antibody CDw78121. These domains were enriched with the CD86 co-stimulatory 
molecule and the peptide editor HLA-DM, and carried a restricted peptide 
repertoire. In contrast, the HLA-DR molecules found in rafts displayed a highly 
diverse peptide repertoire120. However, these studies must be interpreted with 
caution since the specificity of the CDw78 antibody has been questioned122. Silencing 
of tetraspanins CD9, CD63 and CD81 (but not CD82) resulted in increased MHC class 
II expression, but did not affect MHC class II peptide loading123. Still, the importance 
of tetraspanins in antigen presentation and T cell activation has been validated by 
studies with APCs from tetraspanin-deficient mice. DCs lacking CD37 or CD151 are 
hyper-stimulatory to T cells by different mechanisms. Whereas CD151 regulates co-
stimulation, CD37 is implicated in inhibiting antigen presentation via MHC class I and 
class II molecules124. Thus, individual tetraspanins on APCs have specific functions 
that can even be opposing, for example tetraspanins CD9 and CD82 may promote 
MHC clustering, whereas others, such as CD37 may dysregulate MHC clustering 
at the plasma membrane. In addition, cooperation between tetraspanins has also 
been demonstrated; CD37xTssc6 double knockout DCs were significantly more 
hyper-stimulatory than DCs isolated from either single knockout mouse125. Taken 
together, TEMs have been implicated in the assembly (clustering), stabilization and/
or trafficking of MHC class II-peptide complexes. The complexity of the composition 
of the tetraspanin web and their localization within the cell warrants further studies 
to clarify the precise function of TEMs in the MHC class II lifecycle.
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B cell antigen receptor
The BCR complex is composed of a membrane-bound immunoglobulin which 
mediates binding to antigen, and the Igα/Igβ (CD79) heterodimer which couples 
the receptor to downstream signaling pathways. Igα and Igβ contain an ITAM 
motif, which becomes phosphorylated by Src-family tyrosine kinases after receptor 
engagement. This allows for recruitment and activation of the cytosolic Syk/Zap70 
family of protein tyrosine kinases, leading to downstream signaling126. In resting 
B cells, BCRs are located into non-raft areas of the plasma cell membrane. Upon 
antigen binding, BCR molecules oligomerize, and rapidly translocate into lipid rafts 
where BCR signaling is facilitated. This was not only determined using biochemical 
methods127, but was also visualized in living cells by fluorescent microscopy128,129. 
Partitioning into lipid rafts is intrinsic to the BCR itself and independent of BCR 
signaling or the actin cytoskeleton130 .
 CD19 forms together with complement receptor CD21, tetraspanin CD81 and Leu-
13 an essential co-receptor complex for the BCR. This co-receptor complex lowers 
the threshold for B cell activation, as activated CD19 recruits signaling molecules 
to the BCR131. Interestingly, BCR that is co-ligated to the CD19/CD21 complex has a 
longer retention time in lipid rafts, resulting in the formation of a stable signaling-
active complex at the plasma membrane132. Subsequently, BCR internalization and 
targeting of the BCR to MHC class II peptide-loading compartments is required 
for antigen presentation. This process was found to depend on the association of 
phosphorylated clathrin with lipid rafts133. The BCR is able to continue signaling 
after being endocytosed, providing a means to activate different kinases at different 
subcellular locations134. The role of tetraspanin CD81 in the BCR co-receptor complex 
is critical, since CD81 is required for stabilizing mature CD19 on the plasma membrane 
of both human and murine B cells135-139. Moreover, CD19, CD21 and the BCR fail 
to translocate into DRMs in CD81-deficient cells after co-ligation of CD21 and the 
BCR32. Palmitoylation of the cytoplasmic tail of CD81 is increased upon co-ligation 
of the BCR and CD19/CD21/CD81 complex, which is needed for the stabilization of 
protein complexes in both lipid rafts140 and TEMs. Thus CD81 is critically involved in 
BCR localization to microdomains and thereby promotes BCR signaling. The finding 
that CD81 can localize to both TEMs and lipid rafts exemplifies again the dynamics 
and molecular exchange that occurs between different types of microdomains. 
 An additional means through which the BCR can be compartmentalized is via 
the cortical actin cytoskeleton. The actin cytoskeleton acts as a barrier to BCR 
diffusion, compartmentalizing the BCR from activating co-receptors including CD19, 
thereby preventing spontaneous BCR signaling in resting B cells. Disruption of the 
actin network is sufficient to induce robust signaling in B cells in the absence of 
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BCR stimulation141. After B cell activation, however, the cortical actin cytoskeleton 
needs to be remodeled, in order for BCR clusters and rafts to coalesce and to form 
stable signaling platforms142,143. Ezrin-Radixin-Moesin proteins, which link the actin 
cytoskeleton with plasma membrane proteins are transiently dephosphorylated 
upon BCR stimulation. This results in dissociation of the plasma membrane from 
the underlying actin cytoskeleton, and a transient increase in BCR diffusion142,144. 
Recently, Mattila and colleagues elegantly showed that signaling through the BCR 
is regulated by combined action of the actin cytoskeleton and the CD81 tetraspanin 
web in primary B cells145. Using super-resolution microscopy techniques and CD19- 
and CD81-deficient B cells, they deciphered the role of the tetraspanin network in 
BCR signaling induced by cytoskeleton disruption. In contrast to the release of the 
BCR, CD19 diffusion is not altered upon disruption of the cytoskeleton. Instead, CD19 
is restrained by the tetraspanin network, shown by the significantly faster diffusion 
of CD19 in CD81-deficient cells. CD81 thus holds co-receptor CD19 in place to interact 
with mobile BCR nanoclusters released after cytoskeleton disruption. Whether BCR 
signaling is initiated in lipid rafts, or whether initial signaling needs to occur before 
reorganization of the actin cytoskeleton allows the BCR microdomains to move 
into stable raft signaling platforms still needs to be addressed. Taken together, 
these studies demonstrate that the interplay between different microdomains 
including lipid rafts and TEMs is essential for efficient signaling via the BCR. In the 
following section, the relevance of membrane microdomains in different diseases 
will be discussed together with the possibilities to target these structures as novel 
therapeutics.
Implications of microdomains in immune-related diseases
Prevailing evidence suggest that certain pathogens utilize rafts and tetraspanin 
microdomains to gain entry and to survive inside the cell. Pathogens can use 
different strategies to take advantage of microdomains in the membrane. For 
example, bacteria such as Salmonella typhimurium and Legionella pneumophila 
exploit lipid rafts to create phagosomes that allow them to survive inside antigen-
presenting cells (reviewed in [146]). Several bacteria enter phagocytic cells through 
raft-associated proteins (such as CD55 and CD48) that prevents trafficking to 
lysosomes, thus avoiding degradation and antigen presentation. Although there 
is no evidence for the presence of PRRs in caveolar structures, a role for caveolae 
in pathogen uptake has been reported. For example, enrichment of GPI-anchored 
proteins (such as CD48) into caveolae has been documented that can bind bacterial 
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antigens and thereby facilitate pathogen entry into host cells147. In addition, caveolin 
proteins have been reported to inhibit downstream signaling pathways of TLRs148.
 Also, certain viruses including Hepatitis C virus (HCV) and human immunodeficiency 
virus (HIV-1) use rafts and tetraspanin microdomains for virus assembly and budding24 
(reviewed in [149,150]). HCV binds directly to the extracellular loop of tetraspanin 
CD81 to invade not only APCs, but also lymphocytes and hepatocytes. The clinical 
relevance of HCV-CD81 interaction was shown by the capacity of CD81-specific 
antibodies to mediate protection to HCV infection in vivo151. Similarly, blocking CD55 
could prevent host-pathogen interactions146. In addition, cholesterol-sequestering 
agents that interfere with cholesterol biosynthesis (statins) may have therapeutic 
value for patients with infectious disease and sepsis152. Another novel approach is 
the use of recombinant soluble tetraspanin EC2 proteins that may interfere with 
tetraspanin microdomain assembly153 exemplified by their potency to inhibit CCR5-
tropic HIV-1 infection of macrophages154. Taken together, collaboration between 
different PRRs increases the specificity of recognition, extends their signaling 
competence, and enables the host to respond to almost any type of infection. At 
the same time, certain pathogens have evolved mechanisms to take advantage of 
membrane microdomains for their own benefit. The challenge is to translate this 
knowledge into new therapeutic strategies for emerging infectious diseases. 
 The broad influence and the complex role of the tetraspanin web on cell function is 
reflected in the diversity of phenotypes observed in human tetraspanin deficiencies. 
Tetraspanin TM4SF2 is mutated in families with X-linked mental retardation155, and 
mutations in TSPAN12 cause familial exudative vitreoretinopathy156-158. A mutation 
in CD151 leading to loss of the integrin-binding domain, causes defects in assembly 
of basement membranes in kidney and skin. These patients suffer from renal failure, 
pretibial epidermolysis bullosa, sensorineural deafness and β-thalassemia minor159. 
In the immune system, tetraspanin proteins play a crucial role, as demonstrated 
by human tetraspanin deficiencies in CD53 and CD81. Lack of CD53 expression on 
neutrophils was found to be the cause of an immune deficiency syndrome in a family 
which suffered from opportunistic infections and reactivation of chronic silent 
mutations. Although the mechanism underlying this defect in immune cell function 
was not studied, a role for CD53 in the negative regulation of the immune response 
was postulated160. Furthermore, a patient with a gene defect in CD81 was reported 
with severe nephropathy and hypogammaglobulinemia. Absence of CD81 expression 
due to a homozygous splice site mutation resulted in a complete lack of CD19 
expression on B cells. Rescue experiments by transduction of wildtype CD81 into 
the patient B cells showed that the CD81-deficient B cells are able to produce CD19, 
but the maturation and subsequent membrane expression of CD19 are defected in 
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CD81-negative B cells. As a consequence, BCR-mediated stimulation is affected, 
resulting in impaired antibody responses and memory B cell formation139. Taken 
together, defects in individual tetraspanins can result in a wide variety of complex 
phenotypes, and one could speculate that unidentified mutations in tetraspanin 
proteins could be the cause of unexplained human diseases.
Targeted therapy of microdomains
In the last decade, evidence has accumulated that microdomains can be targets 
for novel treatment opportunities. For example, targeting components of lipid 
rafts as therapeutic intervention for cancer has been explored by inhibitors of the 
epidermal growth factor receptor (EGFR) that is overexpressed in breast cancer161. 
In malignancies of the immune system, the B cell marker CD20 has been targeted 
by rituximab, which was shown to be effective against non-Hodgkin’s lymphoma 
and chronic lymphocytic leukemia (CLL) (reviewed in [162]). In lymphoma B cell 
lines, it has been shown that upon binding of rituximab on the cell surface, CD20 
molecules are redistributed to lipid rafts resulting in raft stability and organization, 
and subsequently induction of apoptosis via Src kinase-dependent pathway163,164. 
Rituximab also inhibits BCR signaling by preventing re-localization into lipid rafts165. 
.Although the underlying mechanisms have not thoroughly been investigated, 
lipid raft constituents are being used to predict rituximab treatment affectivity. For 
example, the expression of the raft-associated ganglioside GM1 differs between 
various primary B cell lymphomas, and low GM1 expression has been shown to lead 
to unresponsiveness of lymphoma patients to rituximab treatment166.
 Polyunsaturated fatty acids from fish oil can have a potential therapeutic effect 
for patients suffering from inflammatory or autoimmune diseases, like colitis 
or asthma167. Although the exact underlying mechanisms remain to be defined, 
polyunsaturated fatty acids can enhance B cell function in vivo by increasing MHC 
class II expression and diminishing GM1 microdomain clustering168,169. Lipids in 
microdomains can also serve as a therapeutic target exemplified by mouse anti-
cholesterol antibodies that are specific for clustered cholesterol on the cell surface. 
Binding of this antibody to B cell lymphoma cells in vitro has been reported to recruit 
MHC class II and CD80 molecules into microdomains resulting in effective antigen 
presentation to T cells170.
 TEMs are already targeted by specific antibodies or soluble tetraspanin EC2 
proteins to interfere with viral and bacterial infections as described above. 
Moreover, tetraspanins are currently under detailed investigation as new targets 
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for therapy of hematopoietic malignancies. CD37 is highly expressed on B cells 
and is therefore a candidate therapeutic target for B cell malignancies, like CLL. 
Excitingly, CD37-specific small modular immunopharmaceutical (anti-CD37 SMIP), 
has been shown to induce apoptosis and antibody dependent cellular cytotoxicity in 
lymphoma/leukemia cells in vitro171, and humanized anti-CD37 SMIP is currently in a 
phase I/II clinical trials for relapsed CLL and non-Hodgkin’s lymphoma (http://www.
clinicaltrial.gov/). Anti-CD37 SMIP induces association of CD37 with phosphorylated 
signaling proteins (pSHP1, pLyn and pSrc) within DRMs of CLL patient cells, and 
thereby directly regulates CLL cell death81. Recently, dual-ligand immunoliposomes 
have been tested as a new concept for targeted drug delivery and apoptosis 
in B-CLL cells172. These liposomal nanoconstructs express two types of antibody 
ligands with high affinity for B-CLL cells, such as CD19, CD20, and CD37. The 
antigen expression levels on the cell surface varies between patients and this study 
showed that a combination of anti-CD37 with either anti-CD20 or anti-CD19 led 
to higher binding and delivery efficiency of immunoliposomes than the single-
antibody immunoliposomes. Taken together, these studies show the potential 
of targeting microdomains and provide a solid basis for further research and 
development of new therapies.
Concluding remarks
It is well established that the spatial organization of proteins and lipids in the 
plasma membrane into multi-molecular complexes is fundamental for inter- and 
intracellular communication. In APCs, specialized membrane microdomains are 
emerging as critical players that regulate fundamental immunological processes 
including pathogen recognition, antigen presentation, T cell activation and antibody 
production. Although we are only at the beginning of understanding the biology 
of membrane microdomains in APCs, we anticipate that advanced microscopy 
techniques will provide comprehensive new insights into the formation, dynamics, 
and signaling capacity of these highly specialized membrane structures. In particular, 
pioneering studies at the single molecule level in living cells has revealed that the 
dynamic behavior of components of lipid rafts and TEMs is heterogeneous, ranging 
from rapid diffusion to confinement. This may provide cells with the capacity 
to delicately regulate the formation of immunoreceptor signaling complexes in 
the plasma membrane that are essential for APC function. Indeed, recent studies 
have shown that tetraspanin proteins regulate the mobility of their interacting 
immunoreceptors in the plasma membrane59,60. Since evidence is now accumulating 
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that the development of different human diseases is dependent on early stage 
nanoscale changes of plasma membrane molecules, we envisage the exploitation 
of membrane microdomains as novel therapeutic targets for treatment of infectious 
and malignant diseases. 
Acknowledgements
We thank Geert van den Bogaart and Carl Figdor for critical reading of the 
manuscript. This work is supported by a RUNMC PhD grant. Annemiek van Spriel is 
supported by the Netherlands Organization for Scientific Research (NWO-ALW VIDI 
Grant 864.11.006) and Alessandra Cambi is supported by NWO (Meervoud Grant 
836.09.002), the Human Frontier Science Program (HFSP-RGP0027/2012), and an 
EU grant (Nano-Vista, FP7-2011-7-ICT-288263).
39
1
References
1. Singer SJ, Nicolson GL. The fluid mosaic 
model of the structure of cell membranes. 
Science. 1972;175(4023):720-731.
2. Pike LJ. Rafts defined: a report on the 
Keystone Symposium on Lipid Rafts and Cell 
Function. J Lipid Res. 2006;47(7):1597-1598.
3. Jacobson K, Sheets ED, Simson R. Revisiting 
the fluid mosaic model of membranes. 
Science. 1995;268(5216):1441-1442.
4. Simons K, Ikonen E. Functional rafts in cell 
membranes. Nature. 1997;387(6633):569-
572.
5. Simons K, Sampaio JL. Membrane 
organization and lipid rafts. Cold Spring Harb 
Perspect Biol. 2011;3(10):a004697.
6. Sharma P, Varma R, Sarasij RC, et al. 
Nanoscale organization of multiple GPI-
anchored proteins in living cell membranes. 
Cell. 2004;116(4):577-589.
7. Lingwood D, Simons K. Lipid rafts as a 
membrane-organizing principle. Science. 
2010;327(5961):46-50.
8. Kusumi A, Fujiwara TK, Chadda R, et al. 
Dynamic organizing principles of the plasma 
membrane that regulate signal transduction: 
commemorating the fortieth anniversary of 
Singer and Nicolson’s fluid-mosaic model. 
Annu Rev Cell Dev Biol. 2012;28:215-250.
9. Anderson RG, Jacobson K. A role for lipid 
shells in targeting proteins to caveolae, 
rafts, and other lipid domains. Science. 
2002;296(5574):1821-1825.
10. Palade GE. An electron microscope study 
of the mitochondrial structure. J Histochem 
Cytochem. 1953;1(4):188-211.
11. Yamada E. The fine structure of the gall 
bladder epithelium of the mouse. J Biophys 
Biochem Cytol. 1955;1(5):445-458.
12. van Deurs B, Roepstorff K, Hommelgaard 
AM, Sandvig K. Caveolae: anchored, 
multifunctional platforms in the lipid ocean. 
Trends Cell Biol. 2003;13(2):92-100.
13. Harris J, Werling D, Hope JC, Taylor G, 
Howard CJ. Caveolae and caveolin in immune 
cells: distribution and functions. Trends 
Immunol. 2002;23(3):158-164.
14. Ishikawa H. Formation of elaborate networks 
of T-system tubules in cultured skeletal 
muscle with special reference to the T-system 
formation. J Cell Biol. 1968;38(1):51-66.
15. Werling D, Hope JC, Chaplin P, Collins 
RA, Taylor G, Howard CJ. Involvement 
of caveolae in the uptake of respiratory 
syncytial virus antigen by dendritic cells. J 
Leukoc Biol. 1999;66(1):50-58.
16. Govender P, Romero F, Shah D, et al. Cavin1; 
a regulator of lung function and macrophage 
phenotype. PLoS One. 2013;8(4):e62045.
17. Fu Y, Moore XL, Lee MK, et al. Caveolin-1 
plays a critical role in the differentiation of 
monocytes into macrophages. Arterioscler 
Thromb Vasc Biol. 2012;32(9):e117-125.
18. Rubinstein E, Le Naour F, Lagaudriere-
Gesbert C, Billard M, Conjeaud H, Boucheix C. 
CD9, CD63, CD81, and CD82 are components 
of a surface tetraspan network connected to 
HLA-DR and VLA integrins. Eur J Immunol. 
1996;26(11):2657-2665.
19. Wright MD, Tomlinson MG. The ins and 
outs of the transmembrane 4 superfamily. 
Immunol Today. 1994;15(12):588-594.
20. Yanez-Mo M, Barreiro O, Gordon-Alonso 
M, Sala-Valdes M, Sanchez-Madrid F. 
Tetraspanin-enriched microdomains: a 
functional unit in cell plasma membranes. 
Trends Cell Biol. 2009;19(9):434-446.
21. Hemler ME. Tetraspanin functions and 
associated microdomains. Nat Rev Mol Cell 
Biol. 2005;6(10):801-811.
22. Claas C, Stipp CS, Hemler ME. Evaluation 
of prototype transmembrane 4 superfamily 
protein complexes and their relation to lipid 
rafts. J Biol Chem. 2001;276(11):7974-7984.
23. Boucheix C, Rubinstein E. Tetraspanins. Cell 
Mol Life Sci. 2001;58(9):1189-1205.
40
Membrane landscape shapes APC function
24. Nydegger S, Khurana S, Krementsov DN, Foti 
M, Thali M. Mapping of tetraspanin-enriched 
microdomains that can function as gateways 
for HIV-1. J Cell Biol. 2006;173(5):795-807.
25. Espenel C, Margeat E, Dosset P, et al. 
Single-molecule analysis of CD9 dynamics 
and partitioning reveals multiple modes of 
interaction in the tetraspanin web. J Cell Biol. 
2008;182(4):765-776.
26. Yang X, Claas C, Kraeft SK, et al. Palmitoylation 
of tetraspanin proteins: modulation of CD151 
lateral interactions, subcellular distribution, 
and integrin-dependent cell morphology. Mol 
Biol Cell. 2002;13(3):767-781.
27. Barreiro O, Zamai M, Yanez-Mo M, et al. 
Endothelial adhesion receptors are recruited 
to adherent leukocytes by inclusion in 
preformed tetraspanin nanoplatforms. J Cell 
Biol. 2008;183(3):527-542.
28. Mueller V, Ringemann C, Honigmann A, et al. 
STED nanoscopy reveals molecular details 
of cholesterol- and cytoskeleton-modulated 
lipid interactions in living cells. Biophys J. 
2011;101(7):1651-1660.
29. Helenius A, Simons K. Solubilization of 
membranes by detergents. Biochim Biophys 
Acta. 1975;415(1):29-79.
30. Brown DA, London E. Functions of lipid rafts 
in biological membranes. Annu Rev Cell Dev 
Biol. 1998;14:111-136.
31. Lingwood D, Simons K. Detergent resistance 
as a tool in membrane research. Nat Protoc. 
2007;2(9):2159-2165.
32. Cherukuri A, Shoham T, Sohn HW, et al. The 
tetraspanin CD81 is necessary for partitioning 
of coligated CD19/CD21-B cell antigen 
receptor complexes into signaling-active lipid 
rafts. J Immunol. 2004;172(1):370-380.
33. Akuthota P, Melo RC, Spencer LA, Weller PF. 
MHC Class II and CD9 in human eosinophils 
localize to detergent-resistant membrane 
microdomains. Am J Respir Cell Mol Biol. 
2012;46(2):188-195.
34. Yang X, Kovalenko OV, Tang W, Claas C, Stipp 
CS, Hemler ME. Palmitoylation supports 
assembly and function of integrin-tetraspanin 
complexes. J Cell Biol. 2004;167(6):1231-1240.
35. Le Naour F, Andre M, Boucheix C, Rubinstein 
E. Membrane microdomains and proteomics: 
lessons from tetraspanin microdomains 
and comparison with lipid rafts. Proteomics. 
2006;6(24):6447-6454.
36. Charrin S, Manie S, Thiele C, et al. A physical 
and functional link between cholesterol and 
tetraspanins. Eur J Immunol. 2003;33(9):2479-
2489.
37. Rodal SK, Skretting G, Garred O, Vilhardt F, van 
Deurs B, Sandvig K. Extraction of cholesterol 
with methyl-beta-cyclodextrin perturbs 
formation of clathrin-coated endocytic 
vesicles. Mol Biol Cell. 1999;10(4):961-974.
38. Cambi A, Beeren I, Joosten B, Fransen 
JA, Figdor CG. The C-type lectin DC-SIGN 
internalizes soluble antigens and HIV-1 
virions via a clathrin-dependent mechanism. 
Eur J Immunol. 2009;39(7):1923-1928.
39. Ganguly S, Chattopadhyay A. Cholesterol 
depletion mimics the effect of cytoskeletal 
destabilization on membrane dynamics of 
the serotonin1A receptor: A zFCS study. 
Biophys J. 2010;99(5):1397-1407.
40. Lichtenberg D, Ahyayauch H, Alonso A, Goni 
FM. Detergent solubilization of lipid bilayers: 
a balance of driving forces. Trends Biochem 
Sci. 2013;38(2):85-93.
41. Schuck S, Honsho M, Ekroos K, Shevchenko 
A, Simons K. Resistance of cell membranes to 
different detergents. Proc Natl Acad Sci U S A. 
2003;100(10):5795-5800.
42. Prior IA, Muncke C, Parton RG, Hancock 
JF. Direct visualization of Ras proteins in 
spatially distinct cell surface microdomains. J 
Cell Biol. 2003;160(2):165-170.
43. Wilson BS, Pfeiffer JR, Oliver JM. Observing 
FcepsilonRI signaling from the inside 
of the mast cell membrane. J Cell Biol. 
2000;149(5):1131-1142.
41
1
44. Cambi A, de Lange F, van Maarseveen NM, 
et al. Microdomains of the C-type lectin DC-
SIGN are portals for virus entry into dendritic 
cells. J Cell Biol. 2004;164(1):145-155.
45. Cambi A, Joosten B, Koopman M, et al. 
Organization of the integrin LFA-1 in 
nanoclusters regulates its activity. Mol Biol 
Cell. 2006;17(10):4270-4281.
46. Toomre D, Bewersdorf J. A new wave of 
cellular imaging. Annu Rev Cell Dev Biol. 
2010;26:285-314.
47. van Zanten TS, Cambi A, Garcia-Parajo 
MF. A nanometer scale optical view on the 
compartmentalization of cell membranes. 
Biochim Biophys Acta. 2010;1798(4):777-787.
48. Lidke DS, Lidke KA. Advances in high-
resolution imaging--techniques for three-
dimensional imaging of cellular structures. J 
Cell Sci. 2012;125(Pt 11):2571-2580.
49. van Zanten TS, Cambi A, Koopman M, 
Joosten B, Figdor CG, Garcia-Parajo MF. 
Hotspots of GPI-anchored proteins and 
integrin nanoclusters function as nucleation 
sites for cell adhesion. Proc Natl Acad Sci U S 
A. 2009;106(44):18557-18562.
50. van Zanten TS, Gomez J, Manzo C, et al. 
Direct mapping of nanoscale compositional 
connectivity on intact cell membranes. Proc 
Natl Acad Sci U S A. 2010;107(35):15437-
15442.
51. Eggeling C, Ringemann C, Medda R, et 
al. Direct observation of the nanoscale 
dynamics of membrane lipids in a living cell. 
Nature. 2009;457(7233):1159-1162.
52. Sahl SJ, Leutenegger M, Hilbert M, Hell 
SW, Eggeling C. Fast molecular tracking 
maps nanoscale dynamics of plasma 
membrane lipids. Proc Natl Acad Sci U S A. 
2010;107(15):6829-6834.
53. Sengupta P, Jovanovic-Talisman T, Skoko D, 
Renz M, Veatch SL, Lippincott-Schwartz J. 
Probing protein heterogeneity in the plasma 
membrane using PALM and pair correlation 
analysis. Nat Methods. 2011;8(11):969-975.
54. Lidke DS, Wilson BS. Caught in the act: 
quantifying protein behaviour in living cells. 
Trends Cell Biol. 2009;19(11):566-574.
55. Szollosi J, Horejsi V, Bene L, Angelisova P, 
Damjanovich S. Supramolecular complexes 
of MHC class I, MHC class II, CD20, and 
tetraspan molecules (CD53, CD81, and CD82) 
at the surface of a B cell line JY. J Immunol. 
1996;157(7):2939-2946.
56. Jaqaman K, Kuwata H, Touret N, et al. 
Cytoskeletal control of CD36 diffusion 
promotes its receptor and signaling function. 
Cell. 2011;146(4):593-606.
57. Manzo C, Torreno-Pina JA, Joosten B, et al. 
The neck region of the C-type lectin DC-
SIGN regulates its surface spatiotemporal 
organization and virus-binding capacity 
on antigen-presenting cells. J Biol Chem. 
2012;287(46):38946-38955.
58. Bakker GJ, Eich C, Torreno-Pina JA, et 
al. Lateral mobility of individual integrin 
nanoclusters orchestrates the onset for 
leukocyte adhesion. Proc Natl Acad Sci U S A. 
2012;109(13):4869-4874.
59. Yang XH, Mirchev R, Deng X, et al. CD151 
restricts the alpha6 integrin diffusion mode. 
J Cell Sci. 2012;125(Pt 6):1478-1487.
60. van Spriel AB, de Keijzer S, van der Schaaf A, 
et al. The tetraspanin CD37 orchestrates the 
alpha(4)beta(1) integrin-Akt signaling axis 
and supports long-lived plasma cell survival. 
Sci Signal. 2012;5(250):ra82.
61. Cambi A, Lidke DS. Nanoscale membrane 
organization: where biochemistry meets 
advanced microscopy. ACS Chem Biol. 
2012;7(1):139-149.
62. Groves JT, Kuriyan J. Molecular mechanisms 
in signal transduction at the membrane. Nat 
Struct Mol Biol. 2010;17(6):659-665.
63. Mugler A, Tostevin F, ten Wolde PR. Spatial 
partitioning improves the reliability of 
biochemical signaling. Proc Natl Acad Sci U S 
A. 2013;110(15):5927-5932.
42
Membrane landscape shapes APC function
64. Simons K, Toomre D. Lipid rafts and 
signal transduction. Nat Rev Mol Cell Biol. 
2000;1(1):31-39.
65. Levy S, Shoham T. The tetraspanin web 
modulates immune-signalling complexes. 
Nat Rev Immunol. 2005;5(2):136-148.
66. Zhang XA, Bontrager AL, Hemler ME. 
Transmembrane-4 superfamily proteins 
associate with activated protein kinase 
C (PKC) and link PKC to specific beta(1) 
integrins. J Biol Chem. 2001;276(27):25005-
25013.
67. Suzuki KG. Lipid rafts generate digital-
like signal transduction in cell plasma 
membranes. Biotechnol J. 2012;7(6):753-761.
68. Dykstra M, Cherukuri A, Sohn HW, Tzeng 
SJ, Pierce SK. Location is everything: lipid 
rafts and immune cell signaling. Annu Rev 
Immunol. 2003;21:457-481.
69. Foster LJ, De Hoog CL, Mann M. Unbiased 
quantitative proteomics of lipid rafts reveals 
high specificity for signaling factors. Proc 
Natl Acad Sci U S A. 2003;100(10):5813-5818.
70. Singh G, Hashimoto D, Yan X, et al. R-Ras 
is required for murine dendritic cell 
maturation and CD4+ T-cell priming. Blood. 
2012;119(7):1693-1701.
71. Charrin S, Manie S, Oualid M, Billard M, 
Boucheix C, Rubinstein E. Differential 
stability of tetraspanin/tetraspanin 
interactions: role of palmitoylation. FEBS 
Lett. 2002;516(1-3):139-144.
72. Berditchevski F, Odintsova E, Sawada S, 
Gilbert E. Expression of the palmitoylation-
deficient CD151 weakens the association of 
alpha 3 beta 1 integrin with the tetraspanin-
enriched microdomains and affects 
integrin-dependent signaling. J Biol Chem. 
2002;277(40):36991-37000.
73. Tarrant JM, Robb L, van Spriel AB, Wright 
MD. Tetraspanins: molecular organisers 
of the leukocyte surface. Trends Immunol. 
2003;24(11):610-617.
74. Berditchevski F, Tolias KF, Wong K, Carpenter 
CL, Hemler ME. A novel link between integrins, 
transmembrane-4 superfamily proteins (CD63 
and CD81), and phosphatidylinositol 4-kinase. 
J Biol Chem. 1997;272(5):2595-2598.
75. Yauch RL, Hemler ME. Specific interactions 
among transmembrane 4 superfamily 
(TM4SF) proteins and phosphoinositide 
4-kinase. Biochem J. 2000;351 Pt 3:629-637.
76. Latysheva N, Muratov G, Rajesh S, et al. 
Syntenin-1 is a new component of tetraspanin-
enriched microdomains: mechanisms and 
consequences of the interaction of syntenin-1 
with CD63. Mol Cell Biol. 2006;26(20):7707-
7718.
77. Bosca L, Lazo PA. Induction of nitric oxide 
release by MRC OX-44 (anti-CD53) through 
a protein kinase C-dependent pathway in rat 
macrophages. J Exp Med. 1994;179(4):1119-
1126.
78. Yunta M, Lazo PA. Apoptosis protection 
and survival signal by the CD53 tetraspanin 
antigen. Oncogene. 2003;22(8):1219-1224.
79. Yunta M, Oliva JL, Barcia R, Horejsi V, 
Angelisova P, Lazo PA. Transient activation 
of the c-Jun N-terminal kinase (JNK) activity 
by ligation of the tetraspan CD53 antigen 
in different cell types. Eur J Biochem. 
2002;269(3):1012-1021.
80. Yamada M, Sumida Y, Fujibayashi A, et al. The 
tetraspanin CD151 regulates cell morphology 
and intracellular signaling on laminin-511. 
FEBS J. 2008;275(13):3335-3351.
81. Lapalombella R, Yeh YY, Wang L, et al. 
Tetraspanin CD37 directly mediates 
transduction of survival and apoptotic signals. 
Cancer Cell. 2012;21(5):694-708.
82. Carmo AM, Wright MD. Association of the 
transmembrane 4 superfamily molecule CD53 
with a tyrosine phosphatase activity. Eur J 
Immunol. 1995;25(7):2090-2095.
43
1
83. Chattopadhyay N, Wang Z, Ashman LK, 
Brady-Kalnay SM, Kreidberg JA. alpha3beta1 
integrin-CD151, a component of the 
cadherin-catenin complex, regulates PTPmu 
expression and cell-cell adhesion. J Cell Biol. 
2003;163(6):1351-1362.
84. Imai T, Kakizaki M, Nishimura M, Yoshie O. 
Molecular analyses of the association of CD4 
with two members of the transmembrane 
4 superfamily, CD81 and CD82. J Immunol. 
1995;155(3):1229-1239.
85. van Spriel AB, Puls KL, Sofi M, et al. 
A regulatory role for CD37 in T cell 
proliferation. J Immunol. 2004;172(5): 
2953-2961.
86. Tejera E, Rocha-Perugini V, Lopez-Martin S, 
et al. CD81 regulates cell migration through 
its association with Rac GTPase. Mol Biol Cell. 
2013;24(3):261-273.
87. Douglass AD, Vale RD. Single-molecule 
microscopy reveals plasma membrane 
microdomains created by protein-protein 
networks that exclude or trap signaling 
molecules in T cells. Cell. 2005;121(6): 
937-950.
88. Feinberg H, Guo Y, Mitchell DA, Drickamer 
K, Weis WI. Extended neck regions stabilize 
tetramers of the receptors DC-SIGN and DC-
SIGNR. J Biol Chem. 2005;280(2):1327-1335.
89. Goodridge HS, Reyes CN, Becker CA, et al. 
Activation of the innate immune receptor 
Dectin-1 upon formation of a ‘phagocytic 
synapse’. Nature. 2011;472(7344):471-475.
90. Meyer-Wentrup F, Figdor CG, Ansems M, 
et al. Dectin-1 interaction with tetraspanin 
CD37 inhibits IL-6 production. J Immunol. 
2007;178(1):154-162.
91. Mantegazza AR, Barrio MM, Moutel S, et al. 
CD63 tetraspanin slows down cell migration 
and translocates to the endosomal-
lysosomal-MIICs route after extracellular 
stimuli in human immature dendritic cells. 
Blood. 2004;104(4):1183-1190.
92. Triantafilou M, Miyake K, Golenbock DT, 
Triantafilou K. Mediators of innate immune 
recognition of bacteria concentrate in lipid 
rafts and facilitate lipopolysaccharide-
induced cell activation. J Cell Sci. 2002;115(Pt 
12):2603-2611.
93. Soong G, Reddy B, Sokol S, Adamo R, Prince 
A. TLR2 is mobilized into an apical lipid 
raft receptor complex to signal infection 
in airway epithelial cells. J Clin Invest. 
2004;113(10):1482-1489.
94. Pfeiffer A, Bottcher A, Orso E, et al. 
Lipopolysaccharide and ceramide 
docking to CD14 provokes ligand-specific 
receptor clustering in rafts. Eur J Immunol. 
2001;31(11):3153-3164.
95. Suzuki M, Tachibana I, Takeda Y, et al. 
Tetraspanin CD9 negatively regulates 
lipopolysaccharide-induced macrophage 
activation and lung inflammation. J Immunol. 
2009;182(10):6485-6493.
96. Heit B, Kim H, Cosio G, et al. Multimolecular 
signaling complexes enable Syk-mediated 
signaling of CD36 internalization. Dev Cell. 
2013;24(4):372-383.
97. Toyo-oka K, Yashiro-Ohtani Y, Park CS, et 
al. Association of a tetraspanin CD9 with 
CD5 on the T cell surface: role of particular 
transmembrane domains in the association. 
Int Immunol. 1999;11(12):2043-2052.
98. Figdor CG, van Spriel AB. Fungal pattern-
recognition receptors and tetraspanins: 
partners on antigen-presenting cells. Trends 
Immunol. 2010;31(3):91-96.
99. Hontelez S, Sanecka A, Netea MG, van Spriel 
AB, Adema GJ. Molecular view on PRR cross-
talk in antifungal immunity. Cell Microbiol. 
2012;14(4):467-474.
100. Lee MS, Kim YJ. Signaling pathways 
downstream of pattern-recognition 
receptors and their cross talk. Annu Rev 
Biochem. 2007;76:447-480.
44
Membrane landscape shapes APC function
101. Gantner BN, Simmons RM, Canavera 
SJ, Akira S, Underhill DM. Collaborative 
induction of inflammatory responses by 
dectin-1 and Toll-like receptor 2. J Exp Med. 
2003;197(9):1107-1117.
102. Timmermans K, Plantinga TS, Kox M, et al. 
Blueprints of signaling interactions between 
pattern recognition receptors: implications 
for the design of vaccine adjuvants. Clin 
Vaccine Immunol. 2013;20(3):427-432.
103. Rogers NC, Slack EC, Edwards AD, et al. 
Syk-dependent cytokine induction by 
Dectin-1 reveals a novel pattern recognition 
pathway for C type lectins. Immunity. 
2005;22(4):507-517.
104. Brown JH, Jardetzky TS, Gorga JC, et al. 
Three-dimensional structure of the human 
class II histocompatibility antigen HLA-DR1. 
Nature. 1993;364(6432):33-39.
105. Schafer PH, Pierce SK. Evidence for dimers 
of MHC class II molecules in B lymphocytes 
and their role in low affinity T cell responses. 
Immunity. 1994;1(8):699-707.
106. Jenei A, Varga S, Bene L, et al. HLA class 
I and II antigens are partially co-clustered 
in the plasma membrane of human 
lymphoblastoid cells. Proc Natl Acad Sci U S 
A. 1997;94(14):7269-7274.
107. Turley SJ, Inaba K, Garrett WS, et al. 
Transport of peptide-MHC class II complexes 
in developing dendritic cells. Science. 
2000;288(5465):522-527.
108. Bosch B, Heipertz EL, Drake JR, Roche 
PA. Major Histocompatibility Complex 
(MHC) Class II-Peptide Complexes 
Arrive at the Plasma Membrane in 
Cholesterol-rich Microclusters. J Biol Chem. 
2013;288(19):13236-13242.
109. Vogt AB, Spindeldreher S, Kropshofer H. 
Clustering of MHC-peptide complexes prior 
to their engagement in the immunological 
synapse: lipid raft and tetraspan 
microdomains. Immunol Rev. 2002; 
189:136-151.
110. Anderson HA, Hiltbold EM, Roche PA. 
Concentration of MHC class II molecules in 
lipid rafts facilitates antigen presentation. 
Nat Immunol. 2000;1(2):156-162.
111. Angelisova P, Hilgert I, Horejsi V. Association 
of four antigens of the tetraspans family 
(CD37, CD53, TAPA-1, and R2/C33) with 
MHC class II glycoproteins. Immunogenetics. 
1994;39(4):249-256.
112. Escola JM, Kleijmeer MJ, Stoorvogel W, 
Griffith JM, Yoshie O, Geuze HJ. Selective 
enrichment of tetraspan proteins on 
the internal vesicles of multivesicular 
endosomes and on exosomes secreted 
by human B-lymphocytes. J Biol Chem. 
1998;273(32):20121-20127.
113. Hammond C, Denzin LK, Pan M, Griffith 
JM, Geuze HJ, Cresswell P. The tetraspan 
protein CD82 is a resident of MHC class II 
compartments where it associates with HLA-
DR, -DM, and -DO molecules. J Immunol. 
1998;161(7):3282-3291.
114. Engering A, Pieters J. Association of distinct 
tetraspanins with MHC class II molecules 
at different subcellular locations in human 
immature dendritic cells. Int Immunol. 
2001;13(2):127-134.
115. Mittelbrunn M, Yanez-Mo M, Sancho D, 
Ursa A, Sanchez-Madrid F. Cutting edge: 
dynamic redistribution of tetraspanin CD81 
at the central zone of the immune synapse 
in both T lymphocytes and APC. J Immunol. 
2002;169(12):6691-6695.
116. Unternaehrer JJ, Chow A, Pypaert M, Inaba 
K, Mellman I. The tetraspanin CD9 mediates 
lateral association of MHC class II molecules 
on the dendritic cell surface. Proc Natl Acad 
Sci U S A. 2007;104(1):234-239.
117. Khandelwal S, Roche PA. Distinct MHC class 
II molecules are associated on the dendritic 
cell surface in cholesterol-dependent 
membrane microdomains. J Biol Chem. 
2010;285(46):35303-35310.
45
1
118. Vrljic M, Nishimura SY, Moerner WE, 
McConnell HM. Cholesterol depletion 
suppresses the translational diffusion of 
class II major histocompatibility complex 
proteins in the plasma membrane. 
Biophys J. 2005;88(1):334-347.
119. Umemura YM, Vrljic M, Nishimura SY, 
Fujiwara TK, Suzuki KG, Kusumi A. Both MHC 
class II and its GPI-anchored form undergo 
hop diffusion as observed by single-molecule 
tracking. Biophys J. 2008;95(1):435-450.
120. Kropshofer H, Spindeldreher S, Rohn TA, et 
al. Tetraspan microdomains distinct from 
lipid rafts enrich select peptide-MHC class II 
complexes. Nat Immunol. 2002;3(1):61-68.
121. Drbal K, Angelisova P, Rasmussen AM, 
Hilgert I, Funderud S, Horejsi V. The nature 
of the subset of MHC class II molecules 
carrying the CDw78 epitopes. Int Immunol. 
1999;11(4):491-498.
122. Poloso NJ, Denzin LK, Roche PA. CDw78 
defines MHC class II-peptide complexes 
that require Ii chain-dependent lysosomal 
trafficking, not localization to a specific 
tetraspanin membrane microdomain. 
J Immunol. 2006;177(8):5451-5458.
123. Hoorn T, Paul P, Janssen L, Janssen H, Neefjes 
J. Dynamics within tetraspanin pairs affect 
MHC class II expression. J Cell Sci. 2012;125(Pt 
2):328-339.
124. Sheng KC, van Spriel AB, Gartlan KH, 
et al. Tetraspanins CD37 and CD151 
differentially regulate Ag presentation and 
T-cell co-stimulation by DC. Eur J Immunol. 
2009;39(1):50-55.
125. Gartlan KH, Belz GT, Tarrant JM, et al. 
A complementary role for the tetraspanins 
CD37 and Tssc6 in cellular immunity. 
J Immunol. 2010;185(6):3158-3166.
126. Reth M, Wienands J. Initiation and processing 
of signals from the B cell antigen receptor. 
Annu Rev Immunol. 1997;15:453-479.
127. Cheng PC, Dykstra ML, Mitchell RN, Pierce 
SK. A role for lipid rafts in B cell antigen 
receptor signaling and antigen targeting. J 
Exp Med. 1999;190(11):1549-1560.
128. Gupta N, DeFranco AL. Visualizing lipid raft 
dynamics and early signaling events during 
antigen receptor-mediated B-lymphocyte 
activation. Mol Biol Cell. 2003;14(2):432-444.
129. Sohn HW, Tolar P, Pierce SK. Membrane 
heterogeneities in the formation of B cell 
receptor-Lyn kinase microclusters and the 
immune synapse. J Cell Biol. 2008;182(2): 
367-379.
130. Cheng PC, Brown BK, Song W, Pierce SK. 
Translocation of the B cell antigen receptor 
into lipid rafts reveals a novel step in 
signaling. J Immunol. 2001;166(6):3693-3701.
131. Tedder TF, Inaoki M, Sato S. The CD19-
CD21 complex regulates signal transduction 
thresholds governing humoral immunity and 
autoimmunity. Immunity. 1997;6(2):107-118.
132. Cherukuri A, Cheng PC, Sohn HW, Pierce 
SK. The CD19/CD21 complex functions to 
prolong B cell antigen receptor signaling 
from lipid rafts. Immunity. 2001;14(2): 
169-179.
133. Stoddart A, Dykstra ML, Brown BK, Song 
W, Pierce SK, Brodsky FM. Lipid rafts 
unite signaling cascades with clathrin to 
regulate BCR internalization. Immunity. 
2002;17(4):451-462.
134. Chaturvedi A, Martz R, Dorward D, Waisberg 
M, Pierce SK. Endocytosed BCRs sequentially 
regulate MAPK and Akt signaling pathways 
from intracellular compartments. Nat 
Immunol. 2011;12(11):1119-1126.
135. Shoham T, Rajapaksa R, Boucheix C, et al. 
The tetraspanin CD81 regulates the 
expression of CD19 during B cell 
development in a postendoplasmic reticulum 
compartment. J Immunol. 2003;171(8): 
4062-4072.
46
Membrane landscape shapes APC function
136. Maecker HT, Levy S. Normal lymphocyte 
development but delayed humoral immune 
response in CD81-null mice. J Exp Med. 
1997;185(8):1505-1510.
137. Miyazaki T, Muller U, Campbell KS. Normal 
development but differentially altered 
proliferative responses of lymphocytes in 
mice lacking CD81. EMBO J. 1997;16(14):4217-
4225.
138. Tsitsikov EN, Gutierrez-Ramos JC, Geha RS. 
Impaired CD19 expression and signaling, 
enhanced antibody response to type II T 
independent antigen and reduction of B-1 
cells in CD81-deficient mice. Proc Natl Acad 
Sci U S A. 1997;94(20):10844-10849.
139. van Zelm MC, Smet J, Adams B, et al. 
CD81 gene defect in humans disrupts 
CD19 complex formation and leads 
to antibody deficiency. J Clin Invest. 
2010;120(4):1265-1274.
140. Cherukuri A, Carter RH, Brooks S, et al. 
B cell signaling is regulated by induced 
palmitoylation of CD81. J Biol Chem. 
2004;279(30):31973-31982.
141. Treanor B, Depoil D, Gonzalez-Granja A, 
et al. The membrane skeleton controls 
diffusion dynamics and signaling through 
the B cell receptor. Immunity. 2010;32(2): 
187-199.
142. Treanor B, Depoil D, Bruckbauer A, Batista 
FD. Dynamic cortical actin remodeling by 
ERM proteins controls BCR microcluster 
organization and integrity. J Exp Med. 
2011;208(5):1055-1068.
143. Freeman SA, Lei V, Dang-Lawson M, Mizuno 
K, Roskelley CD, Gold MR. Cofilin-mediated 
F-actin severing is regulated by the Rap 
GTPase and controls the cytoskeletal 
dynamics that drive lymphocyte spreading 
and BCR microcluster formation. J Immunol. 
2011;187(11):5887-5900.
144. Viola A, Gupta N. Tether and trap: regulation 
of membrane-raft dynamics by actin-binding 
proteins. Nat Rev Immunol. 2007;7(11):889-
896.
145. Mattila PK, Feest C, Depoil D, et al. The 
actin and tetraspanin networks organize 
receptor nanoclusters to regulate B cell 
receptor-mediated signaling. Immunity. 
2013;38(3):461-474.
146. Manes S, del Real G, Martinez AC. 
Pathogens: raft hijackers. Nat Rev Immunol. 
2003;3(7):557-568.
147. Shin JS, Gao Z, Abraham SN. Involvement of 
cellular caveolae in bacterial entry into mast 
cells. Science. 2000;289(5480):785-788.
148. Fessler MB, Parks JS. Intracellular lipid flux 
and membrane microdomains as organizing 
principles in inflammatory cell signaling. J 
Immunol. 2011;187(4):1529-1535.
149. Martin F, Roth DM, Jans DA, et al. Tetraspanins 
in viral infections: a fundamental role in viral 
biology? J Virol. 2005;79(17):10839-10851.
150. van Spriel AB, Figdor CG. The role of 
tetraspanins in the pathogenesis of infectious 
diseases. Microbes Infect. 2010;12(2):106-
112.
151. Meuleman P, Hesselgesser J, Paulson M, 
et al. Anti-CD81 antibodies can prevent a 
hepatitis C virus infection in vivo. Hepatology. 
2008;48(6):1761-1768.
152. Terblanche M, Almog Y, Rosenson RS, Smith 
TS, Hackam DG. Statins: panacea for sepsis? 
Lancet Infect Dis. 2006;6(4):242-248.
153. Hemler ME. Targeting of tetraspanin 
proteins--potential benefits and strategies. 
Nat Rev Drug Discov. 2008;7(9):747-758.
154. Ho SH, Martin F, Higginbottom A, et al. 
Recombinant extracellular domains of 
tetraspanin proteins are potent inhibitors 
of the infection of macrophages by human 
immunodeficiency virus type 1. J Virol. 
2006;80(13):6487-6496.
155. Zemni R, Bienvenu T, Vinet MC, et al. 
A new gene involved in X-linked mental 
retardation identified by analysis of an 
X;2 balanced translocation. Nat Genet. 
2000;24(2):167-170.
47
1
156. Poulter JA, Ali M, Gilmour DF, et al. Mutations 
in TSPAN12 cause autosomal-dominant 
familial exudative vitreoretinopathy. Am J 
Hum Genet. 2010;86(2):248-253.
157. Nikopoulos K, Gilissen C, Hoischen A, 
et al. Next-generation sequencing of a 
40 Mb linkage interval reveals TSPAN12 
mutations in patients with familial exudative 
vitreoretinopathy. Am J Hum Genet. 
2010;86(2):240-247.
158. Junge HJ, Yang S, Burton JB, et al. TSPAN12 
regulates retinal vascular development 
by promoting Norrin- but not Wnt-
induced FZD4/beta-catenin signaling. Cell. 
2009;139(2):299-311.
159. Karamatic Crew V, Burton N, Kagan A, 
et al. CD151, the first member of the 
tetraspanin (TM4) superfamily detected 
on erythrocytes, is essential for the correct 
assembly of human basement membranes 
in kidney and skin. Blood. 2004;104(8): 
2217-2223.
160. Mollinedo F, Fontan G, Barasoain I, Lazo 
PA. Recurrent infectious diseases in human 
CD53 deficiency. Clin Diagn Lab Immunol. 
1997;4(2):229-231.
161. Irwin ME, Mueller KL, Bohin N, Ge Y, Boerner 
JL. Lipid raft localization of EGFR alters the 
response of cancer cells to the EGFR tyrosine 
kinase inhibitor gefitinib. J Cell Physiol. 
2011;226(9):2316-2328.
162. Hagemeister F. Rituximab for the 
treatment of non-Hodgkin’s lymphoma 
and chronic lymphocytic leukaemia. Drugs. 
2010;70(3):261-272.
163. Semac I, Palomba C, Kulangara K, et al. 
Anti-CD20 therapeutic antibody rituximab 
modifies the functional organization of rafts/
microdomains of B lymphoma cells. Cancer 
Res. 2003;63(2):534-540.
164. Deans JP, Li H, Polyak MJ. CD20-mediated 
apoptosis: signalling through lipid rafts. 
Immunology. 2002;107(2):176-182.
165. Kheirallah S, Caron P, Gross E, et al. 
Rituximab inhibits B-cell receptor signaling. 
Blood. 2010;115(5):985-994.
166. Meyer zum Buschenfelde C, Feuerstacke 
Y, Gotze KS, Scholze K, Peschel C. GM1 
expression of non-Hodgkin’s lymphoma 
determines susceptibility to rituximab 
treatment. Cancer Res. 2008;68(13): 
5414-5422.
167. Galli C, Calder PC. Effects of fat and fatty 
acid intake on inflammatory and immune 
responses: a critical review. Ann Nutr Metab. 
2009;55(1-3):123-139.
168. Gurzell EA, Teague H, Harris M, Clinthorne 
J, Shaikh SR, Fenton JI. DHA-enriched fish 
oil targets B cell lipid microdomains and 
enhances ex vivo and in vivo B cell function. J 
Leukoc Biol. 2013;93(4):463-470.
169. Shaikh SR, Jolly CA, Chapkin RS. n-3 
Polyunsaturated fatty acids exert 
immunomodulatory effects on lymphocytes 
by targeting plasma membrane 
molecular organization. Mol Aspects Med. 
2012;33(1):46-54.
170. Izsepi E, Balogh A, Farkas A, et al. The AC8 
IgG3 monoclonal anti-cholesterol antibody 
modulates uptake and presentation of 
antigens for T cell activation. Immunol Lett. 
2012;143(1):106-115.
171. Zhao X, Lapalombella R, Joshi T, et 
al. Targeting CD37-positive lymphoid 
malignancies with a novel engineered small 
modular immunopharmaceutical. Blood. 
2007;110(7):2569-2577.
172. Yu B, Mao Y, Yuan Y, et al. Targeted 
drug delivery and cross-linking induced 
apoptosis with anti-CD37 based dual-
ligand immunoliposomes in B chronic 
lymphocytic leukemia cells. Biomaterials. 
2013;34(26):6185-6193.

Chapter 2
Multispectral imaging reveals the 
tissue distribution of tetraspanins 
in lymphoid organs
Charlotte M de Winde*, Malou Zuidscherwoude*, Angela Vasaturo, 
Alie van der Schaaf, Carl G Figdor, Annemiek B van Spriel
*Authors contributed equally
Journal of Leukocyte Biology, 2014, 95:251-63
50
Multispectral imaging of CD37 and CD53
Abstract
Multispectral imaging is a novel microscopy technique that combines imaging with 
spectroscopy to obtain both quantitative expression data and tissue distribution 
of different cellular markers. Tetraspanins CD37 and CD53 are four-transmembrane 
proteins involved in cellular and humoral immune responses. However, comprehensive 
immunohistochemical analyses of CD37 and CD53 in human lymphoid organs have 
not been performed so far. We investigated CD37 and CD53 protein expression on 
primary human immune cell subsets in blood and in primary and secondary lymphoid 
organs. Both tetraspanins were prominently expressed on antigen-presenting 
cells, with highest expression of CD37 on B lymphocytes. Analysis of subcellular 
distribution showed presence of both tetraspanins on the plasma membrane and on 
endosomes. In addition, CD53 was also present on lysosomes. Quantitative analysis 
of expression and localization of CD37 and CD53 on lymphocytes within lymphoid 
tissues by multispectral imaging revealed high expression of both tetraspanins 
on CD20+ cells in B cell follicles in human spleen and appendix. CD3+ T cells within 
splenic T cell zones expressed lower levels of CD37 and CD53 compared to T cells in 
the red pulp of human spleen. B cells in human bone marrow highly expressed CD37, 
whereas the expression of CD53 was low. In conclusion, we demonstrate differential 
expression of CD37 and CD53 on primary human immune cells, their subcellular 
localization, and their quantitative distribution in human lymphoid organs. This 
study provides a solid basis for better insight into the function of tetraspanins in the 
human immune response.
51
2
Introduction
The specific cellular architecture of primary and secondary lymphoid organs aids in 
the complex coordination of the initiation of the immune response against a wide 
variety of pathogens and tumor cells. The microarchitecture of lymphoid organs is 
highly dynamic and its structure changes constantly upon antigen encountering. 
Whereas primary lymphoid organs (bone marrow, thymus) are the major sites 
of lymphocyte development, secondary lymphoid organs (spleen, lymph nodes 
and mucosal-associated lymphoid tissues, like appendix) provide a sophisticated 
environment in which immune cells interact with each other, as well as with 
accessory cells and antigens. Secondary lymphoid organs have a remarkably similar 
microanatomy under homeostatic conditions in which essentially three different 
regions can be distinguished1. The outermost region is the antigen-sampling region 
where antigen-presenting cells, including macrophages and dendritic cells (DCs), 
sample and deliver antigens to the B and T cell areas. The outer cortex contains 
predominantly B cell follicles, where germinal centers (GCs) can develop and the 
inner cortex which comprises mainly T cells. A specialized conduit system, formed 
by interconnected fibroblastic reticular cells, supports migration of DCs and 
lymphocytes through different areas of the lymphoid organs to interact with other 
immune cells. In addition, this system provides a tubular network for distribution of 
small soluble antigens and immune modulators enabling communication between 
the antigen-sampling zone and the T cell zone2. 
 Cell-cell communication and immune cell migration is controlled by a wide 
variety of different immunoreceptors embedded in the plasma membrane. These 
immunoreceptors are non-randomly distributed in the plasma membrane by 
means of specialized membrane domains3. This compartmentalization is essential 
for immune cell function, including pathogen recognition, antigen presentation 
and migration. Tetraspanin-enriched microdomains (TEM) are functional multi-
molecular complexes in the plasma membrane4–7 in which tetraspanins interact 
with each other and with partner molecules, like transmembrane immunoreceptors, 
enzymes and signaling proteins. Tetraspanin proteins belong to the superfamily 
of four-transmembrane proteins that are expressed at the cell surface and in 
intracellular membranes. To date, 33 different tetraspanins have been characterized 
in humans of which tetraspanins CD37 and CD53 are specific for the immune system5. 
Tetraspanin CD37 has been studied extensively in CD37-deficient (Cd37-/-) mice in 
which both the cellular and humoral arms of the immune system are defective. CD37 
inhibits T cell proliferation8, interleukin-6 production by macrophages9, and antigen 
presentation by DCs10. Moreover, CD37 tightly regulates antibody production 
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by B cells11. Cd37-/- mice have a strikingly increased number of IgA+ plasma cells 
in their lymphoid organs, whereas the number of IgG+ plasma cells is low due to 
decreased survival signals in the GCs of the spleen11,12. The function of tetraspanin 
CD53 has not been well studied although recurrent infections have been reported 
in a CD53-deficient family13. The underlying mechanism of tetraspanin function has 
been attributed to specific interactions between tetraspanins and immunoreceptors 
(major histocompatibility complex (MHC) proteins, B cell receptor (BCR), integrins, 
and others) in the plasma membrane.
 Despite the importance of tetraspanins in the immune system, little is known about 
their expression and micro-anatomical location. In this study, tetraspanins CD37 
and CD53 were selected as these are amongst all tetraspanins exclusively present 
in the immune system. We report their membrane and intracellular expression on 
primary human blood immune cell subsets. Furthermore, we performed detailed 
quantitative immunohistochemical analyses using multispectral imaging to reveal 
tetraspanin expression and localization in human primary and secondary lymphoid 
organs. This novel technique allows for direct unbiased overview of different tissues 
with the main advantage that, next to information on the single cell expression level, 
the differential tissue localization of individual cell subsets can be studied.
Materials and methods
Cells
Cells were obtained from buffy coats of healthy individuals with informed consent in 
accordance with institutional and international guidelines following the Declaration 
of Helsinki. Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll 
density centrifugation. PBMCs were cultured in RPMI-1640 supplemented with 
2% human serum (HS) in Costar culture flasks (1x108 cells / 75cm2 flask) to adhere 
monocytes for 1 hour at 37°C. After removal of peripheral blood lymphocytes (PBLs), 
monocytes were harvested with cold PBS. 
Flow cytometry
Single cell suspensions were first stained with primary antibodies against human 
CD53 (mem53, Serotec), CD37 (WR17, home-made) or isotype controls in PBS with 
1% BSA and 0.05% NaN
3
 (PBA) supplemented with 2% HS for 30 min at 4°C, followed 
by incubation with goat-anti-mouse Alexa488 antibody (Molecular Probes). Next, 
cells were stained with the following anti-human antibodies: CD3-PE (HIT3a, Becton 
Dickinson), CD4-APC (RPA-T4, Biolegend), CD8-PerCP (SK1, Becton Dickinson), 
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CD20-APC (2H7, eBioscience), CD14-PE (CLB-mon/1, Pelicluster, Sanquin), CD56-
APC (NCAM16.2, Becton Dickinson), CD19-PerCP (4G7, Becton Dickinson), BDCA1-
FITC (AD5-8E7, Miltenyi) and/or BDCA2-FITC (AC144, Miltenyi). Stained cells were 
analyzed using FACS Calibur (Becton Dickinson) and FlowJo software (version 9.7, 
TreeStar Inc.).
Confocal microscopy
Fibronectin-coated coverslips were made by incubation of 20μg/mL fibronectin 
(Roche) in PBS for 1 hour at 37°C. Monocytes were adhered on fibronectin-coated 
coverslips for 2 hours and subsequently fixed with 2% paraformaldehyde (PFA) and 
blocked with 3% bovine serum albumin (BSA), 1% HS and 10mM glycine in PBS for 30 
min at room temperature (RT). Cells were permeabilized and stained with antibodies 
against CD53 (mem53, Serotec), CD37 (WR17, home-made), calreticulin (ER marker, 
Sigma), syntaxin 12/13 (endosome marker, Synaptic Systems (cat. no. 110132)) and 
Lamp1 (lysosome marker, Sigma-Aldrich) in 0.5% saponin, 1% BSA, 10mM glycine, 
1% HS in PBS, followed by goat-anti-mouse Alexa488 and goat-anti-rabbit Alexa647 
(Molecular Probes). Samples were imaged with an Olympus FV1000 Confocal Laser 
Scanning Microscope. Images were analyzed using Fiji software14.
Tissues
Human spleen samples were obtained from deceased human kidney donors and 
bone marrow and appendix samples were obtained from healthy donors, which was 
approved by the medical ethical committee for human research (Radboudumc, The 
Netherlands). All tissue samples were formalin-fixed, paraffin-embedded, and cut in 
4μm sections according to standard procedures15.
Immunofluorescence
Tissues were deparaffinized, followed by antigen retrieval using 10mM citrate buffer 
and blocked with 10% normal goat serum (NGS) in PBA for 1 hour at RT. Tissues were 
first stained with antibodies against human CD37 (clone 2B8, Thermo Scientific) or 
CD53 (clone EPR4342(2), GenTex) diluted in 2% NGS in PBA for 1 hour at RT, followed 
by incubation with Alexa-conjugated secondary antibodies diluted in 1% NGS in PBA 
for 1 hour at RT. For nuclear staining, tissues were incubated for 5 min with DAPI 
(diluted 1:3000 in PBS). Tissue slides were fixed in 1% PFA in PBS for 15 min at RT and 
embedded in Mowiol mounting medium.
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Immunohistochemistry
Tissues were deparaffinized, followed by antigen retrieval using 10mM citrate buffer, 
and blocked with 3% hydrogen peroxidase (H2O2) in methanol for 10 min at RT. 
Tissues were blocked with 2% HS in Tris-buffered saline (TBS) with 1% BSA for 45 min 
at RT, and stained with primary antibodies against human CD3 (clone CD3-12, AbD 
Serotec) or CD20 (clone L26, Thermo Scientific) diluted in TBS supplemented with 
1% BSA overnight at 4°C. Next, tissues were incubated with biotinylated secondary 
antibodies diluted in TBS with 1% BSA, 1% HS and 1% NGS or normal horse serum 
(NHS) for 45 min at RT. After 1 hour incubation with avidin- and biotin-conjugated 
alkaline phosphatase (ABC-AP) solution, red color was developed by incubation 
with Warp Red Solution for 10 min. Secondly, tissues were stained with antibodies 
against human CD37 (clone 2B8, Thermo Scientific) or CD53 (clone EPR4342(2), 
GenTex) diluted in PBS, 1% BSA, 2% HS for 45 min at RT, followed by incubation with 
biotinylated secondary antibodies in TBS with 1% BSA, 1% HS and 1% NHS or NGS 
for 45 min at RT. After 1h incubation with avidin- and biotin-conjugated horseradish 
peroxidase (ABC-HRP) solution, blue color was developed by incubation with True 
Blue peroxidase substrate for 8 min. For technical reasons, CD20 and CD37 could not 
be stained on the same slide, as such single stainings for CD37 were performed. For 
nuclear staining, tissues were incubated for 1 min with Nuclear Red. Dried sections 
were embedded in Permount. 
Multispectral imaging and quantitative digital analysis
Tissue slides were imaged using Vectra Intelligent Slide Analysis System (Version 2.0.8, 
PerkinElmer Inc.). This imaging technique combines imaging with spectroscopy where 
the entire spectrum is collected at every location of the image plane in an automatic 
manner. Images of single stained tissues for each fluorophore or chromogen, with its 
own unique spectral characteristics, were used to built spectral libraries with Nuance 
Multispectral Imaging System (Version 3.0.2, PerkinElmer Inc.). For correction of 
autofluorescence, an image was made from unstained human spleen tissue and the 
autofluorescence signal was subtracted from the spectrum for each fluorophore. 
These spectral libraries were used to unmix the original multispectral images obtained 
with the Vectra imaging system. Two red chromogens (Warp Red and Nuclear Red) 
with highly similar spectra were used of which correct unmixing has been described 
before16. A selection of 10 representative original multispectral images was used to 
train the inForm Advanced Image Analysis Software (Version 2.0.2, PerkinElmer Inc.) 
for quantitative image analysis (tissue and cell segmentation, quantification of the 
expression levels of proteins of interest) as described before17,18. The threshold for 
dim or bright tetraspanin expression was determined by objective examination of the 
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staining intensity of non-immune cells in true blue negative regions. All the settings 
applied to the training images were saved within an algorithm allowing batch analysis 
of multiple original multispectral images of different samples of the same origin 
equally stained. The number of images used for quantification and statistical analysis 
of CD37 and CD53 distribution was dependent on the acquisition of the tissue slides 
during imaging (i.e. the position of the tissue on the coverslip can vary, leading to 
acquisition of less or more images). If 20x images contained less than 10% of tissue, 
these images were discarded from the analysis. Since not all 20x images contained B 
cell follicles or T cell regions, a higher number of images were analyzed for red pulp or 
lamina propria regions (Supplementary Table 1).
Statistics
Statistical differences of tetraspanin expression between different tissue regions in 
human lymphoid organs were determined using the unpaired Student’s t-test or, 
in case of a non-Gaussian distribution, the Mann-Whitney test (GraphPad Prism 5, 
GraphPad Software, San Diego, CA). All differences with P≤0.05 were considered to 
be statistically significant.
Results
Expression of CD37 and CD53 on immune cell subsets in blood
To investigate cell surface expression of tetraspanins CD37 and CD53 on the plasma 
membrane of different immune cell subsets in blood, PBLs were stained for CD4 
(T cells), CD8/CD3/CD56- (T cells), CD20 (B cells), CD14 (monocytes), CD56/CD3-/
CD8- (NK cells) and BDCA1/CD19- (myeloid DC (mDC)) and BDCA2 (plasmacytoid 
DC (pDC)) (Supplementary Figure 1). We observed the highest CD37 expression on B 
cells and low to medium expression on T cells, monocytes and NK cells (Figure 1A-B). 
CD53 was expressed on all subsets, with highest expression on B cells and monocytes 
(Figure 1A & C). CD37 and CD53 were expressed on both mDCs and pDCs, with no 
apparent differences in expression level between the two DC subsets (Figure 1D-F). It 
has been reported that tetraspanins can be expressed at intracellular membranes19,20, 
which stimulated us to investigate the subcellular localization of CD37 and CD53. 
Monocytes were double stained with CD37 or CD53 antibodies in combination with 
antibodies specific for the endoplasmatic reticulum (ER), endosomes or lysosomes. 
Next to the expression on the plasma membrane, both CD37 and CD53 were 
abundantly expressed in the endosomes, in contrast to the ER (Figure 2A-B). In the 
lysosomes, we observed only CD53 to be present.
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^ Figure 1. Expression of CD37 and CD53 on immune cell subsets in blood. (A) Flow cytometry 
analysis of expression of CD37 or CD53 (black line) on CD4 and CD8 T cells, B cells, monocytes 
and NK cells versus isotype control (grey line). Gating strategy is presented in Supplementary 
Figure 1. (B-C) Expression levels of CD37 (B) and CD53 (C) were normalized for isotype staining 
by background subtraction. Experiments were performed with PBLs from three healthy donors. 
Data present mean±SD. (D) Flow cytometry analysis of expression of CD37 or CD53 (black line) 
on mDCs (BDCA1+CD19-) or pDCs (BDCA2+) versus isotype control (grey line). (E-F) Expression 
levels of CD37 (E) and CD53 (F) were normalized for isotype staining by background subtraction. 
Experiments were performed with PBLs from two healthy donors. Data present mean±SD.
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^  Figure 2. Subcellular localization of CD37 and CD53. (A-B) Localization of (A) CD37 or (B) CD53 
(green) in monocytes was studied by dual staining with calreticulin (ER), syntaxin13 (endosomes) 
or lamp1 (lysosomes) (red). Merge: co-localization in yellow (white arrows). Scale bar = 5μm.
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Multispectral analyses of human lymphoid organs
We investigated the tissue distribution of CD37 and CD53 in human lymphoid 
organs by multispectral imaging. In contrast to classical immunohistochemistry, 
multispectral imaging directly provides quantitative information into the differential 
tissue distribution of individual cell subsets. First, we investigated localization of 
CD37 and CD53 in human spleen. We observed that CD37 was more locally expressed 
in follicle-like structures when compared to CD53 which showed a more dispersed 
expression profile (Figure 3A-E). To explore this in more detail, we performed double 
stainings of either the T cell marker CD3 or the B cell marker CD20 combined with 
CD37 or CD53 on primary (bone marrow) and secondary (spleen and appendix) 
lymphoid tissues. Figure 4 illustrates the technology of multispectral imaging 
and analysis of lymphoid tissue stained for the B cell marker CD20 (Warp Red), 
tetraspanin CD53 (True Blue) and cell nuclei (Nuclear Red). Single stained tissues 
for each chromogen (Warp Red, True Blue and Nuclear Red) were used to create 
a spectral library containing the specific spectra of each used chromogen (Figure 
4A) allowing to unmix the original multispectral images (Figure 4B). This resulted 
in separate images for each marker (Figure 4D-F) that were used to generate the 
composite RGB image (Figure 4C). We made use of two red chromogens (Warp Red 
and Nuclear Red) with highly similar spectra of which correct unmixing has been 
described before16. Next, analysis software was trained using 10 representative 
original multispectral images to segment the different tissue regions (B cell follicle 
and stromal tissue (red pulp in spleen or lamina propria in appendix)) based on a 
combination of parameters including cell morphology and specific staining (Figure 
4G) and individual cells based on nuclear characteristics (Figure 4H). For each 
cell, CD20 positivity and CD53 expression were determined in relation to tissue 
localization (Figure 4I-L). These settings were saved within an algorithm allowing 
batch analysis of multiple original multispectral images of the same tissue and 
stainings. Figure 5 shows similar analysis for lymphoid tissue stained for the T cell 
marker CD3 (Warp Red), tetraspanin CD37 (True Blue) and cell nuclei (Nuclear Red). 
Original multispectral images were unmixed using the spectral library showed in 
Figure 4A (Figure 5A-E). Next, tissue segmentation was performed for T cell zones, 
B cell follicles and red pulp regions (Figure 5F), followed by cell segmentation (Figure 
5G) and analysis of CD3 and CD37 expression within the different tissue regions 
(Figure 5H-L). As expected, B cell follicles mainly consisted of CD20 positive cells, and 
T cell zones contained mainly CD3 positive cells. The stromal tissue consisted of both 
CD20 or CD3 negative and positive cells. Altogether, we established multispectral 
imaging analysis to combine quantitative tetraspanin expression data with specific 
tissue localization in human lymphoid tissues. 
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Figure 3
B. CompositeA. Original
C. CD37 D. CD53
E. DAPI
^ Figure 3. Expression of CD37 and CD53 on human spleen. (A) Original multispectral image 
of human spleen stained for CD37 (Alexa488), CD53 (Alexa568) and cell nuclei (DAPI). Scale 
bar = 100μm. (B-E) Composite RGB image (B) of unmixed CD37 (C, in green), CD53 (D, in red) 
and DAPI (E, in blue) signal after correction for autofluorescence. One representative image 
is shown.
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Figure 4
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^ Figure 4. Spectral imaging analysis of human spleen stained for CD20 (Warp Red), CD53 
(True Blue) and cell nuclei (Nuclear Red). (A) A spectral library of 3 chromogens (Warp Red (red 
line), True Blue (blue line) and Nuclear Red (green line)) was built in Nuance software using single 
stained human spleen tissues. (B) Representative original multispectral image. Scale bar = 100μm. 
(C-F), composite RGB image (C) of unmixed CD20 (D, in red), CD53 (E, in blue) and nuclei (F, in 
green in composite RGB image) signal. (G) Tissue segmentation; B cell follicle (B, yellow), red pulp 
(RP, green) and other tissue (blood vessels, collagen; blue). (H) Segmentation of individual cells 
(green) based on Nuclear Red staining. (I) Thresholds for Warp Red and True Blue staining were 
set to score CD20-CD53dim (blue), CD20+CD53dim (red), CD20+CD53bright (yellow) or CD20-CD53bright 
(green) cells. (J-L) Scatter plots showing optical densities for CD20 (Y-axis) and CD53 (X-axis) of 
individual cells in B cell follicles (J & L, blue) and red pulp (K-L, red) and thresholds used for scoring 
(dotted lines). A representative of 2000 cells per tissue region is plotted. 
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Figure 5
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^ Figure 5. Spectral imaging analysis of human spleen stained for CD3 (Warp Red), CD37 (True 
Blue) and cell nuclei (Nuclear Red). (A) Representative original multispectral image. Scale bar = 
100μm. (B-E) Composite RGB image (B) of unmixed CD3 (C, in red), CD37 (D, in blue) and Nuclear 
Red (E, in green in composite RGB image) signal using the spectral library (Figure 4A). (F) Tissue 
segmentation; B cell follicle (B, yellow), T cell zone (T, red), red pulp (RP, green) and other tissue 
(blood vessels, collagen; blue). (G) Segmentation of individual cells (green) based on Nuclear 
Red staining. (H) Thresholds for Warp Red and True Blue staining were set to score CD3-CD37dim 
(blue), CD3+CD37dim (red), CD3+CD37bright (yellow) or CD3-CD37bright (green) cells. (I-L) Scatter plots 
showing optical densities for CD3 (Y-axis) and CD37 (X-axis) of individual cells in T cell zones (I & L, 
green), B cell follicles (J & L, blue) and red pulp regions (K-L, red) and thresholds used for scoring 
(dotted lines). A representative of 2000 cells per tissue region is plotted.
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Localization and quantitative expression of CD37 and CD53 in lymphoid 
organs
We studied the localization and expression of tetraspanin CD37 in primary and 
secondary lymphoid organs. Since bone marrow does not contain different T and B 
cell areas, tissue segmentation was not applicable and only cell segmentation was 
performed (Figure 6A-C and Figure 7A-C). The intensity (optical density (OD)) of 
CD37 in bone marrow ranged from 0.05 – 0.85, with a mean of 0.29 (ODmean; Figure 
6D). We observed around 80% of all bone marrow cells to be CD37bright (Figure 6E), 
and 90% of all T cells to be highly positive for CD37 (Figure 6F). The scatter plots with 
the set thresholds to annotate cells with dim and bright expression of CD37 and CD53 
are shown in Figure j-L, Figure 5I-L and Supplementary Figures 2 and 3. In human 
spleen, B cell follicles, T cell zones and red pulp areas were efficiently distinguished 
(Figure 6G-I and Figure 7G-I). CD37 showed highest expression in the B cell follicles 
(ODmean = 0.22) compared to the T cell zones and red pulp areas (ODmean = 0.15; Figure 
6J). In splenic B cell follicles, twice as many cells were CD37bright, compared to the 
red pulp where only 45% of the cells was CD37bright (Figure 6K). When focusing on 
CD37 expression on splenic T cells we observed that significantly more T cells were 
CD37bright in the red pulp as compared to T cells in T cell zones (Figure 6L). In the 
appendix, B cell follicles and lamina propria regions were located immediately below 
the crypts (Figure 6M-O and Figure 7M-O). CD37 showed highest expression in B cell 
follicles (ODmean = 0.12) compared to the lamina propria (ODmean = 0.09) in appendix 
(Figure 6P) which is in line with CD37 expression in spleen. In the B cell follicles in 
human appendix almost all cells were CD37bright, which was significantly more than 
in the lamina propria where around 80% of total cells expressed high levels of CD37 
(Figure 6Q). Similar to the red pulp in spleen, significantly more T cells in the lamina 
> Figure 6. Localization and expression of CD37 in bone marrow (A-F), spleen (G-L) and 
appendix (M-R). (A, G, M) Representative original multispectral image of lymphoid organ stained 
for CD3 (Warp Red), CD37 (True Blue) and cell nuclei (Nuclear Red). Scale bars = 100μm. (B, H, N) 
Composite RGB image after spectral unmixing of original image (red = CD3, blue = CD37, green 
= nuclei). (C, I, O) Image showing scoring of CD3-CD37dim (blue), CD3+CD37dim (red), CD3+CD37bright 
(yellow) or CD3-CD37bright (green) cells. (D, J, P) Optical density of CD37 on individual cells in 
human bone marrow (D), in B cell follicle (blue line) and in T cell zone and red pulp (red line) in 
human spleen (J) and in B cell follicle (blue line) and in lamina propria (red line) in human appendix 
(P). Optical densities were binned per 0.05 and normalized to % of max. (E-F) Percentage of 
CD37dim and CD37bright cells in total bone marrow (E) and in the CD3+ cell population in human 
bone marrow (F). (K-L) Percentage of total CD37bright cells in B cell follicle and red pulp (K), and 
in the CD3+ cell population in T cell zone and red pulp (L) in human spleen. (Q-R) Percentage of 
total CD37bright cells (Q) and in the CD3+ cell population (R) in B cell follicle and lamina propria in 
human appendix. Each dot represents data of one 20x image from the lymphoid tissue. The red 
line represents the mean. *P<0.05, ****P<0.0001.
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propria were CD37bright compared to the T cells within B cell follicles of the appendix 
(Figure 6R). However, we need to be careful with interpreting these data, because 
the frequency of T cells in the appendix is very low.
 Next, we performed multispectral imaging analyses for tetraspanin CD53 in 
human bone marrow, spleen and appendix. In bone marrow, the OD of CD53 ranged 
between 0.05 – 0.60, with an ODmean of 0.13 (Figure 7D). The CD20
+ B cells in bone 
marrow were mostly CD53dim (Figure 7E), contrary to the majority of CD3+ T cells that 
were CD53bright (Figure 7F). In human spleen, we observed CD53 to be expressed at 
higher levels in B cell follicles (ODmean = 0.15) than in the red pulp and T cell zones 
(ODmean = 0.09; Figure 7J). In contrast to human bone marrow, almost 100% of CD20
+ 
B cells in the spleen were CD53bright, significantly more than in the splenic red pulp 
where 85% of B cells expressed high levels of CD53 (Figure 7K). Similar to CD37 
expression, significantly more T cells in the red pulp compared to the T cell zone 
were CD53bright (Figure 7L). In human appendix, CD53 was slightly higher expressed in 
B cell follicles (ODmean = 0.10) than in the lamina propria regions (ODmean = 0.07; Figure 
7P). B cells within B cell follicles and lamina propria, expressed similar levels of CD53 
(Figure 7Q), whereas significantly more T cells in the B cell follicle expressed high 
levels of CD53 compared to T cells in the lamina propria (Figure 7R). Together, these 
data demonstrate that CD37 and CD53 are differentially localized and expressed in 
human bone marrow and in B cell, T cell and red pulp or lamina propria regions in 
human spleen and appendix. Furthermore, B and T cells have different expression 
levels of tetraspanin proteins depending on their localization within the tissue.
> Figure 7. Localization and expression of CD53 in bone marrow (A-F), spleen (G-L) and 
appendix (M-R). (A, G, M) Representative original multispectral image of lymphoid organ 
stained for CD20 (Warp Red), CD53 (True Blue) and cell nuclei (Nuclear Red). Scale bars = 100μm. 
(B, H, N) Composite RGB image after spectral unmixing of original image (red = CD20, blue = 
CD53, green = nuclei). (C, I, O) Image showing scoring of CD20-CD53dim (blue), CD20+CD53dim 
(red), CD20+CD53bright (yellow) or CD20-CD53bright (green) cells. (D, J, P) Optical density of CD53 
on individual cells in human bone marrow (D), in B cell follicle (blue line) and in T cell zone and 
red pulp (red line) in human spleen (J) and in B cell follicle (blue line) and in lamina propria (red 
line) in human appendix (P). Optical densities were binned per 0.05 and normalized to % of max. 
(E-F) Percentage of CD53dim and CD53bright cells in the CD20+ cell population (E) and in the CD3+ 
cell population (F) in human bone marrow. (K-L) Percentage of CD53bright cells in the CD20+ cell 
population in the B cell follicle and red pulp (K) in the CD3+ cell population in the T cell zone and 
red pulp (L) in human spleen. (Q-R) Percentage of CD53bright cells in the CD20+ cell population (Q) 
and in the CD3+ cell population (R) in the B cell follicle and lamina propria in human appendix. 
Each dot represents data of one 20x image from the lymphoid tissue. The red line represents the 
mean. *P<0.05, ****P<0.0001.
65
2
Figure 7
D E F
J K L
Optical density total CD53
%
 o
f m
ax
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
0
20
40
60
80
100
Optical density total CD53
%
 o
f m
ax
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7
0
20
40
60
80
100 B cell follicle
T cell zone & red pulp
%
 o
f C
D
20
+ 
ce
lls
di
m
C
D
53 b
rig
ht
C
D
53
0
20
40
60
80
100
%
 o
f C
D
3+
 c
el
ls
di
m
C
D
53 b
rig
ht
C
D
53
0
20
40
60
80
100
%
 C
D
53
br
ig
ht
 o
f C
D
20
+ 
ce
lls
B cell
follicle
Red pulp
0
20
40
60
80
100
T cell zone Red pulp
0
20
40
60
80
100
%
 C
D
53
br
ig
ht
 o
f C
D
3+
 c
el
ls
A. Original B. Composite C. Scoring
G. Original H. Composite I. Scoring
M. Original N. Composite O. Scoring
P
Optical density total CD53
%
 o
f m
ax
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8
0
20
40
60
80
100 B cell follicle
Lamina propria
Q R
B cell
follicle
Lamina
propria
0
20
40
60
80
100
%
 C
D
53
br
ig
ht
 o
f C
D
20
+ 
ce
lls
0
20
40
60
80
100
B cell
follicle
Lamina
propria
%
 C
D
53
br
ig
ht
 o
f C
D
3+
 c
el
ls
**** ****
**** *
****
66
Multispectral imaging of CD37 and CD53
Discussion
Here, we provide the quantitative expression of tetraspanins directly linked to tissue 
distribution in human lymphoid organs using multispectral imaging. Tetraspanin 
proteins are important in controlling cellular immune responses which is evidenced 
by the defects in the immune system of different tetraspanin-deficient mice10,21–24. 
 We demonstrate abundant expression of CD53 on lysosomes and of both 
tetraspanins on endosomes in human monocytes. The presence of tetraspanin 
proteins in intracellular vesicles has been linked to their function to regulate the 
trafficking of their partner proteins through the cell7,25. In B cells, both CD37 and 
CD53 can be found in multivesicular endosomes, called MHC class II-enriched 
compartments26. Furthermore, it has been described that CD37 contains a tyrosine-
based sorting motif which targets this protein to endocytic vesicles25.
 The predominant expression of CD37 observed on B lymphocytes and in B cell 
follicles is in line with former studies reporting an important role for CD37 in B cell 
function11,12,21,27. In the cytoplasmic tails of CD37 “ITIM-like” and “ITAM-like” motifs 
have been reported that regulate B cell death and survival respectively27. Interestingly, 
the dynamic process of B cell differentiation and selection in GCs coincides with 
lower CD37 expression towards plasma cell differentiation28. Tetraspanins play a 
well-established role in cancer development and progression29, and CD37-directed 
targeted therapies are currently under investigation in clinical trials in patients with 
B cell malignancies30–32.
 We observed primary myeloid and plasmacytoid DCs in human blood to express 
CD37 protein suggesting that CD37 may be involved in human DC function. This 
is supported by studies with DCs of CD37-deficient mice which show that CD37 
promotes cell migration33 and inhibits antigen presentation via MHC class II 
molecules10. T cells present in lymphoid organs were mostly CD37bright, which may be 
linked to the reported function of CD37 in T cell proliferation, which predominantly 
takes place in lymphoid organs upon antigen presentation by DCs. T cells that are 
deficient in CD37 have disturbed regulation of T cell receptor signaling leading to 
increased proliferation8. Remarkably, lymphocytes in various tissue regions within 
spleen and appendix often expressed significantly different levels of CD37 and CD53. 
For example, significantly more T cells in the red pulp were CD37bright compared to T 
cells in the T cell zone, suggesting that CD37 expression correlates with immune cell 
localization though it is also possible that these represent different T cell subsets.
 The role of CD53 in the immune system has not been clearly defined although a 
CD53-deficient family has been reported that suffered from recurrent infections13. 
Our study now demonstrates that CD53 in blood is expressed on all immune cells 
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with the highest expression on B cells, monocytes and mDC and pDC subsets. Within 
the secondary lymphoid tissues spleen and appendix, CD53 was highly expressed 
on both CD20+ and CD3+ cells. Surprisingly, we found CD20+ B lymphocytes in bone 
marrow to be mostly CD53dim which may be related to the finding that CD53 is 
under the control of the transcription factor early B cell factor-1 (EBF-1)34. EBF-1 is 
essential for B cell development by inducing expression of the genes encoding the 
(pre-)BCR, from which production is started in pre-B cells. CD53 has also been shown 
to interact with protein kinase C (PKC) ([35]; personal communication), a central 
signaling molecule important in cell proliferation, differentiation, and apoptosis. We 
anticipate that CD53 may only be expressed during later stages of B cell development 
in the bone marrow when the (pre-)BCR is expressed, which is in line with an earlier 
study showing lower levels of CD53 in earlier maturation stages of B cells within bone 
marrow28. Furthermore, we demonstrate abundant CD53 expression on T cells within 
blood and lymphoid organs. Although CD53 function in T cells is largely unknown 
to date, a strong correlation between CD53 expression on murine thymocytes and 
positive selection has been reported in the thymus36.
 In conclusion, we demonstrate the differential expression of tetraspanins CD37 
and CD53 in the human immune system. Multispectral imaging allowed us to obtain 
quantitative expression data that is directly linked to tissue distribution. This study 
offers guidance for further exploring tetraspanin function in the human immune 
system using this novel imaging technique.
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Supplementary Information
^ Supplementary Figure 1. Flow cytometry gating strategy of immune cell subsets in PBLs. (A-H) 
Live cells were gated on FSC-SSC plots (A). From the live cells, CD4+ T cells (B), CD8+ (CD3+CD56-) T 
cells (C), CD20+ B cells (D), CD14+ monocytes (E), CD56+ (CD3-CD8-) NK cells (F), BDCA1+CD19- mDCs 
(G) and BDCA2+ pDCs (H) were gated.
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^ Supplementary Figure 2. Scatter plots of CD3 and CD37 expression in human bone marrow, 
spleen and appendix. (A-B) Expression of CD3 and CD37 (A) and CD37 alone (B) in human bone 
marrow. (C) Expression of CD37 alone in human spleen (scatter plots of CD3 and CD37 shown in 
Figure 5I-L). Blue = B cell follicle, red = red pulp & T cell zone. (D-E) Expression of CD3 and CD37 
(D) and CD37 alone (E) in human appendix. Blue = B cell follicle, red = lamina propria. Dotted lines 
represent threshold used for analysis of scoring CD3 positive and negative cells (horizontal line) or 
CD37dim and CD37bright cells (vertical line) in inForm software. Data of 2000 representative cells per 
tissue region are shown.
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< Supplementary Figure 3. Scatter plots of CD3 or CD20 and CD53 expression in human bone 
marrow, spleen and appendix. (A-B) Expression of CD3 (A) or CD20 (B) and CD53 in human bone 
marrow. (C) Expression of CD3 and CD53 in human spleen (scatter plots of CD20 and CD53 shown 
in Figure 4j-l). Green = T cell zone, blue = B cell follicle, red = red pulp. (D-E) Expression of CD3 (D) 
or CD20 (E) and CD53 in human appendix. Blue = B cell follicle, red = lamina propria. Dotted lines 
represent threshold used for analysis of scoring CD3 or CD20 positive and negative cells (horizon-
tal line) or CD53dim and CD53bright cells (vertical line) in inForm software. Data of 2000 representa-
tive cells per tissue region are shown.
Supplementary Table 1. Number of 20x images used for quantification and statistical analysis of 
CD37 and CD53 distribution in Figure 6 and 7. 
Figure # Organ # of images used for quantification and statistical analysis
6e Bone marrow 35
6f Bone marrow 40
7e Bone marrow 41
7f Bone marrow 38
B cell follicle or T cell zone Red pulp
6k Spleen 296 311
6l Spleen 174 273
7k Spleen 233 325
7l Spleen 182 298
B cell follicle Lamina propria
6q Appendix 94 120
6r Appendix 50 112
7q Appendix 65 124
7r Appendix 69 107
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CD37 controls CLEC-2 function in DCs
Abstract
Cell migration is central to evoke a potent immune response. Dendritic cell (DC) 
migration to the lymph node is dependent on the interaction of C-type lectin-like 
receptor 2 (CLEC-2) on DCs with podoplanin (PDPN) on lymph node stromal cells 
(LNSCs). However, the underlying molecular mechanisms of CLEC-2 function in 
DC migration remain elusive. Here, we show that CLEC-2 function is controlled by 
tetraspanin CD37, a membrane-organizing protein. We discovered that CLEC-2+ DCs 
that lack CD37 (Cd37-/-) have impaired adhesion, migration velocity and displacement 
on LNSCs. Moreover, actin protrusion formation upon PDPN stimulation in a 3D 
collagen matrix was significantly decreased in Cd37-/- DCs, similar to DCs selectively 
lacking CLEC-2 (CD11cΔCLEC-2). Microcontact printing of PDPN revealed that CD37 
controls CLEC-2 recruitment to PDPN, which was verified by a direct molecular 
interaction between CLEC-2 and CD37. Finally, our findings demonstrate that 
signaling downstream of CLEC-2 and its related receptor Dectin-1 is inhibited by 
CD37. This study reveals that tetraspanin CD37 directly controls the behavior of 
C-type lectin receptors in the plasma membrane which has important consequences 
for understanding (immune) cell function.
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Introduction
Cell migration is key in the activation of immune responses. Upon encountering 
an antigen, dendritic cells (DCs) migrate to the secondary lymphoid organs (i.e. 
lymph nodes, spleen) and present the antigen on major histocompatibility complex 
(MHC) to activate T and B lymphocytes. In the lymphatic system, DCs move along 
lymph node stromal cells (LNSCs), such as lymphatic endothelial cells (LECs) and 
fibroblastic reticular cells (FRCs). During this process, the interaction between C-type 
lectin-like receptor 2 (CLEC-2) on DCs with podoplanin (PDPN) on LNSCs is essential 
for optimal DC migration to and within the lymph node1. Despite its well established 
role in DC migration, the molecular mechanisms underlying CLEC-2 function on DCs 
remain to be elucidated.
 CLEC-2 (encoded by the gene Clec1b) is expressed on platelets2 and myeloid 
immune cells, including DCs3, macrophages4, and peripheral blood neutrophils5. 
CLEC-2 plays a key role in fetal development as demonstrated by Clec1b-knockout 
mice that show defective lymphatic development leading to perinatal death6,7. 
Besides PDPN, the snake venom toxin rhodocytin serves as ligand for CLEC-2, and 
initiates downstream signaling via Syk resulting in cell activation2,8,9. Activation of 
Syk requires the binding of two phosphorylation motifs via its two Src homology 2 
(SH2) domains. Since the intracellular tail of CLEC-2 contains only a single tyrosine 
phosphorylation (YXXL) motif, dimerization of CLEC-2 is required for Syk binding. 
This makes CLEC-2 a hemITAM (hemi-Immunoreceptor Tyrosine-based Activation 
Motif) C-type lectin receptor (CLR), similar to its homologous family member 
Dectin-1 (also known as CLEC7A)10. Dectin-1 is a pattern-recognition receptor (PRR) 
that recognizes β-glucans in fungal cell walls11.
 For proper ligand binding and induction of signaling, CLRs are dependent on 
localization into membrane microdomains, like lipid rafts and tetraspanin-enriched 
microdomains (TEMs). Clustering of the CLR DC-SIGN into lipid rafts on DCs enhances 
ligand binding12. Binding and phagocytosis of particulate, and not soluble, β-glucan 
requires reorganization of Dectin-1 molecules into a “phagocytic cup”13. Based on 
biochemical studies, Dectin-1 has been proposed to be present in lipid rafts on 
DCs14 and monocytes15. In contrast, functional studies have provided evidence that 
Dectin-1 is regulated by tetraspanins and present in TEMs. Tetraspanins, a family 
of four-transmembrane proteins, interact with each other and partner proteins to 
form these TEMs, also referred to as the tetraspanin web16–19. A direct interaction 
between tetraspanin CD63 and Dectin-1 has been reported, which may be involved 
in phagocytosis of yeast cells20. Furthermore, tetraspanin CD37 directly interacts 
with and stabilizes Dectin-1 on the plasma membrane of myeloid cells, and inhibits 
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IL-6 production upon Dectin-1 stimulation21,22. Tetraspanin CD37 is exclusively 
expressed on immune cells with highest expression on B lymphocytes and DCs23. The 
importance of CD37 in the immune system has been demonstrated in CD37-deficient 
mice (Cd37-/-) that have defective humoral and cellular immune responses21,24. 
DCs that lack CD37 show impaired spreading, adhesion and migration, leading to 
defective initiation of the cellular immune response25,26. 
 In blood platelets, it is debated whether CLEC-2 clustering and signaling is 
dependent on lipid rafts27,28. CLEC-2 was shown to be present as single molecules 
or homodimers on resting platelets, but larger clusters are being formed upon 
rhodocytin stimulation9. In contrast, membrane organization of CLEC-2 on myeloid 
cells has thus far not been investigated. In this study, we show that CLEC-2 expression 
and cytokine production by myeloid cells is regulated by CD37. Moreover, actin 
protrusion formation by DCs and recruitment of CLEC-2 to PDPN is dependent on 
CD37 expression, which is mediated by a direct molecular interaction between CD37 
and CLEC-2. Finally, we demonstrate that signaling downstream of CLEC-2 and its 
related receptor Dectin-1 is inhibited by CD37. 
Materials and methods
Mice
Cd37-/- mice were generated by homologous recombination29 and fully backcrossed 
to the C57BL/6J background30. Cd37+/+ (WT) littermates were matched for age and 
gender. Cd37+/+ and Cd37-/- mice were bred in the Central Animal Laboratory of 
Radboud University Medical Center. CD11cΔCLEC-2 mice, selectively lacking CLEC-2 in 
CD11c+ cells, were generated by crossing Cd11c-cre and Clec1bfl/fl mice as previously 
described31. All murine studies complied with European legislation (directive 2010/63/
EU of the European Commission) and were approved by local authorities (CCD, The 
Hague, the Netherlands, and Institutional Animal Ethics Committee Review Board, 
Cancer Research UK and the UK Home Office, United Kingdom) for the care and use 
of animals with related codes of practice. All mice were housed in top-filter cages 
and fed a standard diet with freely available water and food.
Isolation of whole blood
Mice were anesthetized with isoflurane and whole blood was harvested via retro-
orbital punction and collected in a tube containing acid-citrate-dextrose mixture 
(ACD; 25g/L sodium citrate, 20g/L glucose and 15g/L citric acid) to prevent clotting. 
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Cell culture
Bone marrow-derived DCs (BMDCs) were generated by culturing total murine 
bone marrow cells in complete medium (RPMI 1640 medium (Gibco), 10% fetal 
calf serum (FCS), 1% UltraGlutamine-I (UG; Lonza), 1% antibiotic-antimycotic (AA; 
Gibco) and 50µM β-mercapto-ethanol (Sigma-Aldrich)), containing 20ng/mL murine 
granulocyte-macrophage colony stimulating factor (mGM-CSF, Peprotech), as 
adapted from previously described protocols32. On day 6, BMDCs were additionally 
stimulated with 10ng/mL LPS for 24h, unless stated otherwise.
 Primary human dermal lymphatic endothelial cells (LEC) were purchased from 
PromoCell and cultured in manufacturer’s recommended medium (Endothelial Cell 
Growth Medium MV2, PromoCell, Heidelberg, Germany) supplemented with 35µg/
mL gentamicin (Gibco). LECs were dissociated using trypsin/EDTA (Sigma-Aldrich) 
and seeded on 12-well tissue culture plates coated with 2% gelatine (Sigma-Aldrich). 
Seeding density was chosen to yield a confluent LEC monolayer within 24h. TNF-
alpha (TNFα; 100U/ml; Sigma-Aldrich) was added to confluent LEC monolayers for 
24h before analyzing static adhesion and migration of DCs33–35. 
 RAW264.7 murine macrophages (RAW; originally from ATCC) were cultured in 
RPMI 1640 medium supplemented with 10% FCS, 1% UG and 1% AA. The human 
embryonic kidney 293 cell line expressing the large T-antigen of simian virus 40 (HEK-
293T) was cultured in complete DMEM medium (Sigma-Aldrich) supplemented with 
10% FCS (Gibco), 100U/mL penicillin, 100μg/mL streptomycin and 4mM L-glutamine 
(Sigma-Aldrich). The Jurkat T cell line was cultured in RPMI 1640 medium (Sigma-
Aldrich) supplemented as described for HEK-293T cells.
Constructs and transfection
mCD37-pmCherry was generated by fluorescent protein swap of GFP from mCD37-
pEGFP21 with mCherry from pmCherry-N1 (Clontech) using AgeI and BsrGI restriction 
sites (New England Biolabs). RAW macrophages (5x105 cells/transfection) were 
transfected with 0.5µg mCD37-mCherry and/or 0.5µg pAcGFP-mCLEC-2 (previously 
described36) using FuGENE HD according to manufacturer’s instructions (Promega). 
 Human (h)CLEC-2-MYC and mouse Dectin-1-MYC constructs with C-terminal MYC 
tags8, and human Fc receptor γ (FcRγ)37 were generated in the pEF6 expression vector 
(Invitrogen). Human glycoprotein VI (GPVI)-MYC with a C-terminal MYC tag was 
generated in the pRC expression vector37. FLAG-human CD37 wild-type (WT) construct 
was produced using the pEF6 expression vector with an N-terminal FLAG tag38, and 
tetraspanin cDNA was cloned as described previously39. A FLAG-tagged palmitoylation 
mutant of CD37 (FLAG-hCD37PM) was generated by a two-PCR strategy40 that mutated 
all cysteine residues at the plasma membrane-cytoplasm interface to serines.
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Flow cytometry
Murine whole blood was incubated in phosphate-buffered saline (PBS) in presence 
of 1mM EDTA to prevent platelet aggregation, and 2% normal goat serum (NGS) 
to block Fc receptors for 15 min at 4°C. Next, murine blood cells were stained with 
anti-mouse CLEC-2 (clone INU1; a kind gift from Bernhard Nieswandt, University of 
Würzburg, Germany) or appropriate isotype control, and subsequently with goat-
anti-rat IgG-APC (BD). To discriminate blood platelets, staining with anti-mouse 
CD41-PE (clone MWReg30, BD) was performed.
 Splenocytes or cell lines were stained for 30 min at 4°C in PBS containing 1% 
bovine serum albumin (BSA) and 0.05% NaN
3
, and supplemented with 2% NGS, 
with the following primary anti-mouse antibodies: CLEC-2 (clone INU1), CD37 
(clone Duno85, Biolegend), B220-FITC (CD45R, clone RA3-6B2, Biolegend), CD11c-
Alexa488 (clone N418, Biolegend), NK1.1-PE (clone PK136, BD), GR1-PE (clone 
RB6-8C5, Biolegend), CD11b-PerCP (clone M1/70, Biolegend), CD3-biotin (CD3ε, 
clone 145-2C11, eBioscience), or appropriate isotype controls. This was followed 
by incubation with streptavidin-PerCP (Biolegend) or goat-anti-rat IgG Alexa647 
(Invitrogen). Stained cells were analyzed using FACSCalibur (Becton Dickinson) or 
CyanADP (Beckman Coulter) flow cytometer, and FlowJo software (TreeStar Inc.).
Rhodocytin stimulation and cytokine production
Single cell suspensions of splenocytes were generated by passing spleens through a 
100µm cell strainer (Falcon, Corning). To lyse erythrocytes, splenocytes were treated 
with ACK lysis buffer (0.15M NH
4
Cl, 10mM KHCO
3
, 0.1mM EDTA; pH 7.3) for 2 min on 
ice. Splenocytes (5x105 cells) were stimulated with either 15µg rhodocytin, purified 
by Prof. Johannes Eble as previously described41, PMA/ionomycin (100ng/mL and 
500ng/mL, respectively), or with complete medium (unstimulated), and incubated 
overnight at 37°C, 5% CO2. IL-6 levels in supernatant were measured using standard 
ELISA procedures. Briefly, NUNC Maxisorp 96-well plates (eBioscience) were coated 
with capture anti-mouse IL-6 antibody (MP5-20F3, 2μg/mL, BD Pharmingen) in 0.1M 
carbonate buffer (pH 9.6) overnight at 4°C. Wells were blocked with PBS containing 
1% BSA and 1% FCS for 1 hour at room temperature (RT), washed, and incubated 
with 50μL of sample and standard (2-fold serial dilutions starting from 10000pg/ml) 
(eBioscience). After 2-hour incubation at RT wells were incubated with biotinylated 
anti-mouse IL-6 (MP5-32C11, 1μg/ml, BD Pharmingen) for 1 hour at RT, followed by 
incubation with HRP-conjugated streptavidin (1:5000) for 30 min at RT. Complexes 
were visualized using TMB substrate (Sigma-Aldrich), and reactions were stopped 
by adding 0.8M H2SO4. Absorbance was measured at 450nm using an iMark plate 
reader (Bio-Rad).
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Static adhesion and migration assay
Adhesion was assessed by direct microscopic observation as previously described42. 
LEC in 12-well plates were washed three times with Medium 199 supplemented 
with 0.15% BSA Fraction V 7.5% (M199BSA, both from Gibco) to remove residual 
cytokines. BMDCs (1x106) were added on top of the LEC monolayer and incubated 
for 10 min at 37°C, 5% CO2. Non-adherent cells were removed from the LECs by 
gentle washing three times with M199BSA medium. Imaging was performed using 
an Olympus Invert X70 microscope. Video recordings of five fields of view of the LEC 
surface were made using phase-contrast video microscopy immediately and 10 min 
after washing away non-adherent cells. In between, time-lapse imaging (1 image 
every 10 sec) was performed for 5 min of one field of view to assess cell migration at 
37°C. The video recordings were digitized and analyzed using Image-Pro software 
(version 6.2, DataCell, Finchampstead, UK). The numbers of adherent cells were 
counted in the video fields, averaged, converted to cells per mm2 using the calibrated 
microscope field dimensions, and multiplied by the known surface area of the well to 
calculate the total number of adherent cells. This number was divided by the known 
total number of cells added to obtain the percentage of the cells that had adhered. 
Cell tracks of live cells were analyzed using the Manual Tracking plugin in Fiji/ImageJ 
software. Migration velocity was calculated as the length of each cell path/time (µm/
min), and the xy trajectories were converted into mean square displacement (MSD, 
in µm2) as previously described43.
3D protrusion assay
BMDCs (0.3x106) were seeded into a 3D collagen (type I, rat tail)/matrigel matrix 
(both from Corning) supplemented with 10% minimum essential medium alpha 
medium (MEMalpha, Invitrogen) and 10% FCS on glass-bottomed cell culture plates 
(MatTek). For CLEC-2 activation, 20µg/mL recombinant PDPN-Fc (rPDPN-Fc)1 was 
added to the gel as all components were mixed. Gels were incubated overnight at 
37°C, 5% CO2. The next day, cultures were fixed with 4% paraformaldehyde (PFA) 
for 3h at RT, followed by blocking and permeabilization with 3% BSA, 1% normal 
mouse serum and 0.3% Triton in 0.1M Tris for 2h at RT before staining. F-actin 
and cell nuclei were visualized using TRITC-phalloidin and DAPI, respectively 
(1:500 dilution, both from Invitrogen). Cells were imaged on a Leica SP5 confocal 
microscope, and analyzed using Fiji/ImageJ software. Z stacks of 120µm (10µm/
step) were projected with ImageJ Z Project (maximum projection), and number and 
length of protrusions were measured. Cell morphology (= perimeter2/4πarea) was 
calculated using the area and perimeter of cells by manually drawing around the 
cell shape using F-actin staining.
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Microcontact printing
PDMS (poly(dimethylsiloxane)) stamps with a regular pattern of 5µm circular spots 
were prepared as previously described44. Stamps were incubated with 200µg/mL 
rPDPN-Fc (Sino Biological Inc., for CLEC-2 stimulation), and 10μg/mL donkey anti-
rabbit IgG (H&L)-Alexa647 (Invitrogen, to visualize the spots) diluted in PBS for 1 hour 
at RT. Stamps were washed with demineralized water and dried under a nitrogen 
stream. The stamp was applied to a cleaned glass coverslip for 1 min and subsequently 
removed. Transfected RAW macrophages were seeded on the stamped area and 
incubated for 12 min at 37˚C. Cells were fixed with 4% PFA for 20 min at RT. Samples 
were washed with PBS and demineralized water and embedded in Mowiol (Sigma). 
Imaging was performed on an epi-fluorescence Leica DMI6000 microscope, and plot 
profiles were created using Fiji/ImageJ software. For the population of cells in contact 
with rPDPN-Fc spots, we determined the percentage showing on-stamp enrichment 
of mCLEC-2-GFP by independent visual analysis with support of Fiji/ImageJ software.
Immunoprecipitation
HEK-293T cells were transiently transfected with hCLEC-2-MYC and FLAG-hCD37WT 
or FLAG-hCD37PM using polyethylenimine (Sigma) as described previously45,46. Cells 
were lysed in 1% digitonin and immunoprecipitated with anti-FLAG antibody (clone 
M2, Sigma) as described previously39. Western blots were stained with anti-MYC (clone 
9B11, Cell Signaling Technology) or rabbit anti-FLAG (Sigma) antibodies, followed by 
IRDye® 680RD- or 800CW-conjugated secondary antibodies (LI-COR Biosciences), 
and imaged using the Odyssey Infrared Imaging System (LI-COR Biosciences).
NFAT-luciferase reporter assay
Jurkat T cells were transfected as previously described37, using 20µg of a NFAT/
AP-1-luciferase reporter construct, 2µg of a β-galactosidase construct to control 
for transfection efficiency, together with CLEC-2-MYC (10µg), Dectin-1-MYC 
(10µg), GPVI-MYC/FcRγ (5µg of each) or empty vector controls. Transfected cells 
were stimulated with 50nM rhodocytin, 250µg/ml curdlan (Sigma) or 5µg/ml Horm 
collagen (Nycomed). The luciferase and β-galactosidase assays were conducted as 
described previously37. The data was normalized for β-galactosidase expression and 
adjusted such that the relative CLEC-2, Dectin-1 or GPVI/FcRγ signaling responses 
upon stimulation in absence of CD37 were 100.
RNA isolation, cDNA synthesis and qPCR
Isolation of RNA and DNase treatment of WT and Cd37-/- BMDCs stimulated with 
10ng/mL LPS for 0, 4, 6 or 24 hours was performed using the Quick-RNA miniprep 
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kit (Zymo Research). RNA quantity and purity were determined on a NanoDrop 
spectrophotometer. RNA was reverse transcribed to cDNA by using random 
hexamers and Moloney murine leukemia virus reverse transcriptase (Invitrogen). 
Clec1b mRNA levels were determined with a CFX96 Sequence Detection System 
(Bio-Rad) with SYBR Green (Roche) as the fluorophore and the following gene-
specific oligonucleotide primers: forward 5’- GGAGCCATGCAGGATGAAGA, and 
reverse 5’- AGAGCCACGAGTCCAACAAC. Reaction mixtures and program conditions 
were used as recommended by the manufacturer (Bio-Rad). Quantitative PCR data 
were analyzed with the CFX Manager software (Bio-Rad) and checked for correct 
amplification and dissociation of the products. Clec1b Ct values were normalized to 
the Ct value of the housekeeping gene Pbgd.
Statistics
Statistical differences between two groups (e.g. WT and Cd37-/- cells) with regard 
to IL-6 production, adhesion, CLEC-2 enrichment and NFAT-luciferase activity were 
determined using (un)paired Student’s t-test or non-parametric Mann-Whitney test 
(in case of non-Gaussian distribution). Statistical differences between three groups 
(e.g. WT, Cd37-/- and CD11cΔCLEC-2 cells) or two or more parameters (e.g. genotype 
and time) were determined using two-way ANOVA with Sidak’s or Tukey’s multiple 
comparisons test. Statistical tests were performed using GraphPad Prism software, 
and all differences were considered to be statistically significant at p≤0.05.
Results
Cd37-/- myeloid cells show aberrant CLEC-2 expression and cytokine 
production
The finding that CD37 controls expression of Dectin-121 prompted us to investigate 
CLEC-2 expression on WT and Cd37-/- immune cell subsets. CLEC-2 expression on 
splenocytes of naïve mice was low, but Cd37-/- myeloid cells expressed significantly 
lower CLEC-2 levels compared to WT splenocytes (Supplementary Figure 1). It was 
reported that CLEC-2 expression is increased on myeloid cells upon in vivo LPS 
stimulation4. Therefore, we analyzed CLEC-2 expression on different immune cell 
subsets from spleens of Cd37-/- and Cd37+/+ (WT) mice that were stimulated with 
LPS. CLEC-2 expression was significantly decreased on activated Cd37-/- myeloid 
cells (DCs, macrophages, granulocytes), compared to WT myeloid cells (Figure 1A-B). 
This was in contrast to WT and Cd37-/- lymphoid cells (B cells, T cells and NK cells) that 
expressed comparable CLEC-2 levels. As control, we investigated CLEC-2 expression 
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on platelets which do not express CD37, and observed similar CLEC-2 expression on 
platelets of WT and Cd37-/- mice (Supplementary Figure 2).
 Next, we investigated whether decreased CLEC-2 expression on Cd37-/- immune 
cells had functional consequences by analyzing cytokine production. Stimulation of 
splenocytes with the CLEC-2 ligand rhodocytin resulted in significantly increased 
IL-6 production by Cd37-/- splenocytes compared to WT splenocytes. This was not 
due to decreased cell viability or a general defect of the Cd37-/- immune cells since 
stimulation with PMA/ionomycin resulted in normal IL-6 production (Figure 1C). 
Together, these results show that CD37 regulates CLEC-2 expression on myeloid cell 
subsets, and is important for IL-6 production upon CLEC-2 stimulation.
CD37 controls DC migration over LNSCs and protrusion formation in response 
to PDPN
CLEC-2 is essential for DC migration through the lymphatic system1. To investigate 
whether CD37 was required for the migratory capacity of LPS-stimulated CLEC-
2+ DCs (Supplementary Figure 3, and ref. 1), we performed static adhesion and 
migration assays of WT and Cd37-/- CLEC-2+ DCs on LECs (Figure 2A). Adhesion of 
both WT and Cd37-/- CLEC-2+ DCs was stable for the duration of the experiment, 
but the amount of Cd37-/- DCs adhering to LECs was reduced compared to WT DCs 
(Figure 2B). Moreover, migration velocity and mean square displacement of DCs were 
significantly decreased in absence of CD37 (Figure 2C-D, Supplementary movies 1A-
B). To investigate whether this was due to deregulated CLEC-2 function in absence 
of CD37, we performed 3D protrusion assays in a collagen matrix with and without 
PDPN, the CLEC-2 agonist expressed by LNSCs (Figure 3A, Supplementary Figure 4). 
Whereas Cd37-/- DCs were capable of making actin protrusions (Figure 3B), the length 
of the protrusions (Figure 3C) and morphology index (Figure 3D) were significantly 
decreased compared to WT DCs upon PDPN stimulation. As control, we included DCs 
selectively lacking CLEC-2 (CD11cΔCLEC-2)31 which also showed impaired actin protrusion 
formation in response to PDPN (Figure 3C-D). Together, these data demonstrate that 
CD37-deficiency, similar to CLEC-2-deficiency, results in aberrant DC adhesion and 
migration, and impaired actin protrusion formation in response to PDPN.
CLEC-2 recruitment to PDPN is dependent on CD37
To gain insight into the underlying mechanism how CD37 controls CLEC-2 function, 
we analyzed local CLEC-2 recruitment to PDPN by means of microcontact printing 
of recombinant PDPN protein. Myeloid cells were transiently transfected with 
GFP-mCLEC-2 with or without mCD37-mCherry (Figure 4A), resulting in increased 
extracellular expression of mCD37 and cell surface expression of CLEC-2 (Figure 4B). 
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^ Figure 1. CD37-deficiency impairs CLEC2 expression and myeloid cell function. (A) Flow 
cytometric analysis of CLEC-2 expression on splenic immune cell subsets in WT (black line) and 
Cd37-/- (dashed line) mice 24h post-i.p. injection with LPS. CD11c was used to stain DCs, CD11b 
for macrophages, GR-1 for granulocytes and B220 for B cells. A representative FACS plot for one 
WT and one Cd37-/- mouse per immune cell type is shown. (B) Quantification of flow cytometric 
analysis of CLEC-2 expression of WT (white bars) and Cd37-/- (black bars) cells. CD11c was used 
to stain DCs, CD11b for macrophages, GR-1 for granulocytes, B220 for B cells, CD3ε for T cells and 
NK1.1 for NK cells. Values are corrected for isotype controls. MFI = mean fluorescence intensity. 
Data are shown as mean+SD from n=2-3 mice per genotype. Two-way ANOVA with Sidak’s 
multiple comparisons test, *p=0.0475, **p=0.0086, ***p=0.0002. (C) IL-6 production (in pg/mL) by 
total splenocytes from naive WT (white bars) and Cd37-/- (black bars) mice after ex vivo stimulation 
with medium (unstimulated, negative control), 15µg/mL rhodocytin (CLEC-2 agonist) or PMA/
ionomycin (positive control). Data are shown as mean+SEM from 3 independent experiments, total 
n=6-8 mice per genotype. Non-parametric Mann-Whitney test, two-tailed, *p=0.0215.
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^ Figure 2. CD37 controls DC adhesion, migration velocity and displacement on lymphatic 
endothelial cells. (A) Adherence of WT (left) and Cd37-/- (right) DCs on TNFα-stimulated lymphatic 
endothelial cells (LEC). One representative image per genotype is shown. Scale bar = 50µm. (B) 
Adhesion (% of total cells added per well) of WT (black line) and Cd37-/- (grey line) DCs on LECs for 
the duration of the experiment. Data shown from one representative experiment. (C) Migration 
velocity (µm/min) of WT (white box) and Cd37-/- (grey box) DCs over LECs. Data are shown as Tukey 
Box & whiskers from two independent experiments, n=107-115 cells per genotype, respectively. 
Unpaired Student’s t-test, two-tailed, ****p<0.0001. (D) Left: zoom of field of view shown in (A) 
with individual cell tracks. Upper image= WT, lower image = Cd37-/-. Scale bar = 25µm. Right: Mean 
square displacement (MSD, in µm2) of WT (black line) and Cd37-/- (grey line) DCs on LEC. Data are 
shown as mean±SEM from two independent experiments. Two-way ANOVA with Sidak’s multiple 
comparisons, ****p<0.0001 at t=5 min.
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^ Figure 3. CD37 controls formation of actin 
protrusions by DCs in response to PDPN. (A) 
WT (left), Cd37-/- (middle) or CD11cΔCLEC-2 (right) 
DCs were stimulated in a 3D collagen gel with 
(bottom row) or without (upper row) recombinant 
PDPN-FC (rPDPN-Fc). Cells were stained for 
F-actin (red) and nucleus (blue) and imaged with 
a Leica SP5 confocal fluorescence microscope. 
One representative cell is shown for each 
condition (overview with more cells is provided in 
Supplementary Figure 4). Scale bar = 10µm. (B-D) 
Number (B) and length (C) of actin protrusions, 
and morphology index (D) of WT (left), Cd37-
/- (middle) or CD11cΔCLEC-2 (right) BMDCs upon 
rPDPN-Fc stimulation (grey boxes) compared to 
no ligand (white boxes). Data are shown as Tukey 
Box & whiskers from 3 independent experiments, 
total n=3 mice per genotype. Two-way ANOVA 
with Tukey’s multiple comparisons, ***p<0.001, 
****p<0.0001.
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Next, transfected myeloid cells were incubated on the PDPN spots in order to 
locally engage CLEC-2 molecules. Myeloid cells expressing both GFP-mCLEC-2 and 
mCD37-mCherry showed a >2-fold higher percentage of cells with local (on-stamp) 
CLEC-2 enrichment at sites of PDPN, compared to cells only expressing GFP-mCLEC-2 
(Figure 4C-D, Supplementary Figure 5). These data indicate that CD37 directly 
controls CLEC-2 recruitment in response to PDPN.
CD37 directly interacts with CLEC-2 and inhibits hemITAM downstream 
signaling
To investigate the possibility of a direct molecular interaction between CLEC-2 and 
CD37, we performed co-immunoprecipitation (co-IP) experiments with HEK-293T 
cells transfected with hCLEC-2-MYC and FLAG-hCD37WT or hCLEC-2-MYC and 
empty vector (pEF6). These experiments revealed that CLEC-2 interacted with CD37 
under conditions using 1% digitonin (Figure 5A). Formation of TEMs via secondary 
interactions between tetraspanins is promoted by palmitoylation of intracellular 
cysteines present in tetraspanins16–18. To validate a direct interaction between CLEC-
2 and CD37, and not an interaction via secondary interactions, we performed co-IP 
experiments with HEK-293T cells transfected with hCLEC-2-MYC and palmitoylation-
deficient CD37 (FLAG-hCD37PM). FLAG-hCD37PM showed similar capacity to interact 
with hCLEC-2-MYC as FLAG-hCD37WT (Figure 5A, right lane). This indicates that the 
CLEC-2 interaction with CD37 is direct and not dependent on palmitoylation of CD37. 
Next, we studied CLEC-2 downstream signaling by using a NFAT/AP-1-luciferase 
reporter assay in presence or absence of CD37. This revealed that CD37 significantly 
inhibited signaling of CLEC-2 upon rhodocytin stimulation (Figure 5B). As positive 
control, we investigated NFAT activity upon stimulation of Dectin-1, the homologous 
hemITAM family member of CLEC-2 known to directly interact with CD3721. Upon 
> Figure 4. CLEC-2 recruitment to PDPN is dependent on CD37. (A) Percentage of positive 
RAW macrophages after transfection with either GFP-mCLEC-2 alone (middle) or in combination 
with mCD37-mCherry (right). Mock transfected cells (left) were used as negative control. 
TF = transfection condition. (B) Extracellular expression of mCD37 (left) and mCLEC-2 (right) on 
mock (black line) or transfected (dashed line) RAW macrophages. Grey = isotype control. (C) GFP-
mCLEC-2 (upper row) or in combination with mCD37-mCherry (bottom row) transfected RAW 
macrophages were incubated on recombinant PDPN-Fc (rPDPN-Fc) spots and analyzed after 
12 min using an epi-fluorescence microscope. Left: Green = GFP, red = mCherry, blue = rPDPN-Fc 
spots. One representative cell shown per condition (three more representative cells per condition 
are shown in Supplementary Figure 5). Scale bar = 10µm. Right: Graphs represent intensity profile 
of GFP-mCLEC-2 (green line) or rPDPN-Fc spot (black line) across the yellow line. (D) Percentage 
of GFP-mCLEC-2 (white bar) or in combination with mCD37-mCherry (black bar) transfected 
RAW macrophages showing enrichment of GFP-mCLEC-2 on rPDPN-Fc spots. Data are shown as 
mean+SEM from three independent experiments. Paired Student’s t-test, one-tailed, *p=0.0372.
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stimulation with the Dectin-1 ligand curdlan, expression of CD37 resulted in inhibition 
of Dectin-1 signaling (Figure 5C). Expression levels of both CLEC-2 and Dectin-1 
were comparable in presence or absence of CD37 (data not shown).  To investigate 
whether the inhibition of hemITAM CLR signaling by CD37 was specific, signaling 
of the ITAM-bearing receptors GPVI and FcRγ was studied in the same cell system. 
Overexpression of CD37 did not inhibit NFAT activity downstream of GPVI/FcRγ upon 
collagen stimulation (Figure 5D). In summary, CLEC-2 directly interacts with CD37 
and expression of CD37 inhibits signaling via hemITAM CLRs CLEC-2 and Dectin-1.
Discussion
It has been well-established that CLEC-2 interaction with PDPN is essential for DC 
migration and initiation of the cellular immune response1,31,47. For efficient ligand 
binding and activation of downstream signaling, CLRs are dependent on spatiotemporal 
localization into microdomains on the plasma membrane12,21,48. CLEC-2 has been 
found to be present in clusters on blood platelets9, but the underlying mechanism is 
incompletely understood, and membrane organization of CLEC-2 on myeloid cells has 
thus far not been investigated. Here, we show that tetraspanin CD37 is required for 
CLEC-2 recruitment and actin protrusion formation in response to PDPN, and controls 
CLEC-2+ DC migration over LNSCs. 
 Previous studies investigating CLEC-2 membrane organization debated whether 
CLEC-2 is present in lipid rafts27,28. Reports stating that C-type lectin-like receptors are 
localized in lipid rafts, use cholesterol depletion27 or label the lipid raft marker GM1 
with cholera toxin B (CTB)14,15. However, both methods do not rule out involvement of 
TEMs, since cholesterol depletion also disrupts TEMs49, and CTB can bind glycosylated 
surface proteins50, including tetraspanins51. In this study, we discovered that tetraspanin 
CD37 directly interacts with CLEC-2. Furthermore, we show that absence of CD37 
prevents CLEC-2 recruitment to PDPN, and significantly decreases CLEC-2 expression 
on different myeloid cell subsets. These results indicate that CLEC-2 function is 
regulated by tetraspanin CD37 microdomains on DCs. Our data are in line with the 
demonstration that expression of the homologous CLR Dectin-1 on macrophages is 
dependent on CD37 that stabilizes Dectin-1 at the plasma membrane21. 
 Our results show that CLEC-2+ Cd37-/- DCs have an impaired capacity to adhere to 
PDPN+ LECs, and lower migration velocity and displacement. This is in accordance 
with studies showing impaired migration of Cd37-/- DCs in vivo25. Although in 
previous studies the underlying mechanism was not identified, it was postulated that 
CD37 interaction with α4β1 integrin was important for cell migration25,26,52. We now 
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^ Figure 5. CD37 interacts with CLEC-2 and inhibits downstream signaling. (A) HEK-293T 
cells were transfected with MYC-tagged human CLEC-2 (hCLEC-2-MYC) and FLAG-tagged 
hCD37, either wild-type (FLAG-hCD37WT) or palmitoylation-deficient (FLAG-hCD37PM). Cells 
were lysed in 1% digitonin and immunoprecipitated with anti-FLAG antibodies. Western blots 
were stained for MYC (upper panel) and FLAG (lower panel). Results shown are noncontiguous 
lanes from the same gel for either anti-MYC or anti-FLAG. (B-D) Jurkat T cells were transiently 
transfected with a NFAT/AP-1-luciferase reporter construct and CLEC-2 (B), Dectin-1 (C) or 
glycoprotein VI/Fc receptor γ (GPVI/FcRγ) (D) with or without CD37, or empty vector as control 
(mock). Cells were treated with media alone (unstimulated, white bars), or (B) rhodocytin 
(CLEC-2 agonist), (C) β-glucan-containing curdlan (Dectin-1 agonist), or (D) collagen (GPVI/FcRγ 
agonist) for 6 hours (black bars). Luciferase activity was measured following stimulation and 
transfection efficiency was corrected to β-galactosidase activity in individual experiments. Data 
shown as mean±SD from three individual experiments. Two-way ANOVA with Tukey’s multiple 
comparisons, ***p<0.001.
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demonstrate a specific role for CD37 in controlling CLEC-2 function in DCs. Cd37-/- DCs 
show impaired actin protrusion formation upon PDPN stimulation, which is similar 
to the phenotype of CD11cΔCLEC-2 DCs. Rearrangements of the actin cytoskeleton and 
subsequent cell movement are controlled by Rho GTPases, including RhoA and Rac1. 
RhoA increases actomyosin contractility via its interaction with Rho kinases53, whereas 
Rac1 supports actin polymerization, spreading of lamellipodia and formation of 
membrane ruffles54,55. Activity of Rho GTPases has been shown to change upon CLEC-
2 activation by PDPN or rhodocytin (i.e. downregulation of RhoA and upregulation of 
Rac1)1. Interestingly, Cd37-/- DCs have been reported to have impaired activation of 
Rac-126 indicating that CD37 can couple to intracellular GTPases. This data combined 
with our study support a model in which CD37 is important for CLEC-2 recruitment on 
myeloid cells upon PDPN activation, which results in Syk activation and changes in 
Rho GTPase activity (e.g. increased Rac1 and decreased RhoA activation) leading to 
cell migration (Figure 6A). 
 Besides activation of Rho GTPases, CLRs can initiate Syk-dependent signaling 
cascades leading to cytokine production or activation of the transcription factor 
NFAT56. We found that Cd37-/- myeloid cells produce higher IL-6 levels upon CLEC-2 
stimulation by rhodocytin, which is in line with previous reports showing production 
of pro-inflammatory cytokines (i.e. IL-6 and TNFα) by neutrophils and RAW 
macrophages upon stimulation with rhodocytin5,57. Additionally, IL-10 production 
by RAW macrophages and BMDCs co-stimulated with LPS and anti-CLEC-2 Fab 
fragments could be reversed by inhibition of Syk4. In this same study it was found 
that NFAT signaling in DCs was significantly upregulated upon CLEC-2 stimulation 
using transcriptome analysis4. Moreover, Dectin-1 stimulation using zymosan or C. 
albicans initiated NFAT activation in macrophages and DCs, and cytokine production 
in DCs was shown to be controlled by NFAT13. Here, we studied NFAT activity in 
absence or presence of CD37 upon CLEC-2 and Dectin-1 stimulation by rhodocytin 
and curdlan, respectively. Our data shows that CD37 inhibited activation of NFAT upon 
stimulation of the hemITAM CLRs CLEC-2 and Dectin-1. In contrast, NFAT activity 
upon collagen stimulation of the ITAM-bearing receptors GPVI and FcRγ was not 
inhibited by CD37 expression. Similar to CLEC-2, these co-associated receptors are 
important for activation of mouse platelets via Syk signaling58,59. Our results suggest 
that CD37 directly controls Syk signaling downstream of hemITAM CLRs and as such 
inhibits cytokine production and NFAT activity, probably by controlling phosphatase 
activity60–62 (Figure 6B). Syk activation has been reported to be negatively regulated 
by SH2 domain-containing protein tyrosine phosphatase 1 (SHP-1)56,63. SHP-1 and 
CD37 have been shown to associate via the N-terminal ITIM-like domain of CD37 in 
chronic lymphocytic leukemia (CLL) cells, which induced tumor cell death via negative 
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regulation of AKT-mediated pro-apoptotic signaling64. The binding of cytoplasmic 
signaling proteins, like protein kinase C (PKC)65, Rac166, and suppressor of cytokine 
signaling 3 (SOCS3)67 has been reported for different tetraspanins (reviewed in van 
Deventer et al. Biochem Soc Trans, in press). Still, further research is necessary to 
unravel the exact mechanism of hemITAM C-type lectin signaling inhibition by CD37.
 Our data indicates that CD37 has two functions in controlling CLEC-2 in the 
plasma membrane of myeloid cells. First, CD37 is important for recruitment of 
CLEC-2 to PDPN, the ligand expressed by LNSCs. Second, CD37 inhibits CLEC-2 
downstream signaling (NFAT activity, cytokine production) upon rhodocytin 
stimulation. The difference between the two functions is the nature of the ligand 
used to stimulate CLEC-2; PDPN is membrane-bound, whereas rhodoytin is a soluble 
ligand. This suggests that the function of CLEC-2 and the activation of a specific signal 
transduction pathway are determined by the nature of the ligand that binds to CLEC-2 
(Figure 6). In conclusion, this study demonstrates that CD37 drives DC migration by 
recruitment of CLEC-2 to PDPN and controls signaling outcome upon stimulation of 
hemITAM CLRs. This study provides molecular insight in the regulation and function of 
CLRs on myeloid cells and may be extended to non-immune cells and blood platelets.
^ Figure 6. Model illustrating that CD37 drives hemITAM C-type lectin receptor recruitment 
and signaling. (A) CLEC-2 protein recruitment to PDPN is controlled by CD37. CLEC-2-induced 
Syk activation leads to DC migration via changes in the activity of Rho GTPases. (B) C-type lectin 
receptor (CLR) engagement by a soluble ligand (e.g. rhodocytin, or β-glucan containing curdlan) 
results in Syk activation, cytokine production and NFAT activity. CD37 inhibits this hemITAM CLR 
downstream signaling possibly by controlling phosphatase activity.
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Supplementary Information
^ Supplementary Figure 1. CD37 controls CLEC-2 expression in naïve myeloid cells. Flow cyto-
metric analysis of CLEC-2 expression on naive splenic immune cell subsets in WT (white bars) 
and Cd37-/- (black bars) mice. CD11c was used to stain DCs, CD11b for macrophages, GR-1 for 
granulocytes, B220 for B cells, CD3ε for T cells and NK1.1 for NK cells. Values are corrected for 
isotype controls. MFI = mean fluorescence intensity. Data are shown as mean+SD from n=3 mice 
per genotype. Two-way ANOVA with Sidak’s multiple comparisons test, *p=0.0253**p=0.0099, 
****p<0.0001.
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^ Supplementary Figure 2. Cd37-/- platelets express normal CLEC-2 levels. (A) Flow cytomet-
ric analysis of CLEC-2 expression (right histogram, black line) on murine CD41+ blood platelets 
(middle histogram) from WT (upper panel) and Cd37-/- (lower panel) mice. RBC = red blood cells, 
WBC = white blood cells. (B) Quantification of flow cytometric analysis of CLEC-2 expression on 
WT (white bar) and Cd37-/- (black bar) CD41+ platelets. Values are corrected for isotype control. 
gMFI = geometric mean fluorescence intensity. Data are shown as mean+SEM from n=6 mice per 
genotype.
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CD37 controls CLEC-2 function in DCs
^ Supplementary Figure 3. Cd37-/- bone marrow-derived DCs (BMDCs) express lower Clec1b 
mRNA levels upon LPS stimulation. Clec1b mRNA expression in WT (white boxes) and Cd37-/- 
(grey boxes) BMDCs after indicated time points of LPS stimulation. Clec1b mRNA expression is 
calculated as fold change compared to unstimulated (0h) for each genotype. Data shown as Tukey 
Box & whiskers from n=4-8 independent cultures per time point.
^ Supplementary Figure 4. CD37 controls formation of actin protrusions by DCs in response to 
PDPN. WT (left), Cd37-/- (middle) or CD11cΔCLEC-2 (right) DCs were stimulated in a 3D collagen gel 
with (bottom row) or without (upper row) recombinant PDPN-FC (rPDPN-Fc). Cells were stained 
for F-actin (red) and nucleus (blue) and imaged with a Leica SP5 confocal fluorescence microscope. 
One representative image shown for each condition. Scale bar = 50µm.
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^ Supplementary Figure 5. CLEC-2 recruitment to PDPN is dependent on CD37. RAW macrophages 
transfected with GFP-mCLEC-2 alone (upper three rows) or in combination with mCD37-mCherry 
(bottom three rows) were incubated on recombinant PDPN-FC (rPDPN-Fc) spots and analyzed after 
12min using an epi-fluorescence microscope. Left: Green = GFP, red = mCherry, blue = rPDPN-Fc 
spots. Two representative cells shown per condition. Scale bar = 10µm. Right: Graphs represent 
intensity profile of GFP-mCLEC-2 (green line) or rPDPN-Fc spot (black line) across the yellow line.
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Abstract
B cell non-Hodgkin lymphoma, worldwide the most common hematological 
malignancy, remains a clinical problem. The molecular events leading to B cell 
lymphoma are only partially defined. We now provide evidence that deficiency of 
CD37, a tetraspanin superfamily member important for B cell function, induces the 
development of B cell lymphoma in vivo. Cd37-deficient mice develop germinal 
center-derived B cell lymphoma in lymph nodes and spleen with higher incidence 
than Bcl2 transgenic mice. We discovered that CD37 interacts with SOCS3, and 
when absent drives tumor development through constitutive activation of the 
IL-6 signaling pathway. The importance of the IL-6 pathway was confirmed by 
investigating Cd37xIl6 double knock-out strains that were fully protected against 
lymphoma development. Moreover, loss of CD37 on neoplastic cells in patients with 
diffuse large B cell lymphoma (DLBCL) is directly correlated with activation of the IL-6 
signaling pathway and with worse progression-free and overall survival. Together, 
this study identifies CD37 as a novel tumor suppressor that directly protects against B 
cell lymphomagenesis, and provides a strong rationale for blocking the IL-6 pathway 
in patients with CD37-negative B cell malignancies as therapeutic intervention.
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Introduction
The majority of B cell lymphomas originate from germinal center (GC)-derived 
B cells, which is the result of genetic defects during VDJ recombination, somatic 
hypermutation and class-switching recombination1. The best known chromosomal 
aberration in follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL) 
is translocation of t(14;18) resulting in constitutive expression of Bcl-2 and defective 
apoptosis2 which is correlated with worse survival in DLBCL patients3. However, 
the t(14;18) can also be detected in B cells of healthy individuals, suggesting that 
the translocation by itself is insufficient and other genetic alterations are required 
to induce B cell lymphoma4,5. Detailed genomic analyses revealed the complexity 
of different pathways that are recurrently altered in lymphomas including B cell 
receptor, Toll-like receptor, Notch, and NFκB signaling pathways6,7. The challenge is 
to identify the driver mutations of these altered pathways in order to unravel how 
these genetic aberrations contribute to B cell lymphomagenesis. 
 IL-6, originally identified as a B cell-differentiating factor, contributes to the growth 
of many types of cancer, including hematological tumors8,9. IL-6 exerts its biological 
function via a receptor complex composed of the IL-6 receptor alpha chain (IL-6Rα) 
and the common signaling receptor gp13010 that together activate three pathways: 
JAK/STAT311, PI3K/AKT12, and Ras/MAPK pathway13. Activation of the IL-6 signaling 
pathway is negatively regulated by SOCS3, which is transcribed upon DNA-binding 
of STAT3-homodimers14. Cytosolic SOCS3 translocates to the plasma membrane 
where its SH2 domain binds gp130 to prevent binding and phosphorylation of STAT3 
proteins15,16. Simultaneously, SOCS3 binds JAK1/2 with its kinase-inhibitory region 
(KIR), which targets these proteins for ubiquitination17. In B cell lymphoma, proteins 
of the JAK/STAT3 signaling pathway are frequently overexpressed contributing to 
cancer development and progression18,19. In addition, autocrine IL-6 production in 
DLBCL provides proliferative and anti-apoptotic signals, and IL-6 levels in serum 
correlate with the prognosis of the disease20. To date, the underlying mechanism 
responsible for the constitutive activation of the IL-6 pathway in cancer is largely 
unknown. 
 Tetraspanins belong to the superfamily of transmembrane-four proteins that form 
multimolecular complexes with other tetraspanin proteins, integrins, growth factors 
and signaling molecules21-24. Targeting of CD37 is currently under investigation in 
clinical trials for patients with B cell malignancies, but the molecular pathways have 
not been fully resolved25,26. CD37 is highly expressed on mature B cells and is required 
for optimal germinal center function and long-lived antibody production27,28. Mice 
deficient for CD37 (Cd37-/-) have impaired humoral and cellular immune responses29-31. 
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This paper provides the first evidence that CD37 is a novel tumor suppressor that acts 
to suppress IL-6-driven B cell transformation in vivo. 
Methods
Mice
Cd37-/- mice were generated by homologous recombination32 and backcrossed to 
the C57BL/6J background29. Cd37-/-xIl6-/- mice were generated by crossing Cd37-/- 
mice with Il6-/- mice33. Cd37+/+ WT littermates were matched for age and gender. 
BALB/cAnNRj-Foxn1nu (nude) mice were purchased from Janvier Labs and NOD/SCID/
IL2Rγnull (NSG) mice were originally purchased from Jackson Laboratories. Cd37+/+, 
Cd37-/-, Cd37-/-xIl6-/- and NSG mice were bred in the Radboud university medical 
center (Radboudumc) Central Animal Laboratory. All mice were housed in top-filter 
cages and fed a standard diet with freely available water and food. 
Patients
Biopsies of 47 patients with de novo GCB-DLBCL and 50 patients with ABC-DLBCL 
were obtained and stained for CD37 using immunohistochemistry. Patients were 
diagnosed between 2001 and 2008 and the lymphomas were classified according to 
the World Health Organization 2008 classification criteria, and the pathology was 
reviewed and validated. The median age was 61 years and all patients underwent 
standard R-CHOP chemotherapy. Thirty-five patients had died by the last follow-up. 
The median follow-up interval for the 62 censored patients was 59.6 months (range 
from 12.2 to 186.7 months). Some of the GCB-DLBCL and ABC-DLBCL patients had 
serum available, which was used to evaluate IL-6 levels.
Histology and immunohistochemistry
Collected tissues were fixed in phosphate buffered 4% paraformaldehyde (PFA) and 
embedded in paraffin wax. Serial tissue sections of 5mm were stained with H&E prior 
to microscopical analysis. Two independent pathologists (M.G. and K.M.H.) classified 
the lymphomas according to the “Bethesda proposals for classification of murine 
lymphoid neoplasms”34. Immunohistochemical stainings were performed on OCT-
embedded frozen tissue sections. Tissue slides were dried at room temperature (RT) 
for 30 min, fixed in 2% PFA for 10 min and treated with 3% H2O2 in methanol for 15 min 
at RT. After blocking Fcg receptors with normal serum in which the secondary Ab was 
produced, tissue sections were stained against IL-6 (MP5-32C11, BD Pharmingen), 
B220 (RA3-6B2, BD Pharmingen), CD19 (1D3, eBioScience), CD3 (Cd3-12, Serotec), 
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F4/80 (CI:A3-1, Serotec), CD68 (FA-11, Serotec), Gr1 (RB6-8C5, BD Pharmingen), 
PNA-biotin (Sigma), GL7 (GL-7, eBioScience), CD138 (281-2, Biolegend), IgA (C10-
1, BD Pharmingen), phospho-STAT3 (Tyr705, D3A7, Cell Signaling Technology) and 
phospho-AKT (Ser473, D9E, Cell Signaling Technology) for 1h at RT. Subsequently, 
tissue slides were subjected to incubation with appropriate biotinylated secondary 
antibodies for 45 min at RT followed by avidin-biotin complex detection (Vectastain, 
Vector) according to manufacturer’s instructions. Complexes were visualized using 
Fast Red Substrate, counterstained with hematoxylin, and mounted with Kaisers 
glycerin gelatin. Immunohistochemistry staining on human lymphoma tissues of 
DLBCL patients was performed on formalin-fixed and paraffin-embedded tissue 
micro arrays (TMA) following manufacturer’s instructions using monoclonal antibody 
specific for CD37 (clone 2B8, ThermoFisher Scientific) and p-STAT335 followed by 
hematoxylin counterstaining. Assessment of CD37 and p-STAT3 protein expression 
was performed by two pathologists (K.J.J. and K.H.Y.) individually blinded from 
the clinical outcomes. The interobserver agreement was 98% of the samples and 
disagreements were resolved by joint review on a multi-head microscope.
Immunofluorescent staining of immunoglobulins
Cryostat sections of 4μm were dried at RT for 30 min and fixed in acetone for 10 min 
at -20°C. Subsequently, tissue sections were treated with 5% normal horse serum 
for 30 min at RT. After blocking, tissue sections were stained with AffiniPureF(ab’)2 
Fragment Goat Anti-Mouse IgG (2µg/ml, Jackson ImmunoResearch Laboratories), 
goat anti-mouse IgM (5µg/ml, Vector Laboratories) or rat anti-mouse IgA (C10-1, 
2µg/ml, BD Pharmingen) for 45 min at RT, followed by incubation with appropriate 
secondary antibodies (Alexa-488, Life Technologies) for 45 min at RT. Sections were 
fixed in 1% PFA, enclosed in Mowiol (EMD Biosciences, La Jolla, CA) and imaged by 
fluorescent microscopy (Leica DM).
Flow cytometry and antibodies
Single cell suspensions were stained for 30 min at 4°C in PBS, 1% BSA, 2% normal 
goat serum with the following primary mouse antibodies: anti-CD19-APC (1D3, 
eBioscience), anti-CD3-APC (145-2C11, BD Pharmingen), anti-B220-FITC (RA3-
6B2, Biolegend), anti-IgA-FITC (mA-6E1, eBioscience), IgD-FITC (11-26c.2a, BD 
Pharmingen), anti-CD86-PE (GL1, BD Pharmingen), anti-MHC-II-PE (M5/114.15.2, 
eBioscience), anti-CD40-PE (3/23, BD Pharmingen), anti-CD43-PE (S7, BD 
Pharmingen), anti-B220-Alexa-647 (RA3-6B2, BD Pharmingen); biotinylated anti-
IgM (Vector Laboratories), anti-IgA (C10-1, BD Pharmingen), PNA (Sigma), anti-
CD138 (281-2, BD Pharmingen), anti-CD37 (WR-17, home-made), anti-IL6Rα/CD126 
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(D7715A7, Biolegend) or anti-gp130 (M-20, Santa Cruz Biotechnology), followed by 
incubation with streptavidin conjugated to PE or PerCP, or appropriate secondary 
antibodies (PerCP, BD Pharmingen or Alexa-conjugated, Life Technologies). 
Intracellular stainings for p-STAT3 (Tyr705) and p-AKT (Ser473) were performed as 
described27. Stained cells were analyzed using FACS Calibur (Becton Dickinson) and 
FlowJo software version 9.6 (TreeStar Inc.).
Assessment of immunoglobulin heavy chain rearrangements
IGH rearrangements were assessed using the standardized multiplex PCR protocols 
(35 PCR-cycles) developed by the BIOMED-2 concerted action BMH4-CT98-393636. The 
IGH complete (VDJ)–rearrangements were assessed in the three Framework regions in 
the IGH variable genes. Multiplex PCR products were monitored by GeneScan analysis 
on an ABI 3730 platform (Life Technologies, Foster City, USA) and processed by the 
Genemapper software (version 4.0, ABI prism). Interpretation of the clonality findings 
was performed according to the EuroClonality guidelines37. This test to perform 
clonality assessment on human samples is validated for use in murine samples. 
Adoptive transfer experiments
Tumors from Cd37-/- mice were incubated with collagenase and DNAse in order to 
obtain single-cell suspensions. Freshly isolated tumor cells (5x106) were injected 
subcutaneously into the flank or intravenously into the tail vein of gender-matched 
6-8 weeks old Cd37-/-, WT or immunocompromised recipients. Tumor growth was 
measured over time. In case of subcutaneous injection, human endpoint was reached 
at tumor size >2cm2.
RNA isolation and quantitative PCR analysis
For PCR-based gene profiling, the following protocol was used. Total RNA was prepared 
from Cd37-/- tumor or WT control mLN using the MagNA Lyser Instrument (Roche) 
and the RNeasy kit (Qiagen). Total RNA was reverse transcribed to cDNA using RT2 
First Strand Kit (Qiagen) following manufacturer’s instructions. Array plates of Mouse 
Oncogenes and Tumor Suppressor Genes (SA Bioscience) were run according to the 
manufacturer’s instructions using the ABI/Prism 7000 sequence detection system 
(Applied Biosystems, Foster City, CA). The ∆Ct value was calculated by determining 
the difference between the Ct value of the gene of interest and the average Ct value 
of five different housekeeping genes (Gusb, Hprt1, Hsp90ab1, Gapdh, Actb). The ∆∆Ct 
value was calculated by subtracting the WT ∆Ct value from Cd37-/- ∆Ct value. The fold 
change for each gene from WT to Cd37-/- was measured as 2(-∆∆Ct). For quantitative 
PCR (qPCR) analysis of individual genes in Cd37-/- tumor cells and WT control cells, 
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RNA was isolated using the Quick-RNA Miniprep kit (Zymo Research). RNA quantity 
and purity were determined on a NanoDrop spectrophotometer. RNA was treated 
with DNase I (amplification grade; Invitrogen) and reverse transcribed to cDNA by 
using random hexamers and Moloney murine leukemia virus reverse transcriptase 
(Invitrogen). mRNA levels of the genes of interest were determined with a CFX96 
sequence detection system (Bio-Rad) with SYBR Green (Roche) as the fluorophore 
and gene-specific oligonucleotide primers. Primers used are as follows (forward, 
reverse): Casp8 (5’-CAACTTCCTAGACTGCAACCG, 5’-TCCAACTCGCTCACTTCTTCT), 
Ctnnb1 (5’-CATCTTAAGCCCTCGCTCGG, 5’-AGTAGCCATTGTCCACGCAG). Reaction 
mixtures and program conditions were used as recommended by the manufacturer 
(Bio-Rad). qPCR data was analyzed with the CFX Manager software (Bio-Rad) and 
checked for correct amplification and dissociation of the products. Ct values of the 
genes of interest were normalized to Ct value of the housekeeping gene Pbgd.
Determination of IL-6 levels
IL-6 levels in serum and supernatant were measured using standard ELISA procedures. 
Briefly, NUNC Maxisorp 96-well plates (eBioscience) were coated with capture 
anti-mouse IL-6 antibody (MP5-20F3, 2µg/ml, BD Pharmingen) in 0.1 M Carbonate 
buffer (pH 9.6) overnight at 4°C. Wells were blocked with PBS containing 1% BSA, 
1% FCS for 1h at RT, washed, and incubated with 50ml of sample and standard (2-
fold serial dilutions starting from 10000pg/ml) (eBioscience). After 2h incubation at 
RT, wells were incubated with biotinylated anti-mouse IL-6 (MP5-32C11, 1μg/ml, BD 
Pharmingen) for 1h at RT followed by incubation with HRP-conjugated streptavidin 
(1:5000) for 30 min at RT. Complexes were visualized using TMB substrate (Sigma) 
and reaction was stopped by adding 0.8M H2SO4. Absorbance was measured at 
450 nm using an ELISA plate reader (iMark, BioRad). IL-6 levels in serum of DLBCL 
patients were measured using Pelipair reagent set for human IL-6 (M9316, Sanquin) 
according to manufacturer’s instructions.
Cell culture, survival assays and transfection
Freshly isolated Cd37-/- tumor cells were cultured in RPMI 1640 (Invitrogen) 
containing 10% FCS, 1% ultraglutamine, 1% antibiotic-antimycototic, 1 mM sodium 
pyruvate and 30 µM β-Mercaptoethanol (β-ME), in the presence or absence of 10µg/
ml anti-mouse IL-6 (MP5-20F3, BD Pharmingen) or appropriate isotype control. For 
survival assays, viability of the neoplastic cells was assessed by trypan blue exclusion. 
The human B cell lymphoblastoid JY cell line, human pre-B cell line NALM-6 and 
HEK293 cells (all from ATCC) were cultured in RPMI 1640 (Invitrogen) supplemented 
with 10% FCS, 1% antibiotic-antimycototic and 1% stable glutamine. Human CD37 
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construct38 was cloned into psGFP2-N1 vector placing the psGFP2 moiety on the C 
terminus of the protein. NALM-6 cells were transiently transfected with hCD37-GFP 
using SF Cell Line 4D-Nucleofector® X Kit and 4D NucleofectorTM system (Lonza).
IL-6 stimulation
Human NALM-6 pre-B cells (10x106) or JY B cells (2x106) were stimulated with 15ng/
mL recombinant IL-6 (CellGro) for respectively 60 or 75 min at 37°C, 5% CO2.
Determination of SOCS3 and p-STAT3 expression
Freshly isolated WT control and Cd37-/- tumor mLN cells (10x106) were lysed in 
150mM NaCl, 10mM TrisHCl, 1% Triton, 100nM NaVO
3
, 500mM NaF, 100mM PMSF 
and Complete Mini EDTA-free Protease Inhibitor Cocktail Tablet (Roche) and 
separated by reducing SDS-polyacrylamide gel electrophoresis. Western blots were 
incubated with goat anti-SOCS3 (M-20, 1:1000, Santa Cruz) or rabbit anti-p-STAT3 
(Tyr705, D3A7, 1:2000, Cell Signaling) and rabbit anti-actin (20-33, 1:1000, Sigma) 
or rabbit anti-STAT3 (79D7, 1:2000, Cell Signaling) as loading control, followed by 
secondary IRDye anti-goat or anti-rabbit antibodies (LI-COR) and Odyssey infrared 
detection and Odyssey analysis software.
Co-immunoprecipitation experiments
Human CD37-EGFP (pEGFP-N1) or empty pEGFP, and SOCS3 (SIN-pgk) were transiently 
co-transfected into HEK293 cells using metafectene (Biontex). After 16h, cells were 
lysed in lysis buffer (0.5% NP40, 10mM TrisHCl pH 7.4, 150mM NaCl, 1mM EDTA, 1mM 
Na
3
VO
4
 pH 10.0, 1mM NaF and 1x Protease Inhibitor Cocktail (Pharmingen)). Lysates 
were precleared with isotype control antibodies bound to protein G Sepharose 
beads, followed by incubation with either mouse anti-GFP (Roche), mouse anti-CD37 
(WR17, home-made39), or mouse IgG isotype control antibodies. After incubating 
for 2h at 4°C, beads were washed three times in lysis buffer and SDS sample buffer 
containing 5% β-ME was added. Samples were separated by SDS-PAGE, and Western 
blots were incubated with rabbit anti-GFP (home-made) or rabbit anti-SOCS3 (Cell 
Signaling, #2923) in TBS supplemented with 0.3% BSA and 0.1% skim milk powder at 
4°C overnight, and stained with secondary IRDye anti-rabbit antibodies (Invitrogen) 
followed by scanning membranes on the Odyssey Scanner (Westburg).
Co-patching experiments
Human JY B cells were blocked with 3% BSA, 10mM glycine, 1% filtered human 
serum in PBS and stained with primary antibodies against human CD37 (WR17), 
IL6Rα/CD126 (M5, BD) or isotype controls for 30 min at 4°C. Secondary Alexa-488 
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or 647 antibodies (Invitrogen) were incubated for 30 min at 4°C, followed by 1h at 
12°C. Cells were fixed with 2% PFA for 15 min at 4°C followed by 15 min at RT and 
mounted on poly-L-lysine coated glass slides at RT. For intracellular SOCS3 staining, 
the cell membrane was permeabilized with 0.5% saponin, 1% BSA, 10mM glycine, 
1% filtered human serum in PBS and cells were stained with anti-SOCS3 (M-20, 
Santa Cruz) or isotype control for 45 min at RT, followed by secondary Alexa-488 or 
647 antibodies (Invitrogen) for 30 min at RT. Glass slides were sealed with Mowiol 
(EMD Biosciences, La Jolla, CA) on coverslips and imaged with an Olympus FV1000 
Confocal Laser Scanning Microscope. Images were analyzed using Fiji software and 
Manders coefficients were determined using the JACoP plugin.
Human IL6 and AKT1 mRNA expression
Gene expression analysis was performed on lymphoma tissues of GCB-DLBCL 
patients (n=47) and mRNA expression of IL6 and AKT1 was retrieved from the gene 
expression profiling data obtained from the Affymetrix GeneChip Human Genome 
HG-U133 Plus 2.0. The log2 expression values of the probe-sets IL6 (205207_at) and 
AKT1 (207163_s_at) were used for analysis.
Statistics
Statistical differences in viability of Cd37-/- tumor cells and between CD37+ and 
CD37- groups were determined using unpaired Student’s t-test (one-tailed) or 
nonparametric Mann-Whitney test (one-tailed; in case of non-Gaussian distribution). 
Statistical differences in IL-6 production in murine serum were determined using 
Kruskal-Wallis one-way ANOVA test. OS was calculated from the time of diagnosis 
to death from any cause or last follow-up. PFS was calculated from the time of 
diagnosis to disease progression, relapse or death from any cause. Patients who 
remained alive or progression-free were censored at last follow-up. Survival analysis 
was performed using the Kaplan–Meier method with GraphPad Prism 5 (GraphPad 
Software, San Diego, CA), and differences were compared using the Log-rank 
(Mantel-Cox) test. All differences with P ≤ 0.05 were considered to be statistically 
significant.
Study approval
All murine studies complied with national legislation, and were approved by local 
authorities for the care and use of animals with related codes of practice. Studies on 
human DLBCL tumor tissue were conducted in accordance with Declaration of Helsinki 
and were approved as being of minimal to no risk or as exempt by the Institutional 
Review Boards (IRB) at The University of Texas MD Anderson Cancer Center.
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Results
CD37-deficiency predisposes mice to develop spontaneous B cell lymphoma
CD37 is highly expressed on mature B cells and plays a fundamental role in B cell 
function and humoral immunity27,28. Although Cd37-/- mice develop normally with 
unaltered numbers of lymphoid and myeloid cells in lymphoid organs32, we observed 
that Cd37-/- mice became diseased during aging. By 15 months of age, Cd37-/- mice 
spontaneously developed large neoplasms in mesenteric lymph nodes (mLN), spleen 
and liver in contrast to age-matched Cd37+/+ WT littermates (referred to as WT mice; 
Figure 1A-B). Extensive analyses of mice at different ages revealed that over 50% of 
Cd37-/- mice developed tumors starting at 12 months. In contrast, only ~15% of WT mice 
developed tumors at the age of 22 months (Figure 1B, Supplementary Table 1), which 
is in line with the reported tumor occurrence in aged inbred C57BL/6 mice34,40. Cd37+/- 
heterozygous mice were healthy and did not develop lymphomas until 20 months of 
age with the same incidence as Cd37+/+ WT mice (data not shown). The neoplasms in 
Cd37-/- mice were characterized by nodular growth of small and large pleiomorphic 
B cells, the presence of some mitotic figures, histocytes, multinucleated giant cells 
and focal necrosis (Figure 1C). Immunohistochemical analyses demonstrated that 
the lymphomas were strongly positive for both B cell markers B220 and CD19 (Figure 
1D). CD3+ T cells and CD68+ macrophages were apparent (Figure 1D), whereas Gr1+ 
myeloid cells and CD138+ plasma cells were scarce (Supplementary Figure 1A). 
Quantification of different immune cell subsets in Cd37-/- lymphomas and WT mLN 
control tissues by flow cytometry confirmed these results (Supplementary Figure 2). 
These data demonstrate that Cd37-deficiency promotes spontaneous development 
of B cell lymphoma in vivo.
Neoplastic cells are IgA-positive GC-derived tumor cells
Expression of co-stimulatory molecules (CD86, CD40), MHC-II, PNA, and CD43 
revealed that the lymphoma cells phenotypically resembled mature GC B cells 
(Figure 2A). This was confirmed by high expression of the GC markers PNA and GL7 in 
lymphomas of aged Cd37-/- mice (Figure 2B). Next, we characterized the Ig phenotype 
of the mature lymphoma cells by flow cytometry. Cd37-/- lymphomas were all negative 
for IgD, IgM and IgG, whereas IgA was the most abundant immunoglobulin expressed 
by the neoplastic cells (Figure 2C and Supplementary Figure 1B). This was in contrast 
to the few lymphomas that were found in ~15% of aged Cd37+/+ (WT) mice, which 
were of the IgG or IgM phenotype (Supplementary Figure 3). Taken together, these 
data demonstrate that the Cd37-/- neoplasms consist of mature isotype-switched 
IgA+ B cells that originate from the germinal center. 
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^ Figure 1. Spontaneous development of B cell lymphoma in Cd37-deficient mice. (A) Cd37-/- 
mice demonstrate splenomegaly (0.09±0.01 vs. 0.21±0.04 gram spleen weight in WT and Cd37-/- 
mice, respectively (n=10, *P<0.02)). (B) Cd37-/- mice develop large malignancies in mLN upon 
aging. Macroscopic incidence of lymphomas in Cd37-/- mice (n=48) versus age-matched Cd37+/+ WT 
littermates (n=52). (C) Histological analyses of the mLN from 18-month old WT (upper) and Cd37-/- 
(lower) mice using H&E tissue stainings. Cd37-/- mLN were diagnosed as mature B cell lymphomas. 
Scale bars are 300, 80, 40, 20μm (from left to right). (D) Immunohistochemical analyses of mLN from 
18-month old WT (upper) and Cd37-/- (lower) mice. Tissues were stained for B220, CD19, CD3, and CD68 
using Fast-red and Hematoxylin counterstaining (F4/80, Gr1, CD138, and isotype control stainings are 
presented in Supplementary Figure 1A). Note the disorganization of Cd37-/- mLN tissues that consist of 
small and large pleiomorphic B cells, and presence of infiltrating T cells, histocytes and macrophages. 
Black lines indicate the border between the B cell follicle and T cell area in WT tissues. Scale bars are 
25μm. Experiments were repeated 5 times with at least 4 mice of each genotype per group.
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Neoplastic Cd37-/- cells are of monoclonal origin and induce disease upon 
transfer into young mice
To investigate the clonality status of the neoplastic Cd37-/- cells, molecular genetic 
analysis of the B cell receptor was adapted using fresh lymphoma tissues from Cd37-
/- mice and mLN tissue samples from aged WT mice as control. In normal mLN tissue 
from WT mice, VJ gene rearrangements of the IGH locus demonstrated a Gaussian-like 
distribution of peaks, which is the result of the polyclonal nature of B cells. In contrast, 
Cd37-/- B cell lymphomas showed a single dominant peak indicating a clear clonal IGH 
rearrangement in all framework regions (FR1,2,3), indicative of B cell lymphoma (Figure 
3A, Supplementary Figure 4). Next, adoptive transfer experiments were performed 
to explore whether freshly isolated B cell lymphoma cells could be transferred into 
young (6-8 weeks old) Cd37-/- mice. Transfer of fresh neoplastic cells from aged Cd37-
/- mice rapidly induced tumor growth in healthy recipient Cd37-/- mice irrespective 
of their age (Figure 3B). The lymphoma cells showed clear metastatic capacity as 
several tumor deposits were found in secondary lymphoid organs including spleen, 
inguinal, brachial, and axillary lymph nodes. Predominant expression of CD19 and 
B220 as well as high expression of GL7, CD86, MHC-II, CD43, PNA, and IgA confirmed 
that all neoplasms resembled mature isotype-switched IgA+ B cells of GC-origin, and 
showed a phenotype similar to the original transferred tumor (Supplementary Figure 
5). Next, neoplastic cells from aged Cd37-/- mice were transferred subcutaneously 
or intravenously into young WT and immunocompromised mice that lack the 
lymphocyte compartment, including CD19+B220+ B cells. Whereas tumor cells did 
not grow in WT mice (data not shown), evident lymphoma growth was observed in 
the immunocompromised mice, similar to young Cd37-/- mice after subcutaneous 
injection (Figure 3C). Similarly, Cd37-/- neoplastic CD19+B220+ B cells were clearly 
traced back in mLN (Figure 3D) and spleens (Figure 3E) of immunocompromised mice 
after intravenous adoptive transfer. Thus, the neoplastic cells derived from aged 
Cd37-/- mice are of monoclonal origin, and can induce disease and exhibit metastatic 
capacity upon adoptive transfer. 
Constitutive activation of the IL-6 signaling pathway in Cd37-/- lymphomas
To gain insight in the mechanism underlying the spontaneous lymphoma 
development in Cd37-/- mice, we performed a quantitative Mouse Oncogene and 
Tumor Suppressor Gene PCR array on mLN from tumor-bearing Cd37-/- mice and 
age-matched WT littermates. Among the 84 cancer-associated genes, 6 genes were 
up-regulated ≥2-fold in the neoplastic Cd37-/- tissue compared to normal WT mLN 
tissue (Supplementary Table 2). Three of the up-regulated genes were prominent 
115
4
^ Figure 2. Phenotypical characterization of the Cd37-/- B cell lymphomas. (A) Flow cytometry 
analyses of B cells of mLN from 18-month old WT and Cd37-/- mice. B cells were identified by gating 
on CD19+B220+ cells that were stained for CD86, MHC-II, PNA, CD138, CD43, and CD40 (thick black 
line = Cd37-/-, thin black line = WT, versus isotype control (grey line)). (B) Immunohistochemical 
analyses of mLN from 18-month old WT (upper) and Cd37-/- (lower) mice using germinal center 
specific-staining with PNA (left) and GL7 antibody (right). Scale bars are 300, 50, 300, 50μm (from 
left to right). Lines indicate border of the B cell follicle. (C) Characterization of the B cell receptor 
(immunoglobulin) isotype on B cells from mLN of 18-month old WT (upper) and Cd37-/- (lower) 
mice. CD19+B220+ cells were stained for IgM, IgG and IgA, followed by immunofluorescence 
(left three panels) and immunohistochemistry (right panel). Scale bars: 70μm. Experiments were 
performed 4 times with at least 4 mice of each genotype per group.
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members of the IL-6 signaling pathway (Jun, Akt1, Stat3; Figure 4A, Supplementary 
Table 2). We could verify this at the mRNA level (data not shown) and protein level 
by tissue immunohistochemistry analyses demonstrating increased STAT3 and AKT 
phosphorylation (indicative of STAT3 and AKT activation) in lymphoma tissues of 
Cd37-/- mice (Figure 4B). Furthermore, levels of phosphorylated STAT3 (p-STAT3) 
were enhanced in Cd37-/- lymphoma cells (derived from mLN or spleens) compared 
to WT controls as determined by quantitative Western blot analysis, indicating that 
the IL-6 signaling pathway is activated in Cd37-/- lymphoma cells (Figure 4C-D). 
Expression of the proto-oncogene Ctnnb1, encoding β-catenin41, was also 
enhanced, whereas expression of the pro-apoptotic gene Casp8, encoding caspase 
842, was decreased in Cd37-/- tumors (Supplementary Figure 6). The role of IL-6 
in lymphomagenesis was further validated by quantifying IL-6 levels in serum of 
Cd37-/- and WT mice during aging. Cd37-/- mice with lymphomas exhibited increased 
levels of IL-6 in serum compared to mice without tumors (Figure 5A). In addition, 
tumor cells derived from Cd37-/- mice spontaneously produced IL-6 ex vivo in 
contrast to mLN-derived cells from WT mice (Figure 5B), which was confirmed by 
immunohistochemistry studies (Figure 5C). To verify whether IL-6 was involved in 
the enhanced phosphorylation of both STAT3 and AKT, blocking IL-6 mAb or isotype 
control mAb were added to freshly isolated Cd37-/- tumor cells. Blocking of IL-6 
reduced STAT3 and AKT phosphorylation as assessed by intracellular flow cytometry 
(Figure 5D). These reduced levels of p-STAT3 and phosphorylated AKT (p-AKT) after 
blocking IL-6 were associated with decreased viability of the neoplastic cells during 
> Figure 3. Clonality of Cd37-/- B cell lymphomas and adoptive transfer to young mice. (A) DNA was 
extracted from mLN of 18-month old WT and Cd37-/- mice. VJ joinings from Ig heavy chain genes were 
amplified by the BIOMED-2 multiplex PCRs for IGH-VJ rearrangements, showing FR2 (FR1 and FR3 are 
shown in Supplementary Figure 4). Experiments were performed 2 times with 3 mice of each genotype. 
Data shown for two lymphomas and one WT control tissue, as well as human polyclonal and monoclonal 
control samples. (B) Lymphoma cells (5x106 cells) were injected s.c. in the flank of 6-8 weeks old Cd37-/- 
mice (n=12), and tumor growth was measured in time. Each line represents an individual mouse. When 
tumors reached a size >2cm2, mice were sacrificed and lymphoid tissues were analyzed macroscopically, 
by flow cytometry, histology and immunohistochemistry (Supplementary Figure 5). (C) Lymphoma cells 
(5x106 cells) were injected s.c. in the flank of 6-8 weeks old Cd37-/- mice or immunocompromised nude 
mice (n=6 mice per group), and tumor growth was measured in time. Data represent mean±SEM. (D-E) 
Lymphoma cells (5x106 cells) were injected i.v. in the tail vein of 6-8 weeks old immunocompromised NOD 
scid gamma (NSG) mice (n=6). These mice lack the lymphocyte compartment, including CD19+B220+ 
B cells. Mice were sacrificed after 11 days and mLN (D) and spleen (E) were analyzed for presence of 
CD19+B220+ B cells by flow cytometry (left panel). In the right panel, each dot represents the percentage 
of CD19+B220+ B cells in the mLN (D) or spleen (E) per mouse. Black lines represent mean±SEM.
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ex vivo cell culture (Figure 5E). Together, these data support the importance of IL-6 
in B cell lymphoma development in Cd37-/- mice. 
CD37 regulates IL-6 responses through direct interaction with SOCS3
Since IL-6 signaling appeared to be directly correlated with B cell lymphomagenesis in 
Cd37-/- mice, we first evaluated whether the components of the IL-6R complex were 
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differentially expressed on B cells in the absence of CD37. We found no differences in 
expression of IL-6Rα or its signaling chain gp130 between B cells derived from aged 
Cd37-/- mice and WT mice (Figure 6A). These data indicate that the IL-6R itself is 
functional, but likely the negative feedback machinery of the IL-6 pathway is disturbed 
in B cells from Cd37-/- mice. To address the possibility that Cd37-/- B cells have 
evolved to escape control of SOCS3, the major negative feedback regulator of IL-6 
signaling, we determined the expression levels of SOCS3 in B cells from Cd37-/- mice. 
Surprisingly, Cd37-/- lymphoma cells from 18-month old Cd37-/- mice contained very 
high basal levels of SOCS3 in contrast to WT controls (Figure 6B). Based on the finding 
^ Figure 4. Constitutive activation of the IL-6 pathway in Cd37-/- B cell lymphomas. (A) Cancer gene 
profiling was performed as described in Methods. Among the 84 cancer-associated genes, 6 genes were 
up-regulated and 7 genes were down-regulated by ≥2 fold in neoplastic tissue compared to control mLN 
tissue (see also Supplementary Table 2). (B) Immunohistochemistry analysis of p-AKT and p-STAT3 in 
mLN from 18-month old WT (left) and Cd37-/- (right) mice. Scale bars are 50μm. Experiments were 
performed 3 times with 4 mice per group. (C-D) Protein levels of p-STAT3 (78-76 kD) in mLN and spleen 
cells from 18-month old WT and Cd37-/- mice as detected by Western blot (n≥4 mice per genotype). 
p-STAT3 protein levels were normalized to total STAT3 levels. Data present mean±SEM, *P<0.05; 
Mann-Whitney nonparametric test was used for statistical analysis.
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that this high SOCS3 expression in Cd37-/- lymphomas was unable to inhibit the IL-6 
signaling pathway (Figure 5), we hypothesized that CD37 itself might interfere with 
this negative feedback machinery. This was investigated by co-immunoprecipitation 
experiments, which revealed that CD37 was indeed able to directly interact with 
SOCS3 (Figure 6C). Next, we studied the localization of endogenous CD37 and SOCS3 
in human B cells using confocal microscopy. In the absence of IL-6, SOCS3 was 
predominantly localized in the cytoplasm (Figure 6D, upper). IL-6 stimulation clearly 
induced translocation of SOCS3 to CD37 microdomains in the plasma membrane of 
human B cells, which was significantly higher than in unstimulated B cells (Figure 6D). 
To confirm that these microdomains were also enriched in the IL-6R complex, clear 
co-localization was observed between CD37 and IL-6Rα in the plasma membrane of 
resting human B cells (Manders coefficient = 0.69; Figure 6E). Human pre-B cells, 
which have very low levels of endogenous CD37, but do express the main components 
involved in IL-6R signaling (Supplementary Figure 7), were transfected with CD37-GFP 
and analyzed for activation of the IL-6 pathway. We observed CD37-expressing B cells 
to contain lower levels of p-STAT3 upon IL-6 stimulation than CD37-negative B cells 
(Figure 6F), thus (partially) rescuing the phenotype of Cd37-/- cells. Together, these 
data support the role for CD37 in inhibition of the IL-6 signaling pathway through its 
interaction with SOCS3. 
 To prove that the development of B cell malignancies in Cd37-/- mice was 
dependent on enhanced IL-6 signaling in vivo, we generated Cd37xIl6 double knock-
out (Cd37-/-xIl6-/-) mice and investigated whether ablation of CD37 in the absence 
of IL-6 could prevent the development of spontaneous malignancies during aging. 
Strikingly, Cd37-/-xIl6-/- mice were rescued from cancer development (only 1 out-of 
26 (4%) mice developed lymphoma; Figure 6G, Supplementary Table 1) confirming 
that Cd37-/- mice develop B cell lymphomas in an IL-6-dependent manner.
Loss of CD37 correlates with upregulated IL-6 signaling and poor survival in 
patients with diffuse large B cell lymphoma
To validate the role of CD37 in human B cell lymphoma, we investigated CD37 surface 
expression in biopsies of 47 patients with de novo GC B cell-like (GCB) diffuse large 
B cell lymphoma (DLBCL) and 50 patients with activated B cell-like (ABC) DLBCL 
uniformly treated with standard R-CHOP chemotherapy. Cell-of-origin classification 
of GCB-DLBCL was determined by gene expression profiling in these patients43. 
Approximately 32% of GCB-DLBCL and 46% of ABC-DLBCL tissues expressed ample 
CD37 protein at the cell membrane, whereas up to 68% of GCB-DLBCL and 54% of 
ABC-DLBCL totally lost CD37 protein expression (two representative CD37-positive 
(CD37+) and CD37-negative (CD37-) GCB-DLBCL tissues are shown in Figure 7A).
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 Consistent with B cell lymphoma development in Cd37-/- mice, loss of CD37 
expression in human B cell lymphomas correlated with upregulated IL6 mRNA levels 
in the tumor (P=0.0098; Figure 7B), and with presence of IL-6 protein in serum of those 
patients (P=0.0084; Figure 7C). Moreover, CD37- DLBCL tumors had significantly 
higher AKT1 mRNA levels (P=0.0476; Figure 7D) and a trend towards higher mean value 
of nuclear expression of p-STAT3 (P=0.0915; Figure 7E) compared to CD37+ tumors.
 Strikingly, Kaplan-Meier analysis showed a significant worse overall survival (OS; 
hazard ratio, 3.14; 95% CI of ratio, 1.17-8.41; P=0.02) and progression-free survival (PFS; 
hazard ratio, 2.58; 95% CI of ratio, 0.99-6.68; P=0.05) in GCB-DLBCL patients without 
CD37 expression compared to patients with CD37+ tumors (Figure 8A-B). The median 
OS was 86 months for patients with CD37- tumors and not reached for patients with 
CD37+ tumors, and the median PFS was 63.8 months for patients with CD37- tumors 
and not reached for patients with CD37+ tumors. These findings were confirmed in 
patients with activated B cell-like DLBCL (ABC-DLBCL). ABC-DLBCL patients with 
CD37- tumors had a worse OS (hazard ratio, 2.87; 95% CI of ratio, 1.13-7.29; P=0.03) 
and PFS (hazard ratio, 3.71; 95% CI of ratio, 1.55-8.89; P=0.003) compared to patients 
with CD37+ tumors (Figure 8C-D). In summary, loss of CD37 in tumors of both GCB- 
and ABC-DLBCL patients is significantly correlated with activation of the IL-6 signaling 
pathway and decreased survival.
Discussion
IL-6 has emerged as critical tumor-promoting cytokine in different types of human 
cancer including B cell malignancies8,44. Although IL-6 and its downstream effectors 
are widely studied as therapeutic targets for patients with B cell malignancies, 
> Figure 5. Blocking IL-6 supports B cell lymphoma cell viability. (A) Lymphoma-bearing Cd37-/- 
mice contain significantly (*P=0.016) higher IL-6 levels than aged-matched WT mice. Data present 
mean±SEM, n=6 mice/strain aged 12 months, n=16 mice/strain aged 18 months; Kruskal-Wallis one-way 
ANOVA test was used for statistical analysis. (B) IL-6 produced by ex vivo cultured lymphoma cells from 
6 individual Cd37-/- mice versus WT controls. Data present mean±SD, n=3. (C) Immunohistochemistry 
analysis of IL-6 in mLN tissues from 18-month old WT and Cd37-/- mice (n=6). Scale bars are 50μm. (D) 
B cells of mLN from 18-month old WT and Cd37-/- mice were stained for intracellular p-AKT and 
p-STAT3, and analyzed by flow cytometry. Percentage of p-AKT+ and p-STAT3+ lymphoma cells is 
reduced by IL-6 neutralizing antibodies (anti-IL-6) (lower). (E) Viability of lymphoma cells of Cd37-/- 
mice upon ex vivo culture with anti-IL-6 as detected by trypan blue exclusion at different time points. 
Data present mean±SEM, *P<0.0001. Experiments were performed 3 times with at least 3 mice per 
genotype; unpaired Student’s t-test was used for statistical analysis.
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very little is known about the underlying mechanisms that induce constitutive IL-6 
signaling in these tumor cells. Here, we demonstrate that deficiency of CD37 leads 
to spontaneous development of GC-derived B cell lymphoma in an IL-6-dependent 
manner. CD37 is a new regulator of SOCS3 and thereby interferes with activation of 
the IL-6 signaling pathway in B cells.
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 Gene expression profiling of tumor suppressor and oncogenes in Cd37-/- 
lymphomas revealed upregulation of Akt1, Stat3 and Jun, that play a central role in 
the IL-6 signaling pathway, and have been implicated in cancer cell survival18,19. The 
constitutive activation of AKT in Cd37-/- lymphomas corresponds to previous work 
showing that CD37 regulates AKT signaling leading to B cell survival27,38. Importantly, 
in 68% of human GCB-DLBCL and in 54% of human ABC-DLBCL tumors CD37 
expression was lost, which correlated with increased IL-6 levels and elevated levels 
of AKT1 mRNA and p-STAT3, validating the findings in Cd37-/- mice.
 Bcl2 transgenic mice develop lymphoma at low frequency (15-20%)45 compared 
to the incidence of 50% observed in the Cd37-deficient mouse strain at the same age 
and background. We did not detect enhanced Bcl2 expression in Cd37-/- lymphomas 
(Supplementary Table 2) indicating that the tumor suppressor activity of CD37 is 
independent of Bcl-2. B cells from young Cd37-/- mice are prone to differentiate 
towards IgA-producing plasma cells due to the high IL-6 levels that circulate in vivo28. 
Although in many human FL and DLBCL tumors constitutive expression of the Bcl-2 
protein has been reported46, we now provide a new CD37-dependent mechanism for B 
cell lymphomagenesis. Our findings are in line with studies showing that Il6 transgenic 
mice are prone to develop FL, plasmacytoma and DLBCL47, and IL-6 signaling in B 
cell malignancies can be independent of Bcl-248. The Cd37-/- lymphoma model may 
> Figure 6. CD37 controls the IL-6 pathway via SOCS3 and lymphoma development is dependent 
on IL-6 in vivo. (A) Comparable surface expression of IL-6 receptor alpha chain (IL-6R) and gp130 
in the plasma membrane of B220+IgA+ B cells from 18-month old WT and Cd37-/- mice analyzed by 
flow cytometry (specific antibody staining (black) versus isotype control antibody (grey), MFI: mean 
fluorescence intensity). (B) Protein levels of SOCS3 in mLN cells from 18-month old WT and Cd37-/- 
mice as detected by Western blot (non-contiguous lanes from the same gel). SOCS3 protein levels were 
normalized to actin levels. Data present mean±SEM, n=5 mice per genotype. (C) HEK293 cells were co-
transfected (TF) with CD37-GFP (or GFP alone) and SOCS3, followed by immunoprecipitation (IP) with 
anti-GFP or isotype control IgG. Western blots were probed with anti-SOCS3 (upper, 26kd) and anti-GFP 
(lower, CD37-GFP: 60-75kd, due to heavy glycosylation66; non-contiguous lanes from the same gel). (D) 
Co-localization of CD37 (red) and SOCS3 (green), or control antibody was studied on human JY B cells 
without (-) or with (+) IL-6 stimulation by confocal microscopy. Merge: co-localization in yellow (white 
arrows). Manders coefficient was determined with n≥17 cells from 3 independent experiments (each 
dot represents a single cell). Black lines represent mean±SEM, *P<0.05 (Mann-Whitney nonparametric 
test). (E) Co-localization of CD37 (red) and IL-6Rα (green), or control antibody was studied on human JY 
B cells by confocal microscopy. Co-localization (yellow in merge) was independent of IL-6 stimulation. 
Data shown for B cells without IL-6 stimulation. (F) p-STAT3 (78-76 kD) levels in NALM-6 cells, which 
were mock transfected (white bars) or transfected with CD37-GFP (black bars), with or without 
IL-6 stimulation for 60 min. Actin (42 kD) was used as loading control (non-contiguous lanes from 
the same gel. (G) Cd37-/-xIl6-/- mice are protected against development of B cell lymphoma (n=26) 
(see Supplementary Table 1 for details).
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^ Figure 7. Loss of CD37 in lymphomas of patients with DLBCL correlates with upregulated IL-6 
signaling. (A) CD37 immunohistochemistry staining (red) of GCB-DLBCL biopsies. Cell nuclei were 
counterstained with hematoxylin (blue). Representative stainings of two CD37-positive (CD37+) and 
CD37-negative (CD37-) tumors are shown. (B) Expression of IL6 mRNA levels in lymphomas of 47 
GCB-DLBCL patients expressing (CD37+, n=15, red dots) or not expressing (CD37-, n=32, blue dots) 
cell surface CD37. Data present mean±SD, P=0.0098; unpaired Student’s t-test. (C) Expression of IL-6 
protein levels in serum of DLBCL patients with CD37-negative tumors (CD37-, left bar) (n=3). Cytokine 
levels of DLBCL patients with CD37+ tumors were not detectable above background signal (ND) 
(n=5). Data present mean±SEM, P=0.0084; Mann-Whitney nonparametric test was used for statistical 
analysis. (D) Expression of AKT1 mRNA in lymphomas of GCB-DLBCL patients without CD37 expression 
(CD37-, n=32, blue dots) compared to CD37+ tumors (n=15, red dots). Data present mean±SD, P=0.0476; 
unpaired Student’s t-test. (E) Nuclear expression of (activated) p-STAT3 protein in lymphomas of GCB-
DLBCL patients with CD37- tumors (n=32, blue dots) compared to CD37+ tumors (n=15, red dots). Data 
present mean±SD, P=0.0915; unpaired Student’s t-test. 
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serve as new model for human B cell lymphomas in which the IL-6 signaling pathway 
is constitutively activated. It will be interesting to investigate other IL-6 family 
members in Cd37-/- mice, including IL-11 that was recently reported to play a major 
role in inflammation-induced tumors due to constitutive STAT3 activation49. 
 Importantly, we uncovered the underlying molecular mechanism of the lymphoma 
formation in Cd37-/- mice by investigating SOCS3, the major negative regulator of the 
IL-6 signaling pathway50. SOCS3 is a tumor suppressor as demonstrated in conditional 
Socs3-deficient mice (Socs3 deletion in gastrointestinal epithelial cells) that develop 
gastric cancer51. In human B cell malignancies, hypermethylation of SOCS3 leading 
to hyperactivation of STAT3 has been correlated with worse patient outcome52,53. In 
contrast, increased SOCS3 expression has been reported in melanoma54 and breast 
^ Figure 8. Loss of CD37 in lymphomas of patients with DLBCL correlates with worse survival. 
(A-B) Loss of CD37 correlates with significantly poor overall (A, OS, P=0.02) and progression-free 
(B, PFS, P=0.05) survival in 47 patients with GCB-DLBCL. (C-D) Loss of CD37 correlates with significantly 
poor overall (C, OS, P=0.03) and progression-free (D, PFS, P=0.003) survival in 50 patients with ABC-
DLBCL. Log-rank (Mantel-Cox) test was used for statistical analysis.
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cancer55. Furthermore, increased SOCS3 mRNA levels in peripheral blood of patients 
with non-Hodgkin lymphoma have been found to correlate with worse disease 
outcome56. We found elevated levels of SOCS3 in Cd37-/- tumors compared to WT 
control tissues, indicating that negative feedback regulation by SOCS3 is defective in 
the absence of CD37. Indeed, we observed that CD37 directly interacts with SOCS3. 
Based on these observations, we propose the following model for the role of CD37 
in the IL-6 signaling pathway (Supplementary Figure 8). Upon activation of the IL-
6R complex, AKT and STAT3 are phosphorylated, leading to production of SOCS3 
and subsequent inhibition of the IL-6 signaling cascade by SOCS3 binding to gp130. 
CD37 facilitates this inhibition by binding SOCS3 and stabilizing the IL-6R complex 
in the plasma membrane. In Cd37-/- B cells, SOCS3 cannot bind efficiently to the 
IL-6R complex resulting in defective feedback inhibition. Consequently, SOCS3 
will accumulate in the cytoplasm due to continuous activation of the IL-6 signaling 
pathway through autocrine IL-6 production by the tumor cells. In conclusion, the 
IL-6 signaling pathway is constitutively activated caused by defective regulation by 
SOCS3 due to CD37-deficiency resulting in malignant B cell transformation and tumor 
cell survival.
 The association of tetraspanins with tumor progression has been established 
although the underlying mechanisms have not been fully resolved23,24,57. Little is known 
about tetraspanin involvement in human B cell lymphomagenesis. CD81 protein is 
expressed at high levels in normal GC B cells and in DLBCL58, whereas down-regulation 
of CD9 has been related to lymphoma progression59. Our data now demonstrate that 
loss of CD37 in DLBCL is directly correlated with worse OS and PFS, which shows that 
CD37 may serve as a novel prognostic marker for patients with DLBCL. Sequencing 
of the CD37 gene in human B cell lymphomas did not reveal obvious mutations 
(data not shown). Thus, we postulate that CD37-deficiency in human DLBCL is 
most likely caused by involvement of microRNAs or epigenetic changes, which has 
been reported for different tumor suppressor genes as an alternative mechanism 
of gene silencing in cancer60,61. To the best of our knowledge this study is the first 
to demonstrate that tetraspanin deficiency itself can lead to tumor development. 
In most human B cell malignancies, including chronic lymphocytic leukemia and 
different types of non-Hodgkin lymphoma, CD37 is highly expressed by tumor cells62. 
Since CD37 can directly couple to B cell survival, CD37-targeting is currently under 
investigation in clinical trials in patients with B cell malignancies25,63,64. Our study now 
demonstrates that expression of CD37 is completely lost in 68% of GCB-DLBCL and in 
54% of ABC-DLBCL cases, which has important consequences for selecting patients 
for CD37-based immunotherapies. Furthermore, we anticipate that patients with 
CD37-negative lymphomas may particularly benefit from therapies inhibiting the IL-6 
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pathway, including mAbs that target IL-6(R)8,19, and JAK1/2 inhibitors that can reduce 
p-STAT3 and IL-6 levels in patients with myeloproliferative disorders65.
 Taken together, this study demonstrates that tetraspanin CD37 protects against 
development of GC-derived B cell lymphoma. We identified that CD37 interacts 
with SOCS3 and thereby induces feedback inhibition of the IL-6 signaling pathways 
via STAT3 and AKT, providing direct mechanistic insight into regulation of the IL-6 
signaling pathway in B cell biology and lymphomagenesis in vivo. This study is of major 
clinical relevance in human B cell lymphoma since CD37 expression in patients with 
DLBCL is directly correlated with overall and progression-free survival. Moreover, the 
discovery that >50% of DLBCL tumors are CD37-negative has important consequences 
for CD37-directed immunotherapies that are currently in clinical trials, and provides 
a strong rationale for blocking the IL-6 pathway in patients with CD37-negative B cell 
malignancies as therapeutic intervention.
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Supplementary Information
^ Supplementary Figure 1. Characterization of F4/80, Gr1, CD138, and B cell receptor expression. 
(A) Immunohistochemical analyses of mLN from 18-month old WT (upper) and Cd37-/- (lower) 
mice (n=4). Tissues were stained for, F4/80, Gr1 or CD138, or isotype control (data shown for rat 
IgG2a) using Fast-red and Hematoxylin counterstaining. Scale bars are 25μm. (B) Flow cytometry 
analysis of the B cell receptor (immunoglobulin) isotype on B cells from mLN of 18-month old WT 
(thin line) and Cd37-/- (thick line) mice. CD19+B220+ cells were stained for IgM (x-axis, left histo-
gram), IgD (y-axis), IgG (middle histogram) and IgA (left histogram). Experiments were performed 
4 times with at least 4 mice of each genotype per group.
< Supplementary Figure 2. Percentage of 
leukocyte subsets in Cd37-/- tumors. Flow 
cytometric analyses of leukocyte subsets in 
mLN from 18-month old WT (white bars) and 
Cd37-/- (black bars) mice (n=6). Data show 
percentages of B cells (B220+), CD8+ T cells, 
CD4+ T cells, regulatory T cells (Foxp3+ CD4+), 
NK cells (NK1.1), granulocytes (Gr1+), macro-
phages (F4/80+) and dendritic cells (CD11c+).
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^ Supplementary Figure 3. Phenotypical characterization of mLN of aged tumor-bearing WT 
mice. (A) B cells from mLN of 22-month old tumor-bearing WT mice were identified by gating on 
CD19+B220+ cells that were stained for CD86, MHC-II, PNA, CD138, CD43, CD40, IgM, IgG and IgA 
(black line) versus isotype control (solid grey) using flow cytometry. (B) Characterization of the B 
cell receptor (immunoglobulin) isotype on mLN of 22-month old tumor-bearing WT mice. Tissues 
were stained for IgG, IgM and IgA (green) using immunofluorescence. Nuclear counterstaining was 
performed with DAPI (blue). Scale bars are 70μm. Experiments were performed with tumors of 2 
different WT mice yielding similar results.
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^ Supplementary Figure 4. Immunoglobulin clonality assessment of lymphoma tissues. DNA 
was extracted from mLN of 18-month old WT and Cd37-/- mice. VJ joinings from Ig heavy chain 
genes were amplified by the BIOMED-2 multiplex PCRs for IGH-VJ rearrangements, showing FR1 
(A) and FR3 (B) (FR2 is shown in Figure 3A). In Cd37-/- lymphoma tissue 2 one dominant peak in 
background signal was detected in FR1 and FR2, while in FR3 two dominant peaks in background 
signal were detected. Both FR results are consistent with monoclonality with potential presence 
of bi-allelic IGH rearrangements as indicated by the GeneScan pattern in FR3. Experiments were 
performed 2 times with 3 mice of each genotype. Data shown for two lymphomas and one WT 
control tissue, as well as human polyclonal and monoclonal control samples.
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^ Supplementary Figure 5. Flow cytometric analyses and immunohistochemistry of tumor 
cells after adoptive transfer. (A) B cells were identified by gating on CD19+B220+ cells that were 
stained for CD86, MHC-II, PNA, CD138, CD43 and immunoglobulin receptors (IgM and IgA). Black 
line = WT B cells, solid grey = Cd37-/- B cells. (B) Flow cytometry analyses of in vivo transferred 
lymphoma cells in different organs (draining lymph node (dLN), non-draining lymph node (ndLN), 
and spleen) of 6-8 weeks old Cd37-/- mice using B220, CD19, and CD3 staining. Lymph nodes of 
mice that did not receive adoptively transferred lymphoma cells served as controls. Note the high 
percentage (70-75%) of CD19+B220+ lymphoma cells in the different lymphoid organs of mice 
that received the adoptive transfer indicating in vivo metastases. (C) Histology (H&E staining) and 
immunohistochemistry (B220 and GL7 antibodies) revealed the in vivo transferred lymphomas to 
be of GC-derived origin similar to the parental tumor. Scale bars are 160, 40, 40, 40μm (from left 
to right). Experiments were performed 3 times with at least 6 mice per group.
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^ Supplementary Figure 6. Expression of Casp8 and Ctnnb1 in Cd37-/- lymphoma cells. qPCR 
analysis of Casp8 (A) and Ctnnb1 (B) mRNA levels in WT control and Cd37-/- tumor cells. Ct values 
of the genes of interest were corrected for Ct value of the housekeeping gene Pbgd. Fold change 
of Cd37-/- mRNA levels (n≥5) were normalized to WT mRNA levels which were set at 1. Data rep-
resent mean±SEM.
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^ Supplementary Figure 7. CD37 and IL-6R expression on human NALM-6 pre-B cells. (A) 
Endogenous CD37 expression on NALM-6 cells was determined by flow cytometry. Black line 
= CD37, solid grey = isotype control, grey line = unstained cells. (B) NALM-6 cells were transiently 
transfected with CD37-GFP. Transfection efficiency (= GFP expression) was determined by flow 
cytometry (left panel) and immunofluorescence showed membrane expression of CD37-GFP 
(right panel). (C-D) Endogenous intracellular SOCS3 expression (C) and surface expression of 
IL-6Rα (D) was determined by immunofluorescence. (E) Endogenous gp130 expression on NALM-6 
cells was determined by flow cytometry. Black line = gp130, solid grey = isotype control, grey line 
= unstained cells.
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^ Supplementary Figure 8. Model representing the function of tetraspanin CD37 in putting the 
brake on the IL-6 signaling pathway. In normal B cells, binding of IL-6 to the IL-6 receptor complex, 
consisting of IL-6Rα and two gp130 chains, leads to phosphorylation of AKT and STAT3. This leads 
to short-term activating signals, including feed-forward production of IL-6, and long-term feed-
back inhibition by production of SOCS3. Once produced, SOCS3 translocates from the cytoplasm to 
the plasma membrane, where SOCS3 binds to both CD37 and the IL-6R complex and by this means 
inhibits the IL-6 signaling pathway. In Cd37-/- lymphoma cells, SOCS3 is produced but is not able 
to bind to the IL-6 receptor complex due to absence of CD37. Due to autocrine production of IL-6, 
the IL-6 signaling pathway is constitutively active leading to accumulation of p-AKT and p-STAT3 
and lymphoma cell survival.
Supplementary Table 1. Incidence of B cell lymphomas in aged Cd37+/+, Cd37-/- and Cd37-/-
xIl6-/- mice.
Cd37+/+ (WT) Cd37-/- Cd37-/-xIl6-/-
Number of mice 52 48 26
Age in months (range) 18-23 18-23 10-20
Gender Male 27 27 13
Female 25 21 13
Neoplasms MLN 1 13 1
Spleen 3 8 0
Liver 4 10 0
Cumulative incidence
(18-23 months)
8/52 (15%) 21/48 (44%) 1/26 (4%)
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Supplementary Table 2. Molecular signature of oncogenes and tumor suppressor genes in Cd37-
/- lymphomas. Cancer gene profiling approach by performing an Oncogenes and Tumor suppres-
sor genes Array on mLN from WT mice and lymphoma-bearing Cd37-/- mice (aged-matched). dCt 
values are corrected for mean Ct value of five housekeeping genes (Gusb, Hprt1, Hsp90ab1, Gap-
dh, Actb).
Gene Ct Cd37-/- ∆Ct Cd37-/- Ct WT ∆Ct WT ∆∆Ct Fold change 
Cdkn2a 32.05 4.56 34.48 7.82 -3.26 9.59
Xrcc1 30.12 2.63 30.89 4.23 -1.60 3.04
Akt1 29.65 2.16 30.27 3.61 -1.45 2.74
Cdkn1a 31.69 4.20 31.99 5.33 -1.13 2.19
Ctnnb1 28.66 1.17 28.92 2.26 -1.09 2.13
Jun 32.38 4.89 32.55 5.89 -1.00 2.00
Stat3 35.42 7.93 35.58 8.92 -0.99 1.99
Bax 36.13 8.64 36.17 9.51 -0.87 1.83
Nf2 33.50 6.01 33.51 6.85 -0.84 1.79
Myb 32.28 4.79 32.24 5.58 -0.79 1.73
Egf 35.91 8.42 35.80 9.14 -0.72 1.65
Trp53 30.19 2.70 30.06 3.40 -0.70 1.63
Tnf 35.69 8.20 35.49 8.83 -0.63 1.55
S100a4 30.12 2.63 29.82 3.16 -0.53 1.45
Fos 34.52 7.03 34.13 7.47 -0.44 1.36
Atm 31.01 3.52 30.59 3.93 -0.41 1.33
E2f1 33.78 6.29 33.32 6.66 -0.37 1.29
Nfkbia 27.89 0.40 27.34 0.68 -0.28 1.22
Cdk4 30.76 3.27 30.16 3.50 -0.23 1.17
Brca2 34.02 6.53 33.39 6.73 -0.20 1.15
Mlh1 30.43 2.94 29.72 3.06 -0.12 1.09
Mgmt 33.46 5.97 32.74 6.08 -0.11 1.08
Wwox 35.85 8.36 35.09 8.43 -0.07 1.05
Ets1 31.99 4.50 31.21 4.55 -0.05 1.04
Men1 35.11 7.62 34.31 7.65 -0.03 1.02
Hras1 31.21 3.72 30.41 3.75 -0.03 1.02
Tgfb1 29.67 2.18 28.86 2.20 -0.02 1.02
Kitl 32.55 5.06 31.72 5.06 -0.00 1.00
Igf2r 32.79 5.30 31.95 5.29 0.01 0.99
Pik3c2a 32.99 5.50 32.13 5.47 0.03 0.98
Elk1 36.34 8.85 35.47 8.81 0.04 0.97
Mdm2 30.45 2.96 29.55 2.89 0.07 0.95
140
CD37 protects against B-cell lymphoma
Gene Ct Cd37-/- ∆Ct Cd37-/- Ct WT ∆Ct WT ∆∆Ct Fold change 
Esr1 36.25 8.76 35.32 8.66 0.10 0.93
Raf1 30.53 3.04 29.6 2.94 0.10 0.93
Stk11 30.57 3.08 29.61 2.95 0.13 0.92
Bcl2l1 36.34 8.85 35.32 8.66 0.19 0.88
Src 34.69 7.20 33.6 6.94 0.26 0.84
Nras 31.36 3.87 30.26 3.60 0.27 0.83
Nf1 35.89 8.40 34.76 8.10 0.30 0.81
Cdh1 34.94 7.45 33.79 7.13 0.32 0.80
Cdkn2b 33.73 6.24 32.54 5.88 0.36 0.78
Sh3pxd2a 31.61 4.12 30.36 3.70 0.42 0.75
Hgf 34.25 6.76 32.95 6.29 0.47 0.72
Bcr 36.29 8.80 34.98 8.32 0.48 0.72
Rara 32.62 5.13 31.26 4.60 0.53 0.69
Nfkb1 31.50 4.01 30.14 3.48 0.53 0.69
Rel 32.20 4.71 30.84 4.18 0.53 0.69
Mcl1 29.65 2.16 28.28 1.62 0.54 0.69
Pik3ca 32.87 5.38 31.48 4.82 0.56 0.68
Runx3 32.74 5.25 31.32 4.66 0.59 0.67
Brca1 34.58 7.09 33.14 6.48 0.61 0.66
Kras 31.68 4.19 30.14 3.48 0.71 0.61
Rb1 33.34 5.85 31.78 5.12 0.73 0.60
Vhl 30.45 2.96 28.87 2.21 0.75 0.60
Apc 33.34 5.85 31.74 5.08 0.77 0.59
Kit 33.34 5.85 31.72 5.06 0.79 0.58
Prkca 32.26 4.77 30.61 3.95 0.82 0.57
Zhx2 33.06 5.57 31.33 4.67 0.90 0.54
Ccnd1 33.00 5.51 31.21 4.55 0.96 0.51
Myc 32.51 5.02 30.60 3.94 1.08 0.47
Smad4 31.65 4.16 29.68 3.02 1.14 0.45
Runx1 31.72 4.23 29.74 3.08 1.15 0.45
Rassf1 32.54 5.05 30.48 3.82 1.23 0.43
Bcl2 32.76 5.27 30.23 3.57 1.70 0.31
Casp8 35.17 7.68 32.42 5.76 1.92 0.26
Jak2 34.45 6.96 31.12 4.46 2.50 0.18
 
Supplementary Table 2. Continued
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Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell non-
Hodgkin lymphoma. Recently, we discovered that loss of tetraspanin CD37 protein in 
DLBCL tumors correlates with inferior survival. Tetraspanin CD37, a member of the 
transmembrane-four superfamily, is highly expressed on mature B lymphocytes and 
plays an important role in the germinal center response. There has been accumulating 
evidence that tetraspanin proteins are associated with cancer, but the underlying 
mechanisms of tetraspanin expression in relation to lymphoma development 
remain to be elucidated. Here, we report that acquired genomic mutations in the 
human CD37 gene underlie the absence of CD37 protein expression in ~15% of CD37-
negative DLBCL tumors. Furthermore, a strong decrease in CD37 mRNA levels was 
observed in all CD37-negative DLBCL tumors indicating transcriptional control or 
mRNA stability as important factor in loss of CD37 protein. Functional analysis of 
the discovered CD37 mutations confirmed aberrant CD37 protein expression at the 
plasma membrane of human lymphoma cells. This study provides novel mechanistic 
insight into the pathogenesis of CD37-negative DLBCL, which correlates with an 
unfavorable clinical outcome in patients. 
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of B-cell non-
Hodgkin lymphoma. Several genetic aberrations are known to underlie DLBCL 
development and progression1. Recently, we discovered that loss of tetraspanin CD37 
protein in DLBCL tumors correlates with inferior overall and progression-free survival 
upon standard R-CHOP (combination of rituximab, cyclophosphamide, doxorubicin, 
vincristine and prednisone) treatment2,3. Moreover, CD37 protein expression is an 
independent prognostic factor for patient outcome in R-CHOP-treated DLBCL3. In 
addition, it has been shown that neoplastic B cells in peripheral blood of patients 
with chronic lymphocytic leukemia or follicular lymphoma express significantly lower 
levels of CD37 protein compared to B cells in blood of healthy controls4. Tetraspanin 
CD37, a member of the transmembrane-four superfamily, is exclusively expressed 
in immune cells with highest expression on mature B lymphocytes4,5. CD37 plays an 
important role in the B-cell response where its expression is required for germinal 
center function and antibody production6. Tetraspanins organize the localization of 
proteins in the plasma membrane by the formation of the ‘tetraspanin web’ that 
through specific interactions with (immune) receptors and signaling molecules 
can facilitate intracellular signaling pathways7,8. In the past decade, there has 
been accumulating evidence that tetraspanins are associated with cancer9, but the 
underlying mechanisms for altered tetraspanin expression in relation to lymphoma 
development and progression remain to be elucidated. To date, it is unknown why 
CD37 protein expression is lost in ~50% of DLBCL tumors2,3. In order to unravel the 
driving force behind the absence of CD37 protein expression, we performed genomic 
mutation analysis of the coding sequence of the human CD37 gene. Here, we report 
that absence of CD37 protein expression in ~15% of CD37-negative DLBCL tumors is 
caused by acquired mutations in the human CD37 gene.
Study design
Fifty-four DLBCLs diagnosed between 2001 and 2011 were collected from the 
archive of the Department of Pathology of the Radboud university medical center, 
Nijmegen, The Netherlands (Supplementary Table 1). Immunohistochemistry for 
CD37 expression was performed as reported previously2. mRNA levels of CD37 were 
determined with quantitative RT-PCR analysis using SYBR Green (Roche). Mutation 
analysis of the coding sequence of CD37 and intron-exon boundaries was performed 
on all DLBCLs lacking CD37 protein expression by combining next generation 
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Wildtype         RNA     
CD37  gene (CD37) 
2 3 4 5 6 7 81
1 kb
  Wildtype  protein      Cys  Leu   Leu Gly    Leu  Intron
                     DNA      TGC CTC CTG GGC CTG GTGAG
  Patient #1       DNA      TGC CTC CTG GAC CTG GTGAG
                     protein      Cys  Leu   Leu Asp   Leu  Intron
Wildtype  protein                Intron Leu   Glu   Arg
         DNA      GCC TCT CA    G CTG GAG CGA
Patient #2   DNA      GCC TCT CAC CTG GAG CGA
         protein                Intron        Leu   Glu   Arg
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sequencing with Sanger sequencing, and results were confirmed at the mRNA level 
by Sanger sequencing of tumor cDNA.
 The CD37-G88D-GFP mutant construct was generated by introducing a G263A 
point mutation in hCD37-WT-GFP2 using site-directed mutagenesis (Q5® Site-
Directed Mutagenesis Kit, New England Biolabs). Human BJAB lymphoma B cells 
(2.5x106 cells) were transfected with 1µg human CD37-wild type-GFP (CD37-WT-
GFP) or CD37-G88D-GFP using the AMAXA NucleofectorTM biosystem (Lonza), and 
subsequently analyzed for CD37 protein expression and subcellular localization using 
Western blot and confocal microscopy, respectively.
 More details of experimental procedures, materials, and analysis are provided in 
Supplementary Materials and Methods.
Results and discussion
Decreased CD37 mRNA levels in CD37-negative DLBCL tumors
Fifty-four DLBCLs were analyzed for CD37 protein expression using immuno-
< Figure 1. (A) qPCR analysis of CD37 mRNA levels in CD37-negative (CD37-, n=15, grey) and 
CD37-positive (CD37+, n=5, white) DLBCL tumors. Ct values were corrected for Ct value of the 
housekeeping gene GAPDH. Fold change of CD37 mRNA was normalized to the mean expression 
in reactive lymph node. Data is represented in Whiskers boxplot (Min to Max). **p=0.0068, 
two-tailed Mann-Whitney non-parametric test. (B) qPCR analysis of CD37 mRNA levels in CD37-
negative (CD37-) germinal center B-cell like DLBCL (GCB, grey) and activated B-cell like (ABC-)
DLBCL and unclassified DLBCL (non-GCB, blocked grey) compared to CD37-positive (CD37+) 
GCB and non-GCB DLBCL tumors. Ct values were corrected for Ct values of the housekeeping 
gene GAPDH. Fold change of CD37 mRNA was normalized to the mean expression in reactive 
lymph node. Data is represented in Whiskers boxplot (Min to Max). p=0.0515, two-tailed Mann-
Whitney non-parametric test. (C) Schematic representation of the CD37 gene consisting of 8 
exons. The dark grey boxes represent the coding sequence of CD37; the light grey boxes are the 
non-coding sequence between exon 1 (begin) and exon 8 (end). Patient #1 displayed a missense 
mutation in exon 3 (c.263G>A(p.Gly88Asp; left box). Patient #2 displayed a splice site mutation 
in intron 4 (c.343-1G>C; right box). (D) Sanger sequencing results of the cDNA of the tumor with 
the missense mutation with a forward (left) and reverse (right) primer reaction. Grey = exon 3, 
white = exon 4. The arrow indicates the location of the mutation. (E) Sanger sequencing results 
of the cDNA of the tumor with the splice site mutation with a forward (left) and reverse (right) 
primer reaction showing an 11 base-pair deletion as demonstrated by a double peak pattern in 
the cDNA sequence after this deletion showing the exon 5 sequence in the forward reaction and 
the exon 4 sequence in the reverse reaction below the main peak pattern. White = exon 4, grey = 
exon 5. In the box the frame-shift as a result of the 11 base-pair deletion is visualized.
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histochemistry. Lack of CD37 protein expression was observed in 15 DLBCLs. Next, 
we performed quantitative RT-PCR analysis of both CD37-negative and CD37-positive 
DLBCL tumors to determine CD37 mRNA expression. CD37-negative lymphomas 
displayed significantly decreased CD37 mRNA levels compared to CD37-positive 
lymphomas (Figure 1A), which was independent of DLBCL subtype (Figure 1B). 
Genomic CD37 mutations in CD37-negative DLBCL tumors
 In order to unravel the cause of the absence of CD37 protein expression, mutation 
analysis of the coding sequence of CD37 and intron-exon boundaries was performed 
on all 15 DLBCLs lacking CD37 protein expression. Genomic CD37 mutations were 
identified in 2-out-of-15 CD37-negative DLBCLs (13%), where one represented a 
missense mutation in exon 3 (c.263G>A(p.G88D)) and the other one a splice site 
mutation in intron 4 (c.343-1G>C) (Figure 1C).  Both mutations were absent in control 
(non-tumor) tissue of the same patients, indicating that the discovered mutations 
were acquired prior to or during tumor development and not present in germline DNA 
(data not shown). The DLBCL with the splice site mutation expressed very low levels 
of CD37 mRNA (14-fold lower as compared to reactive lymph node), as did the DLBCL 
with the missense mutation in exon 3 (3-fold lower). The p.G88D missense mutation 
was predicted to be pathogenic by the PolyPhen-2 prediction program (score 1.00)10. 
Sanger sequencing of the cDNA confirmed the presence of this missense mutation 
(Figure 1D). Sequencing of the cDNA of the DLBCL with the splice site mutation 
revealed an 11 base pair deletion (Figure 1E). As a consequence of this deletion, 
a frame-shift occurred in the CD37 mRNA sequence resulting in a protein that is 
completely altered after transmembrane domain 3, and introducing a premature 
stop codon. We predict that the latter results in a non-functional and instable CD37 
protein as the extracellular domain 2 (EC2), which is central for tetraspanin function, 
is truncated11,12. This is in line with previous studies on mutations in tetraspanin CD81 
in B cells13, or its partner CD19 in B-cell acute lymphoblastic leukemia14.
Missense mutation in the CD37 gene causes aberrant cell surface CD37 
expression
Next, we introduced the p.G88D missense mutation in human lymphoma B cells 
using a green fluorescent protein (GFP) expression vector to analyze possible 
defects in protein expression and/or subcellular localization. Western blot analysis 
showed that wild-type CD37 (CD37-WT-GFP) protein appeared as a smear between 
50-75kD as a result of heavy glycosylation15, while protein isoforms with the 
highest glycosylation state (±70kD) were less pronounced in the lymphoma cells 
expressing the mutant CD37-G88D-GFP (Figure 2A). Quantification revealed that 
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overexpressing CD37-WT-GFP or CD37-G88D-GFP. The blot was probed with α-GFP to detect 
CD37-GFP expression (50-75kD; upper blot). α-Tubulin was used as a loading control (lower 
blot). The protein expression level of CD37-G88D-GFP was normalized to CD37-WT-GFP for 
each experiment (n=3). Data represent mean±SD. (B) Confocal microscopy images of BJAB 
cells overexpressing CD37-WT-GFP and CD37-G88D-GFP (green) co-stained for MHC-I (red) to 
define the plasma membrane. Overview images (left) and single cell images (upper right) show 
representative cells of three individual experiments for both CD37-WT-GFP and CD37-G88D-GFP. 
Scale bar = 10µm. The ratio between membrane and cytoplasmic GFP expression was quantified 
from 10 representative cells of each independent experiment (n=3). *p=0.023, paired t-test. Data 
represent mean±SD.
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total protein expression levels of CD37-G88D-GFP were similar to CD37-WT-GFP 
(Figure 2A). Furthermore, we determined the subcellular localization of CD37 using 
confocal microscopy. Lymphoma cells expressing the mutant CD37-G88D-GFP had 
significantly lower CD37 expression at the plasma membrane and more retention 
of intracellular CD37 protein compared to lymphoma cells expressing CD37-WT-GFP 
(Figure 2B). These data indicate that the p.G88D missense mutation results both in 
defective glycosylation and trafficking of CD37 protein in lymphoma B cells, which is 
in line with the reported role of glycosylation as a sorting signal for protein transport 
to the plasma membrane16. Moreover, modification of cell surface proteins by means 
of defective glycosylation frequently contributes to cancer development to enhance 
migration and invasiveness of tumor cells17.
 We previously showed that in ~50% of DLBCL cases, CD37 protein expression was 
lost in the tumor cells resulting in increased activity of the IL-6 signaling pathway 
and inferior survival outcome.2,3 Here, we demonstrate that mutations in the human 
CD37 gene result in aberrant CD37 surface expression in lymphoma B cells. Additional 
factors that can be involved in loss of CD37 protein expression include epigenetic 
regulation18 and mRNA stability. Our data provide mechanistic insight underlying 
the absence of CD37 protein expression on the plasma membrane of DLBCL tumor 
cells. In line with our study, alterations in human tetraspanin expression resulting in 
defective immunity have been reported for CD53 and CD81. Loss of CD53 expression 
on neutrophils led to a hereditary syndrome of recurrent infections19. A homozygous 
splice site mutation in the CD81 gene resulted in defective B-cell receptor-CD19-
CD81 complex formation and antibody deficiency13. 
 In conclusion, we discovered inactivating CD37 gene mutations in two individual 
DLBCL tumors and demonstrated that they both lead to aberrant protein CD37 
expression. This study provides novel mechanistic insight underlying the loss of 
CD37 expression and development of DLBCL. Moreover, these data are important 
for novel immune-therapeutic strategies, as CD37 is currently under investigation in 
clinical trials for B-cell malignancies20.
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Supplementary Information
RNA isolation and cDNA generation
Frozen tumors sections (10µm) of human DLBCL tumors were cut, resuspended in 
TRIzol reagent (Life Technologies) and stored at -80°C until RNA isolation, according 
to manufacturer’s instructions. RNA quantity and purity were determined on a 
NanoDrop spectrophotometer. 2µg RNA was treated with DNase I (amplification 
grade; Invitrogen) and reverse transcribed to cDNA by using random hexamers and 
Moloney murine leukemia virus reverse transcriptase (Invitrogen). 
Quantitative RT-PCR analysis
mRNA levels of CD37 were determined with a CFX96 Sequence Detection 
System (Bio-Rad) with SYBR Green (Roche) as the fluorophore and gene-specific 
oligonucleotide primers. The following primers were used: forward (located on 
CD37 exon 4) 5’-ACACAGATGACCCTGGGAAT, reverse (located on CD37 exon 6) 
5’-CGTTGGTCGCCGACAAGTT. Reaction mixtures and program conditions were 
applied as recommended by the manufacturer (Bio-Rad). Quantitative PCR data 
were analyzed with the CFX Manager software (version 3.1, Bio-Rad) and checked 
for correct amplification and dissociation of the products. Ct values of the genes of 
interest were normalized to the Ct value of the housekeeping gene GAPDH.
Mutation analysis in genomic DNA
Genomic DNA was extracted from formalin-fixed paraffin-embedded or frozen 
tissue. Tissue sections before and after the sections for DNA extraction were 
examined to ensure adequate numbers of tumor cells. Subsequently, amplification 
of the CD37 coding sequence and intron-exon boundaries was performed in three 
reactions with 100ng of DNA input for each reaction in a total volume of 25μL. Exons 
1 through 7 were amplified in two multiplex PCRs and exon 8 was amplified in a 
singleplex PCR (see Supplementary Table 2 for primer sequences). The PCR product 
from exon 8 was analyzed by Sanger sequencing as a sufficient number of reads 
could not be achieved using multiplex PCR. The PCR products from exons 1 through 
7 were pooled and prepared for sequencing analysis using the NEXTflex DNA 
sequencing kit (Bioo Scientific, Austin, Texas, USA) according to the manufacturer’s 
instructions. Sequencing was performed on an Ion Personal Genome machine 
(Life Technologies, Bleiswijk, The Netherlands) according to the manufacturer’s 
instructions. Sequences were analyzed with the SeqNext software package (JSI 
Medical Systems, Kippenheim, 
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Germany). Variants were called if the absolute number of variant reads was 25 or 
higher and if the variant constituted at least 10% of the reads. Intronic mutations, 
known single nucleotide polymorphisms (SNPs), mutations in untranslated regions, 
and silent mutations were filtered out. Mutations were confirmed by conventional 
Sanger chain-terminating sequencing in duplicate. Tissue samples of both DLBCLs 
carrying a mutation in the CD37 gene contained 70% tumor tissue.
Mutation analysis in cDNA
A PCR reaction with tumor cDNA was performed using Q5® Hot Start High-
Fidelity DNA Polymerase (New England Biolabs) according to manufacturer’s 
instructions. The following primers were used: forward (located on CD37 exon 
1) 5’-AAGTACTTCCTCTTCGTTTTCAACCT, reverse (located on CD37 exon 8) 5’- 
ATGAGGACTTGGAACCAGTC. Gel electrophoresis was used to verify the PCR 
product size. PCR product clean-up was performed with the Nucleospin Extract 
II Kit (Macherey-Nagel), followed by Sanger sequencing using 50ng cDNA. 
The following primers were used: forward 5’-CCTCTGCAGATCTGGTCCAA or 
5’-AAGTACTTCCTCTTCGTTTTCAACCT, reverse 5’- ATGAGGACTTGGAACCAGTC. 
Sequence results were analyzed using SnapGene® Viewer (version 3.1.4, GSL Biotech 
LLC).
Cultivation and transfection of the BJAB cell line
The human Burkitt lymphoma B-cell line BJAB (ATCC) was cultured in RPMI-1640 
(Thermo Fischer Scientific) containing 10% fetal bovine serum (FBS, Greiner Bio-One), 
1% antibiotics/antimycotica (AA, Thermo Fischer Scientific) and 1% Ultraglutamine1 
(UG1, 200mM Glutamine in 0.85% sodium chloride solution, Lonza). In order to 
overexpress CD37-WT-GFP or CD37-G88D-GFP, BJAB cells were transfected with 
the corresponding plasmid DNA. Generation of CD37-WT-GFP construct has 
been described before1. The CD37-G88D-GFP mutant construct was generated 
by introducing a G263A point mutation in hCD37-WT-GFP using site-directed 
mutagenesis (Q5® Site-Directed Mutagenesis Kit, New England Biolabs) according to 
manufacturer’s instructions. Transfection of 1µg of these DNA constructs in 2.5x106 
BJAB cells was performed with Mirus transfection buffer (Ingenio® Solution) using 
aluminum electrode cuvettes (Lonza). Electroporation of the cells was done using the 
AMAXA NucleofectorTM biosystem (program M-013, Lonza).
Western Blot
Transfected cells were lysed 16 hours after transfection in 1x sample buffer 
supplemented with 2.5% β-mercaptoethanol, boiled at 95°C for 5 min and separated 
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on a 10% SDS-PAGE gel. Separated proteins were blotted onto a Polyvinylidene 
fluoride (PVDF) membrane and blocked with 4% milk powder (Elk, Campina) in 
0.05% Tween in phosphate buffered saline (PBS-T) for 30 min at room temperature 
(RT). Membranes were then incubated with both 1µg/ml rabbit anti-GFP (polyclonal, 
Rockland) and 0.2µg/ml rat anti-human-α-tubulin (clone YOL1/34, Novus) antibodies 
in blocking solution for 1h at RT, washed three times with PBS-T and stained with 
0.2µg/ml in blocking solution secondary goat anti-rat AF680 (polyclonal, Invitrogen) 
and goat anti-rabbit IRDye800 (polyclonal, LI-COR) antibodies for 45 min at RT. 
Western blots were imaged on Odyssey CLx (LI-COR) and analyzed with the Image 
Studio software (version 5.0, LI-COR).
Immunofluorescence microscopy
Coverslips were coated with 50µg/ml Poly-L-lysine (PLL) for 15 min at 37 °C. 
Cells were adhered on PLL-coated coverslips for 15 min at 37 °C, and fixed in 4% 
paraformaldehyde (PFA) for 20 min at RT. Fixed cells were blocked with 4% bovine 
serum albumin (BSA), 10mM Glycine in PBS for 1h at RT and subsequently incubated 
with 10µg/ml mouse anti-human major histocompatibility complex-I (MHC-I) 
antibody (clone W6/32, Abcam) diluted in blocking buffer for 45 min at RT, followed 
by 2µg/ml secondary goat anti-mouse-IgG2a-Alexa568 antibody (Life Technologies) 
for 30 min at RT. Afterwards cells were stained with 0.3µg/ml 4’,6-diamidino-2-
phenylindole (DAPI) in PBS for 15 min at RT and embedded in Mowiol. Cells were 
imaged using Olympus FV1000 confocal laser scanning microscope. Images were 
analyzed with Fiji2 and Cell Profiler3 software. The latter was used for quantification 
of the ratio of mean GFP-intensity in the membrane over the cytoplasm. The MHC-I 
staining was used to define the membrane and the cytoplasm was calculated by 
subtracting the nuclear (defined by DAPI signal) and membrane area from the cell 
area (defined by DAPI, GFP, and MHC-I signal).
Statistics
Statistical differences were determined using a paired t-test or two-tailed 
nonparametric Mann-Whitney test (in case of non-Gaussian distribution) (GraphPad 
Prism version 5). Differences were considered to be statistically significant at p≤0.05.
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Supplementary Table 1. Subtype and tumor cell percentage of DLBCL patient cohort.
# of DLBCLs
DLBCL subtype Total (N=54) CD37-positive CD37-negative
GCB N=28 N=21 N=7
non-GCB N=26 N=16 N=10
Tumor percentage
50% N=5 N=4 N=1
60% N=7 N=4 N=3
70% N=27 N=17 N=10
80% N=6 N=5 N=1
unknown N=9 N=7 N=2
Supplementary Table 2. Primers used for multiplex PCR and Sanger sequencing of genomic DNA.
Target exon Pool Forward primer sequence
(5’--> 3’)
Reverse primer sequence
(5’--> 3’)
Genomic coordinates
(GRCh37)
Exon 1+2 A CTGTCTCCCCCACTGTCAGC GGGTAGCCATGAGGCAACT 49838733...49838888
Exon 1+2 B TGAGTTGCCTCATGGCTACC GAGACCCCAGGAAGTTGCTT 49838868...49839104
Exon 3 B CTGTGCCACACAGCTCATCA CACTCACCAGGCCCAGGA 49840124…49840297
Exon 3 A CCTCTGCAGATCTGGTCCAA CCATTTTTGAGGGTGGGGATA 49840180...49840349
Exon 4 B TCCTATCCCCACCCTCAAAA GGCCACTGCAGGAAGCTC 49840326...49840498
Exon 5 B GTGGGGCGGGGAAGATAAG AGTCCGGGAGGGAACTGGAG 49841137...49841319
Exon 6 A CCCTCTGACTCGTATCCCTCT CGTTGGTCGCCGACAAGTT 49841931…49842074
Exon 6 B ACTGGTTCCAAGTCCTCATCC ATTCGACAGGTTTATGCTCCGAA 49841988...49842227
Exon 7 A GGGCTTGAGAGTCCCAGAAA CAGGGCCATCTAGGGATTTAGG 49842535...49842724
Exon 8 C CACCCCTTCGACTTCTCTGA GCGAACTGGGGATTAAACAA 49843467...49843677
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Abstract
Standard therapy of patients with B-cell non-Hodgkin lymphoma (B-NHL) mostly 
consists of chemotherapy combined with anti-CD20 (e.g. rituximab) immunotherapy. 
However, relapse of aggressive B-NHL occurs frequently, which may coincide with 
therapy resistance. This demonstrates the urgent need for exploring new lymphoma-
targeted therapies. Here, we review recent insights in the pathophysiology of 
B-NHL, and discuss CD20 and three alternative membrane targets (B-cell receptor, 
immune checkpoints PD-1/PD-L1, tetraspanin CD37) that are currently in the 
spotlight for treatment of B-NHL. Furthermore, we present a novel concept in which 
plasma membrane organization of the lymphoma B cell determines the efficacy of 
membrane-targeted therapies, which has consequences for treatment application 
and clinical outcome for patients with B-cell lymphoma.
Trends
• B-cell lymphoma patients still face disease relapse after standard therapy (e.g. 
R-CHOP).
• The cell surface of lymphoma B cells is the most easily accessible part of the cell, and 
therefore a favorable target. 
• Besides CD20, alternative B-cell membrane proteins, including the B-cell receptor 
and tetraspanin CD37, gained renewed interest as therapeutic target.
• Immune checkpoint inhibitors currently tested in (pre-)clinical studies for B-cell 
lymphoma may stimulate anti-lymphoma immune responses.
• Expression of membrane-organizing proteins, such as tetraspanins, differs on 
lymphoma B cells compared to healthy B cells.
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Origin of B-cell non-Hodgkin lymphoma
B cells undergo several distinct phases of development, starting from pre-B cells 
in the bone marrow towards ultimately the differentiation into antibody-producing 
plasma cells and memory B cells. Upon encountering specific antigens, germinal 
centers (GC, see Glossary) are formed within the lymph node, where B cells undergo 
somatic hypermutation (SHM, see Glossary) and class switch recombination (CSR, 
see Glossary) in order to generate a high affinity B-cell receptor (BCR). However, 
SHM and CSR are error-prone mechanisms, hence the majority of B-cell non-Hodgkin 
lymphomas (B-NHL) arises from GC B cells1. These GC-derived B-cell lymphomas 
frequently harbor chromosomal translocations of proto-oncogenes, like BCL2, BCL6 
or MYC, that are relocated under the control of the active immunoglobulin heavy 
chain (IGH) locus1,2. Since these translocations often involve the non-productively 
rearranged IG loci, most lymphomas still express a functional BCR1.
 The GC-derived B-NHLs include follicular lymphoma (FL, see Glossary), Burkitt 
lymphoma (BL, see Glossary), and diffuse large B-cell lymphoma (DLBCL, see 
Glossary). DLBCL is the most prevalent type, accounting for approximately one 
third of all NHL cases. Two subtypes of DLBCL have been identified: germinal center 
B-cell-like (GCB-)DLBCL, arising from GC B cells, and activated B-cell-like (ABC-)
DLBCL, which has a post-GC origin3. ABC-DLBCL is characterized by constitutively 
active BCR/NF-κB signaling4, and has a worse prognosis than GCB-DLBCL3. The 
hallmark of BL is translocation of MYC to the IGH locus5. Both DLBCL and BL are 
aggressive cancers in contrast to FL, which is an indolent lymphoma. However, in a 
large proportion of FL cases the disease transforms into the more aggressive DLBCL6. 
Current first-line treatment of DLBCL consists of the combination of rituximab (anti-
CD20 monoclonal antibody (mAb)) with CHOP-based (see Glossary) chemotherapy, 
frequently followed by subsequent radiotherapy. BL is treated with CHOP-based 
chemotherapy, sometimes combined with rituximab. For FL, a watch-and-wait policy 
is frequently applied. In case of treatment indication, first-line treatment consists of 
rituximab combined with CHOP- or CVP-based (see Glossary) chemotherapy with or 
without subsequent radiotherapy. The exact protocol depends on the diagnosis and 
condition of the patient7–9.
 Although immunotherapy with rituximab has significantly improved the clinical 
outcome of patients with B-cell malignancies10,11, many patients with DLBCL12, 
BL11 and FL13 suffer from treatment failure or relapse. Several novel targeted 
therapies are currently under (pre-)clinical investigation, including therapies 
targeting the tumor microenvironment (reviewed in [14]), and therapies targeting 
the lymphoma cells directly, either intracellular or at the membrane (reviewed in 
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[15]). Targeting membrane proteins to treat cancer has been extensively studied by 
researchers and clinicians in the last two decades since the cell surface is the easiest 
accessible part of the cell. Rituximab is a clear example of successful antibody-
based immunotherapy targeting a membrane protein. Antibody-based membrane-
targeted therapies act through different mechanisms, including direct cell death 
signaling, antibody-dependent cell-mediated cytotoxicity (ADCC, see Glossary) and 
complement-dependent cytotoxicity (CDC, see Glossary). In this review, we focus on 
recent developments and new membrane-targeted therapies for GC-derived B-cell 
lymphoma (Figure 1a). Furthermore, we propose a model illustrating the dynamic 
cell surface protein landscape of lymphoma B cells that influences the efficacy of 
membrane-targeted therapies in B-NHL. 
CD20 as the first B-cell-specific membrane target to treat 
B-NHL
Anti-CD20 mAb rituximab represents the first mAb approved for cancer therapy 
by the FDA in 1997. CD20 is a four-transmembrane protein expressed on mature B 
cells that is involved in B-cell activation and differentiation, mainly by controlling 
calcium influx16. CD20 was selected in the early 1980’s as new target for B-NHL 
since the majority of B-NHL cells (90%) express CD20 with high density at the cell 
surface17. Pro-B cells and antibody producing plasma cells do not express CD20, 
and are therefore not vulnerable to CD20 targeting. As such, the healthy B cell 
pool is restored after rituximab treatment and B cell immune responses are largely 
preserved.
 Anti-CD20 mAbs have been classified as type I and type II18, which both induce 
ADCC. Type I mAbs (e.g. rituximab and ofatumumab) are regarded as the most 
potent antibodies because of their capacity to initiate CDC in contrast to type II 
mAbs (e.g. obinutuzumab). Furthermore, type II mAbs may induce direct cell death 
(Figure 1b), although the exact mechanism remains to be elucidated. Upon type I 
mAb binding, CD20 is redistributed to specific microdomains, including lipid rafts 
and tetraspanin-enriched microdomains (Box 1), which stimulates clustering of the 
antibody Fc regions involved in CDC. Unfortunately, Fc receptor polymorphisms and 
downregulation of CD20 caused by repeated exposure to rituximab19 demonstrate 
the urgent need for development of alternative membrane-targeted strategies.
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Emerging membrane-targeted therapies for B-cell lymphoma
Besides CD20, numerous other potential membrane targets have been investigated 
in lymphoma including: CD19, CD22, CD23, CD37, CD47, CD52, CD74, CD79α, CD80, 
HLA-DR, and the BCR (idiotype). Furthermore, immune checkpoint inhibitors that 
target programmed cell death protein 1 (PD-1) and programmed cell death ligand 
1 (PD-L1) are currently in the spotlight for treatment of B-NHL. Targeting of some 
of these cell surface proteins with mAbs has shown promising therapeutic efficacy, 
but targeting others seems less suitable due to limited specificity (e.g. CD80 and 
HLA-DR are very broadly expressed) or resistance development (e.g. due to antigen 
shedding or internalization). A few new mAbs directed against B-cell surface 
proteins currently tested in clinical trials show promising results either as first-line 
therapy in combination with rituximab, or as monotherapy for heavily-pretreated 
B-NHL patients (e.g. anti-CD22: epratuzumab; anti-CD37: otlertuzumab; anti-CD74: 
milatuzumab) (reviewed in [15]). Future antibody engineering studies, including 
conjugation to radio/immunotoxins or generation of bispecific antibodies, may 
further improve their anti-lymphoma potency. Below we will discuss recent results 
and focus on novel developments in targeting membrane proteins in B-NHL, 
including immune checkpoints and tetraspanins (Figure 1). 
Box 1. Plasma membrane microdomains
The plasma membrane is composed of multiple different proteins and lipids that are non-
randomly localized into specialized areas (microdomains). Signaling molecules, lipids 
and proteins can cluster together in such organized domains, which is crucial for efficient 
signal transduction73,74. Disrupting membrane organization interferes with several 
membrane-proximal signaling processes, including those involved in tumor cell survival 
and metastasis (reviewed in [73]). Different types of membrane microdomains have been 
reported, including lipid rafts and tetraspanin-enriched microdomains (TEMs)75. Lipid 
rafts were originally identified as membrane fractions that are insoluble in the strong 
detergent Triton X-10076, hence they are also defined as detergent-resistant membrane 
domains (DRMs). They are enriched in densely packed sphingolipids and cholesterol, and 
harbor glycophosphatidylinositol (GPI)-anchored proteins among others77. A different 
type of microdomain is formed by tetraspanin proteins (Box 2) that associate with 
themselves and with specific partner molecules (including CD20, integrins and MHCII) in 
clusters known as the tetraspanin web or TEMs78–80. Although both TEMs and lipid rafts 
are detergent-resistant and present in DRMs, they are very different domains in terms of 
protein composition81,82.
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Aberrant B-cell receptor function in B-NHL 
The BCR, a membrane-bound immunoglobulin (Ig), can be divided in 5 classes (IgG, 
IgD, IgM, IgA or IgE) that are important for antigen recognition and initiation of 
signaling events leading to B-cell survival, proliferation and migration20. The BCR 
forms a complex with CD79α (or Igα) and CD79β (or Igβ) which both contain an 
immunoreceptor tyrosine-based activation motif (ITAM) to transmit intracellular 
signaling. Upon antigen binding, the conformational state of the BCR changes to 
initiate downstream signaling, but the underlying molecular mechanisms are still 
debated. The “conformation-induced oligomerization model”, which proposes that 
single BCRs oligomerize upon antigen recognition21, has recently been challenged by 
super-resolution studies. This has led to convincing evidence for the “dissociation-
activation model”, in which BCR oligomers dissociate upon antigen binding, gaining 
an open conformation22,23. This conformational change influences the distribution of 
BCR co-receptors CD19 and CD20 that interact with IgD oligomers on resting B cells, 
and relocate to IgM oligomers upon B-cell activation23. These changes in plasma 
membrane organization are controlled by a superfamily of membrane-organizing 
proteins, called tetraspanins (Box 2). Tetraspanin CD81 is required for reorganization 
of CD19 to BCR nanoclusters, which enables binding of signaling proteins to the 
intracellular domain of CD19 and initiation of signaling downstream of the BCR24,25.
< Figure 1. Current and novel membrane-targeted therapies in B-cell lymphoma. (A) 
Membrane proteins used in and explored for lymphoma-targeted therapy. Left to right: CD20; 
BCR with its signaling proteins CD79α/β; CD19; PD-L1; tetraspanin CD37 with the IL-6R. (B) 
Targeting CD20 using mAb (e.g. rituximab) will cluster CD20 proteins leading to tumor cell death 
via CDC, ADCC and/or direct apoptosis. (C) In chronic active BCR signaling (i), binding of (self-)
antigens to the BCR triggers recruitment of Syk to the phosphorylated (p-)ITAMs of CD79α/β, 
which leads to translocation of PI3K to CD19. Subsequently, BTK is activated which initiates NF-
κB activation via the CARMA1-BCL10-MALT1 complex resulting in lymphoma B-cell survival. In 
tonic BCR signaling (ii), constitutive activation of PI3K in absence of (self-)antigens results in 
continuous signaling via AKT pathway and lymphoma cell survival. Novel anti-idiotype therapy 
strategies can directly target the BCR. Syk, PI3K and BTK can be inhibited using small molecule 
inhibitors (*). (D) Immune checkpoint inhibitors (e.g. nivolumab, pembrolizumab, pidilimumab) 
bind to PD-L1 expressed on lymphoma B cells or to PD-1 on T cells. This inhibits the immune-
escape mechanism used by ABC-DLBCL and FL cells. (E) In CD37-expressing (CD37+) B-cell 
lymphoma (i), tumor cell death can be induced by targeting CD37-specific mAbs (IMGN529, 
Otlertuzumab). In contrast, CD37-negative (CD37-) B-cell lymphoma (~50% of DLBCL cases) 
(ii), shows constitutive activation of the IL-6 signaling pathway (increased p-AKT and p-STAT3). 
These patients may benefit from α-IL-6(R) therapy.
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 Two modes of BCR signaling have been described: 1) active signaling upon antigen 
binding to the BCR leading to NF-κB activation via Syk, phosphoinositide 3-kinase 
(PI3K) and Bruton’s tyrosine kinase (BTK); and 2) tonic signaling, an antigen-
independent mechanism required for B-cell survival which occurs in mature resting 
B cells via activation of PI3K and protein kinase B (AKT) (reviewed in [26]) (Figure 1c). 
In most GC-derived B-cell lymphomas, BCR signaling is disturbed resulting in 
enhanced B-cell survival and proliferation. BL shows tonic BCR signaling (Figure 1c) 
via constitutive activation of the PI3K pathway driven by MYC translocation to 
the IGH locus during SHM5,27. Chronic active BCR signaling is seen in ABC-DLBCL 
which is evidenced by knockdown experiments of BTK or components of the BCR 
complex that induced killing of lymphoma cells4. In contrast, GCB-DLBCL cells were 
not killed, indicating they do not require BCR signaling to survive. In the majority of 
ABC-DLBCL cases, self-antigens present in the tumor microenvironment may drive 
continuous BCR stimulation (Figure 1c)28. The presence of BCR clusters on ABC-
DLBCL cells resembles BCR clusters observed on normal B cells following antigen 
stimulation4. In 10% of ABC-DLBCL cases, gain-of-function mutations in CARMA1 
(also known as CARD11) were found to result in continuous NF-κB activation29. 
Furthermore, in 20% of ABC-DLBCL cases, somatic mutations in the CD79α/CD79β 
ITAM domains induced chronic active BCR signaling via inhibition of BCR endocytosis 
and prevention of binding of Lyn to CD79β4.
 In FL, constitutive BCR signaling induced by presence of (self-)antigens has 
been found in only 20-25% of the cases30,31, whereas the majority of FL cases (80%) 
bear somatic mutations in the IgM-BCR leading to increased incorporation of 
N-glycosylation sites32,33. If this occurs in the antigen-binding side of the BCR it may 
prevent binding of (self-)antigens, but in turn can be recognized and stimulated by 
lectin receptors on myeloid cells in the tumor microenvironment34,35. This results in 
re-organization of the BCR complex (including CD19) into signaling platforms and 
persistent antigen-independent signaling via Syk and BTK.
 Currently, different small molecule inhibitors targeting signaling proteins 
downstream of the BCR (Syk, Lyn, PI3K, BTK) are under investigation as novel therapy 
for B-NHL (reviewed in [26]). Still, increased understanding into the conformational 
changes in the BCR upon antigen binding may open new opportunities to directly 
target the BCR itself. This idea was originally explored in the 1980’s, in which 
treatment of lymphoma patients with anti-idiotype antibodies (targeting the 
variable region of the BCR) revealed promising clinical results36. However, this 
approach required generation of patient-specific idiotype-antibodies hampering 
clinical implementation. Recently, a new tool has been developed to screen and 
target tumor-specific idiotypes with small peptides linked to a pre-made IgG-Fc 
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protein, so-called anti-idiotype peptibodies37, which directly induce cell death via 
BCR signaling and ADCC. Furthermore, the anti-CD79β antibody-drug conjugate 
polatuzumab vedotin may be promising to treat B-NHL patients38, which is currently 
investigated in clinical trials (https://clinicaltrials.gov/). 
 Therapeutic strategies targeting the BCR co-receptor CD19 are encouraging 
for patients with relapsed/refractory B-NHL. CD19 chimeric-antigen receptors 
expressed by T cells (CD19-CAR T cells) consist of an extracellular domain specific 
for CD19 on B-NHL cells and intracellular domains to provide T cell stimulatory 
signals (e.g. CD3ζ and CD28). Adoptive transfer of CD19-CAR T cells has given 
complete responses in ~50-60% of B-NHL patients in phase I/II clinical trials39. 
Furthermore, blinatumomab, a CD19/CD3 bispecific T-cell engager (BiTE) generated 
from the antigen-binding regions of the single-chain antibodies of CD19 and CD3, 
is approved by the FDA for treatment of acute lymphoblastic leukemia (ALL) and 
clinical results are currently evaluated for treatment of other B-cell malignancies, 
including B-NHL40. Future research is required to determine the consequences of 
targeting the BCR complex in B-NHL patients, and in particular how this changes 
BCR conformation and downstream signaling.
Function and targeting of immune checkpoints PD-1/PD-L1 in 
B-NHL
Cancer immunotherapy has been chosen as the scientific breakthrough of 2013 
by Science journal41, due to promising results with immune checkpoint inhibitors. 
Immune checkpoints are proteins that regulate immune cell activation to maintain 
self-tolerance and prevent autoimmunity (reviewed in [42]). More specifically, these 
checkpoints play an important role in controlling T cell priming and activation. For 
example, PD-1 on T cells transfers an inhibitory signal when engaged by PD-L1 
expressed by tumor cells or activated T cells.
 Tumor cells may exploit these checkpoints to escape or suppress the immune 
system by (over-)expressing PD-L1. Currently, anti-PD-1 mAbs (pembrolizumab 
and nivolumab) and anti-PD-L1 mAbs (atezolizumab and durvalumab) demonstrate 
promising clinical results in the treatment of different solid tumors, including 
metastatic melanoma, urothelial carcinoma and advanced non-small cell lung 
carcinoma (reviewed in [43]). This treatment strategy has also gained more 
attention in the B-cell lymphoma field (Figure 1d) (reviewed in [42]), and nivolumab 
has recently been approved by the FDA for the treatment of relapsed/refractory 
Hodgkin lymphoma due to promising clinical results44.
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For DLBCL, promising clinical results have been obtained with the anti-PD-1 mAbs 
pidilizumab and nivolumab45,46, and both anti-PD-1 and anti-PD-L1 mAbs are currently 
tested in clinical trials (https://clinicaltrials.gov/). It has been shown that a subset of 
ABC-DLBCL tumors (11-31%) display high expression of PD-L1, in contrast to GCB-
DLBCL tumors that virtually lack expression of PD-L1. This high PD-L1 expression 
has been suggested to be involved in the poorer prognosis of ABC-DLBCL patients 
compared to patients with GCB-DLBCL47,48. Since PD-L1 expression is restricted to a 
minority of DLBCL patients, it is likely that only this group will benefit from immune 
checkpoint blockade48,49.
 Although PD-L1 is rarely expressed in FL cells42,47, FL patients may still benefit from 
immune checkpoint blockade, since inhibition of PD-1-expressing tumor-infiltrating 
T cells by PD-L1-expressing non-tumor cells in the tumor microenvironment can be 
reversed50. This has been supported by clinical studies demonstrating good responses 
in FL patients treated with anti-PD-1 mAbs (nivolumab and pidilizumab)46,51. Trials 
with pembrolizumab in FL patients are currently ongoing (https://clinicaltrials.gov/). 
Several studies have reported that BL cells do not express PD-L147,49, and PD-1/PD-L1 
checkpoint inhibitors have therefore not yet been studied in BL. Still, the promising 
results of immune checkpoint inhibition in FL, which rarely expresses PD-L1, may 
be translated to BL. Taken together, targeting the immune checkpoint membrane 
proteins PD-1/PD-L1 seems a promising novel treatment option for a selected group 
of ABC-DLBCL and FL patients. However, it is still debated whether expression 
of PD-1/PD-L1 is of prognostic value for immune checkpoint inhibition therapy in 
B-NHL52,53.
CD37 rediscovered as B-cell membrane target in the 
treatment of B-NHL
Tetraspanin CD37 recently regained attention as promising membrane target for 
mature B-cell malignancies (Box 2). CD37 expression is restricted to the immune 
system with highest abundance on mature B cells, and is absent in earlier stages of 
B-cell development and decreased on plasma cells54,55. This pattern is also reflected 
in different B-cell lymphomas: CD37 is mostly expressed on B-cell malignancies 
derived from mature B cells (although ~50% of DLBCL patients lack CD3756,57, 
discussed below), but not in acute lymphoblastic lymphoma and multiple myeloma58. 
Comparable to CD20, this distinct expression pattern makes CD37 an interesting 
target in GC-derived B-cell lymphomas. Already in 1989, the first CD37-targeting 
antibody (labeled with the radioactive isotope iodine 131) was tested in 10 refractory 
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NHL patients with promising clinical results59. However, as anti-CD20 treatment 
(rituximab) was introduced at the same time, anti-CD37 therapy was forgotten for 
almost two decades, until the development of a novel CD37-targeting mAb-derived 
polypeptide re-established the interest in this target60. 
 Nowadays several different antibody-based CD37-targeting approaches are under 
investigation in phase I and II trials for chronic lymphocytic leukemia (CLL) and 
refractory or relapsed NHL patients (reviewed in [61] and see https://clinicaltrials.
gov/) (Figure 1e). Otlertuzumab (TRU-016), a humanized, antibody-derived CD37-
targeting peptide, is closest to general clinical application in B-cell malignancies. In a 
randomized phase II study, relapsed CLL patients treated with the chemotherapeutic 
bendamustine plus otlertuzumab showed increased progression free survival 
compared to patients treated with bendamustine alone62.
 The anti-tumor mechanisms by which anti-CD37 agents act include ADCC, 
CDC and direct apoptosis signaling60,63,64. Additionally, CD37-antibody complexes 
Box 2. Tetraspanins in cancer development 
Tetraspanins are a family of four-transmembrane proteins involved in plasma membrane 
organization79,82. The mammalian tetraspanin superfamily consists of 33 members, 
which are expressed on almost all cells and tissues83. Tetraspanins consist of four 
transmembrane domains, a short extracellular loop (EC1), a large extracellular loop (EC2) 
containing a conserved CCG region, a small intracellular loop and two short intracellular 
tails [ref. [84] and S. van Deventer et al. Biochem Soc Trans, in press]. Despite its similar 
structure, CD20 cannot be classified as a genuine tetraspanin protein, since it lacks the 
conserved CCG region in the large extracellular loop85. The EC2 and transmembrane 
domains are involved in the formation of tetraspanin-enriched microdomains (TEMs) 
by lateral associations with interaction partners, including other tetraspanins and 
integrins78–80. Their short intracellular tails can interact with cytosolic signaling molecules 
(e.g. PKC, Pi4K, Rac) [ ref. 63,79 and S. van Deventer et al. Biochem Soc Trans, in press]. 
Through their multiple interaction partners, tetraspanins are involved in different 
cellular processes including survival, proliferation, adhesion and migration78. Recently, 
several studies have shown that tetraspanins contribute to cancer development and 
metastasis, and tetraspanin expression has been associated with patient outcome56,86. 
Therefore, tetraspanins are interesting targets for cancer therapy, and different 
(pre-) clinical studies using tetraspanin targeting strategies are currently ongoing 
(https://clinicaltrials.gov/)61,86.
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are known to be internalized, which has led to the generation of novel anti-CD37 
agents coupled to toxins (IMGN529, an anti-CD37 antibody conjugated to an anti-
microtubule agent)64 and radioactive labels (177Lu-tetulomab)65. Both agents showed 
promising results in NHL xenograft mouse models64,65. Moreover, 177Lu-tetulomab 
was internalized with higher efficiency than 177Lu-rituximab complexes in vitro65, and 
IMGN529 showed increased activity compared to rituximab or CVP chemotherapy 
in a FL-derived xenograft mouse model64. A phase I clinical trial completed in July 
2016 studied IMGN529 in relapsed/refractory NHL and CLL patients (NCT01534715), 
and several phase I/II clinical studies to test 177Lu-tetulomab (Betalutin) are currently 
including NHL patients (https://clinicaltrials.gov/).
 Furthermore, new insights into the function of CD37 have prompted the interest 
in combination strategies. CD37 is important for the survival of IgG1-secreting 
plasma cells through the membrane organization of α4β1 integrins, and subsequent 
activation of the AKT signaling pathway66. The intracellular tails of CD37 can be 
tyrosine phosphorylated, leading to the initiation of apoptotic signaling via the 
N-terminal immunoreceptor tyrosine-based inhibition motif (ITIM)-like domain, 
and opposite survival signaling via its C-terminal ITAM domain63. Both pathways 
are induced by the CD37-targeting mAb-derived polypeptide SMIP-016, which was 
the basis for development of TRU-016. Although signaling to apoptosis is the most 
prominent, the efficiency of CD37 targeting could be improved using combination 
therapy with pro-survival PI3K inhibitors63.
 Importantly, recent studies revealed that ~50% of DLBCL tumors are negative for 
CD37 expression, and its loss is a potential risk factor for R-CHOP resistance and 
poor survival rates independent of the International Prognostic Index (IPI)56,57. The 
underlying mechanism involves enhanced activation of the IL-6 signaling pathway 
in CD37-negative lymphomas56. IL-6 is known to be involved in the development 
of many cancers, including hematological malignancies, and several IL-6 targeting 
strategies have been developed (reviewed in [67-68]). Based on these studies, 
inhibition of IL-6 signaling (using mAb anti-IL-6 siltuximab or anti-IL-6R tocilizumab) 
may represent a potential new treatment strategy for patients with CD37-negative 
DLBCL (Figure 1e).
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Dynamic protein interactions shape the organization of the 
B-cell membrane
Proteins in the plasma membrane are not randomly distributed, but instead they 
are localized to specific microdomains (Box 1). One of the first models of membrane 
protein organization on the B-cell membrane was published two decades ago69. 
Using flow cytometry energy transfer (FCET) experiments, it was shown that CD20 
interacts with tetraspanins CD53, CD81, CD82 on a lymphoma B-cell line. In addition, 
confocal microscopy70 and co-immunoprecipitation experiments71 revealed that 
CD20 also clusters with the BCR in specialized microdomains, indicating that they 
are localized in lipid rafts or tetraspanin microdomains (Box 1). The BCR dissociates 
from CD20 to distinct lipid rafts upon stimulation, and is subsequently internalized70. 
A direct interaction between CD20 and the BCR was recently confirmed using 
proximity-ligation assay23. It was shown that CD20 (similar to CD19) interacts with 
different BCR classes (IgD/IgM) on resting and antigen-activated human B cells, 
demonstrating redistribution of CD20 upon BCR stimulation. 
 CD20 has been shown to interact with several tetraspanins (CD53, CD81, CD82)69, 
although CD37 was not studied. Recently, we discovered that both protein and 
mRNA expression of CD20 and CD37 on lymphoma B cells are correlated57. Although 
this is in line with the inferior outcome of CD37-negative DLBCL patients upon 
R-CHOP therapy, the prognostic significance of CD37 seems independent of CD20 
mRNA levels57. Further research is necessary to verify a possible direct interaction 
and co-expression patterns of CD37 and CD20 in B-NHL cases.
 These studies indicate that the organization of the B-cell membrane is shaped 
by dynamic protein-protein interactions that are subject to change upon B-cell 
activation. This protein organization is not only important for B-cell function but 
also for the efficacy of membrane-targeted therapies, as illustrated by clustering 
of CD20 upon rituximab binding18. Likewise, CD37-targeting using SMIP-016 
resulted in translocation into microdomains which was required for efficient tumor 
cell apoptosis63. On lymphoma B cells, changes in membrane protein expression 
(e.g. absence of CD37) or protein clustering (e.g. conformational changes of the 
BCR upon binding of self-antigens), will change the protein organization and 
interactions at the plasma membrane. Based on these studies we propose that the 
changed cell surface protein landscape of lymphoma B cells has consequences for 
the efficacy and application of membrane-targeted therapies (Figure 2). Moreover, 
targeted therapies may alter dynamic protein-protein interactions affecting plasma 
membrane organization and downstream signaling.
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^ Figure 2. Plasma membrane organization of lymphoma B cells determines the efficacy 
of membrane-targeted therapies. The cell membrane (light area) is highly organized into 
specialized microdomains (dark area) that are formed by dynamic homotypic (e.g. CD20-CD20) 
and heterotypic (e.g. CD19-CD81) protein-protein interactions. Upon ligand-receptor binding 
(e.g. IL-6 to IL-6R), induction of a conformational change can lead to rearrangement of protein-
protein interactions and reorganization of the membrane landscape. Lymphoma B cells have a 
disrupted membrane protein organization, e.g. due to constant activation of the BCR by (self-)
antigens, overexpression of PD-L1, or loss of tetraspanin CD37. In addition, BCR activation 
results in CD20 dissociation and redistribution, and anti-CD20 targeted therapy using rituximab 
induces CD20 clustering. These data support a model in which the microdomain organization of 
lymphoma cells determines the efficacy of membrane-targeted therapies, which has important 
implications for treatment application and clinical outcome.
Figure 2
CD20 BCR with
CD79α/β
PD-L1 tetraspanin IL-6RCD19
reported interaction unidentified interaction
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Concluding remarks 
Many patients with B-NHL still face treatment failure or relapse upon standard 
therapy emphasizing the urgent need for new treatment options. The plasma 
membrane is the most easily accessible part of the tumor cell, and exposes a variety 
of different proteins which may serve as treatment target. Here, we discussed the 
widely studied target CD20, and three alternative membrane targets (BCR, PD-L1 
and CD37) that are currently under investigation in clinical trials to treat B-NHL. 
Furthermore, patients with CD37-negative lymphoma B cells have a dismal prognosis 
and may benefit from anti-IL-6(R)-targeted therapy.
 Membrane proteins interact with each other and thereby facilitate various cell 
biological processes, including initiation of downstream signaling. B-cell activation 
will affect these protein interactions through induction of new interactions, 
more clustering, or alternatively by preventing specific interactions. Evidence is 
accumulating that lymphoma B cells contain aberrant cell surface protein expression 
and organization which has important consequences for both application and 
outcome of membrane-targeted therapy for B-NHL patients. 
 We are only at the beginning of understanding membrane organization of normal 
and malignant B cells and further research is required to address the outstanding 
questions in this new and exciting field (see Outstanding Questions). In particular, 
recent advances in super-resolution microscopy enables imaging the membrane 
composition of lymphoma cells at the nanoscale level72. Taking into account 
that lymphomas are heterogeneous tumors2, targeting membrane proteins as 
monotherapy will probably not be sufficient for complete tumor eradication. Thus, 
the use of combination therapies, like immuno-chemotherapy and the additional 
use of small molecule inhibitors, will be important in the future treatment of B-cell 
non-Hodgkin lymphoma.
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Outstanding questions
• What is the effect of membrane-targeted therapies on the plasma membrane 
organization of lymphoma cells? How does this alter signal transduction pathways 
and lymphoma cell death, and what is the effect on clinical outcome? 
• Is it possible to modify plasma membrane organization by targeting the tetraspanin 
web, and thereby induce downstream signaling that drives lymphoma cell eradication?
• What is the effect of BCR-targeted therapies on the conformational state of the BCR, 
and on the BCR complex formation with partner proteins, including CD19, CD20 and 
CD81?
• What is the predictive value of PD-L1 expression upon treatment with immune 
checkpoint inhibitors as measured by clinical relevant outcome parameters, such as 
overall survival and progression free survival?
• Will Burkitt lymphoma patients benefit from immune checkpoint inhibitors 
considering lack of PD-L1 on the lymphoma cells? PD-L1-based therapy may target 
immune cells in the tumor microenvironment, and thereby eliminate the tumor-
induced immune suppression.
• 50% of patients with DLBCL have lost CD37 expression on the tumor cells. Is CD37-
deficiency also apparent in other B-cell malignancies (e.g. FL, BL, CLL) and of 
prognostic value? This may have implications for inclusion criteria, stratification and 
outcome of clinical trials studying CD37-targeted therapies. 
• Is targeting of IL-6, IL-6R or downstream signaling proteins (JAK, STAT3) effective 
in patients with CD37-negative DLBCL that show increased activation of the IL-6 
pathway?
• Which (membrane-targeting) combination therapies would be most effective to treat 
B-cell lymphoma?
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Glossary
• Antibody-dependent cell-mediated cytotoxicity: Induction of cell death via 
binding of an antibody to its cell surface target. The Fc tail of the antibody 
engages Fc receptor-expressing immune cells, like NK cells and macrophages, 
that will kill the antibody-bound target (i.e. tumor) cell.
• Burkitt lymphoma: An aggressive type of B cell non-Hodgkin lymphoma 
characterized by deregulation of the MYC proto-oncogene. 
• CHOP: Abbreviation for Cyclophosphamide – Doxorubicin 
(Hydroxydaunorubicin) – Vincristine (Oncovin) – Prednisone. A chemotherapy 
cocktail mostly used to treat B-cell non-Hodgkin lymphoma patients. Often 
used in combination with anti-CD20 mAb rituximab (R-CHOP).
• Class switch recombination: The process in which the isotype or class of 
immunoglobulin produced by the B cell is switched; e.g. from IgM to IgG. This 
occurs via genomic changes in the constant region of the immunoglobulin 
heavy chain.
• Complement-dependent cytotoxicity: Induction of cell death via activation 
of the complement system (C1q binding to the antibody), which will lyse the 
target (i.e. tumor) cell membrane.
• CVP: Abbreviation for Cyclophosphamide – Vincristine – Prednisone. A 
chemotherapy cocktail used to treat follicular lymphoma patients. 
• Diffuse large B cell lymphoma: The most common and most aggressive type 
of B-cell non-Hodgkin lymphoma, accounting for approximately one third of 
all non-Hodgkin lymphoma cases. 
• Follicular lymphoma: The second most common B-cell non-Hodgkin 
lymphoma. Follicular lymphoma is an indolent cancer, but can transform into 
the more aggressive DLBCL. 
• Germinal center: area in the B-cell follicles of secondary lymphoid tissues 
where B-cell proliferation, class switch recombination, somatic hypermutation 
and selection take place. 
• Somatic hypermutation: The process in which the immunoglobulin-
encoded DNA of mature B cells is subjected to the introduction of random 
point mutations. These modifications occur in the variable region of the 
immunoglobulin gene resulting in affinity maturation (increased affinity BCR).
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Essential for activation of humoral and cellular immune responses is the 
communication between different immune cells. This can be mediated by transfer 
of extracellular signals (e.g. cytokines) or through direct cell-cell interactions 
facilitated by membrane microdomains, like tetraspanin-enriched microdomains. 
Unraveling the protein composition of those membrane microdomains will aid in 
understanding immune cell function. Membrane microdomains are also seen as an 
interesting target for treatment of infectious diseases and cancer, since the plasma 
membrane is the most-easy accessible part of the cell. In B-cell lymphoma, targeting 
the membrane protein CD20 using rituximab is a widely-used therapeutic approach, 
but patients still face disease relapse. More insight into the membrane organization 
on lymphoma B cells is necessary to improve current or develop novel treatment 
strategies. 
 In my research, I discovered that 50% of diffuse large B-cell lymphomas (DLBCL) 
lack tetraspanin CD37 which is correlated with hyperactivation of the IL-6 signaling 
pathway and clinical outcome. Furthermore, I found that normal expression levels of 
CD37 in the human immune system were highest on dendritic cells (DCs) and B cells 
circulating in blood, and on follicle B cells in secondary lymphoid organs (spleen, 
appendix). I also unraveled that CD37 drives CLEC-2 recruitment in response to its 
ligand podoplanin on the plasma membrane of DCs, and inhibits CLEC-2 signaling 
in immune cells. The results described in this thesis emphasize the important role 
of plasma membrane organization in controlling immune cell function and cancer 
development.
Tetraspanin CD37 in the immune system
In total 33 different tetraspanins are known to be expressed in mammalian cells, of 
which 20 are estimated to be expressed on immune cells1,2. Most tetraspanins are 
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broadly expressed, but tetraspanins CD37 and CD53 have an immune cell-restricted 
expression profile. On B cells, tetraspanins are important for humoral immunity as 
they regulate antibody responses upon infection or immunization. Mice lacking 
tetraspanin CD37 (Cd37-/-) are protected from fungal infections by higher production 
of IgA and lower IgG1 levels in contrast to wild-type (WT) mice who mainly produce 
IgG13. Mice lacking tetraspanin CD81 (Cd81-/-) also demonstrated impaired IgG1 
responses upon immunization compared to WT mice4,5. Furthermore, Cd81-/- mice 
showed decreased expression of the CD81 co-receptor CD19 in contrast to WT mice5. 
CD19 and CD81 both belong to the B-cell receptor (BCR) complex that is necessary 
for efficient B-cell activation upon antigen engagement6, indicating that aberrant 
BCR complex formation in Cd81-/- B cells underlies the impaired humoral immune 
response. In line with this, a patient having a splice site mutation in the CD81 
gene completely lacked membrane expression of both CD81 and CD19, resulting 
in defective B-cell antibody responses and decreased number of memory B cells7. 
Recently, it was shown that this CD81 mutant was expressed intracellularly, which 
impaired its function as trafficking partner of CD198. For tetraspanin CD53, our group 
found that it facilitates BCR downstream signaling through a direct interaction with 
protein kinase C type β (PKCβ) at the plasma membrane [Zuidscherwoude and 
Dunlock et al, Science Signaling, in press]. Murine primary B cells and a human B-cell 
line lacking CD53 showed impaired translocation of PKCβ to the plasma membrane 
leading to decreased phosphorylation of PKCβ substrates that regulate B-cell 
survival via NFκB activation. Moreover, lack of CD53 expression on neutrophils was 
found in a family suffering from recurrent infections, but the exact cause for loss of 
CD53 remains unknown9. The pathogenic effects caused by aberrant expression of 
CD53 and CD81 illustrate the importance of tetraspanins on human immune cells.
To identify aberrant tetraspanin expression patterns and their role in immune-
related diseases it is important to know their normal expression pattern on immune 
cells. So far, the normal expression pattern of tetraspanins CD37 and CD53 in the 
human immune system has not been studied extensively. In Chapter 2, I investigated 
their expression and localization in human primary (bone marrow) and secondary 
(spleen, appendix) lymphoid organs, and on immune cells circulating in blood. Flow 
cytometry experiments revealed that both CD37 and CD53 were highly expressed 
on circulating B cells and DCs. CD53 was also highly expressed on monocytes, NK 
cells and T cells, whereas CD37 expression was low on these cells. Lymphoid organs 
were analyzed for expression of CD37 and CD53 using a novel immunohistochemical 
technique that makes use of multispectral imaging. This proved to be a very 
powerful technique to investigate protein expression by means of expression levels 
on specific cell types in relation to tissue localization, and may thus contribute to 
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better understanding tetraspanin function on immune cells located in different 
areas within lymphoid tissues. Within secondary lymphoid organs, the B-cell follicles 
comprise a large population of mature B cells undergoing the germinal center (GC) 
reaction. In the areas surrounding these B-cell follicles, the so-called red pulp, more 
immature B cells and antibody-producing plasma cells are found, next to other 
immune and stromal cells. My results showed that B cells in splenic B-cell follicles 
expressed higher CD37 levels than B cells in the surrounding red pulp, and a similar 
expression pattern was seen in the appendix. In bone marrow, I found that 80% 
of all cells expressed high levels of CD37. My data are in line with a previous flow 
cytometry-based study showing that CD37 is expressed at low levels on pre-B cells in 
the bone marrow and on plasma cells, in contrast to high levels of CD37 found on B 
cells within blood and lymph nodes10. 
 My multispectral imaging data provides a basis for investigating normal 
expression levels and tissue distribution of other tetraspanin proteins in the 
immune system. This can be extended by the use of subset-specific immune cell 
markers (e.g. immature B cells, follicular B cells, plasma B cells) which will facilitate 
characterization of tetraspanin expression levels on these immune cell subsets 
within lymphoid tissues in relation to tetraspanin function. Moreover, when normal 
tetraspanin expression patterns are known, multispectral imaging can be used next 
to flow cytometry studies to detect aberrant tetraspanin expression on specific 
immune cells in different tissue regions.
 
CD37 inhibits cytokine production
The cellular immune response is triggered by antigen-presenting cells (APCs), 
including B cells, macrophages and DCs upon recognition of a foreign antigen. APCs 
recognize pathogens via pattern-recognition receptors (PRRs), such as C-type lectin 
receptors (CLRs). In response, APCs will be activated and start to secrete cytokines 
to attract other immune cells, including T cells. One subfamily of CLRs are the hemi-
Immunoreceptor Tyrosine-based Activation Motif (hemITAM) CLRs that have only 
a single tyrosine phosphorylation motif (YXXL) in their intracellular tail. HemITAM 
CLRs, like Dectin-1 and CLEC-2, need to dimerize in order to initiate downstream 
signaling via spleen tyrosine kinase (Syk), which needs to bind two phosphorylation 
motifs to be activated. Dectin-1 is expressed by macrophages and DCs, and 
recognizes β-glucans in the cell wall of fungi. Tetraspanins CD6311 and CD3712 have 
been reported to directly interact with Dectin-1. Furthermore, CD37 controls 
Dectin-1 membrane expression by stabilizing it in the plasma membrane and inhibits 
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Dectin-1-dependent cytokine production upon β-glucan stimulation12. In Chapter 
3, I extended the role of CD37 in controlling hemITAM CLRs by demonstrating that 
CD37 also directly interacts with CLEC-2 and that CD37 regulates CLEC-2 membrane 
expression in APCs. Furthermore, CD37 inhibits interleukin-6 (IL-6) production 
upon stimulation with the CLEC-2-binding snake venom toxin rhodocytin. This is in 
line with a previous study reporting that GCs of Cd37-/- mice expressed increased 
IL-6 levels after immunization3. This resulted in increased IgA production which 
protected Cd37-/- mice from C. albicans infection. The increased IL-6 production was 
an effect of Dectin-1 stimulation upon infection, since blocking of Dectin-1 inhibited 
IL-6 production by WT and Cd37-/- splenocytes from C. albicans infected mice. 
Furthermore, in vitro restimulation of splenocytes from immunized mice revealed 
that Cd37-/- cells increased their T helper cell (i.e. Th1 and Th17) responses via 
upregulation of interferon-γ (IFN-γ) and IL-17, respectively. In another study, CD37 
was shown to regulate both IL-2 and IL-4 production in activated and proliferating T 
cells, but IFN-γ levels were not affected13. In line with my work, these studies indicate 
that CD37 is important for controlling cytokine responses by different immune cell 
subsets and we slowly get a grasp on the underlying mechanism.
 Cytokine production upon Dectin-1 and CLEC-2 stimulation is dependent on 
signaling downstream of Syk. Since CD37 has an inhibitory role in controlling cytokine 
production, it would be interesting to study cytokine inhibitory signaling routes. A 
negative regulator of Syk is SH2 domain-containing protein tyrosine phosphatase 
1 (SHP-1), which causes Syk dephosphorylation14,15. In leukemic B cells, CD37 has 
been reported to interact with SHP-1 via its N-terminal ITIM-like domain thereby 
regulating cell survival pathways16, but the involvement of this interaction in cytokine 
responses has not been addressed. The major protein family that inhibits cytokine 
signaling by immune cells is the family of suppressor of cytokine signaling (SOCS) 
proteins, which are intracellular proteins that regulate immune responses17. SOCS3 
is known to inhibit IL-6 signaling by binding to the IL-6 receptor (IL-6R) complex 
preventing activation of downstream signaling proteins JAK and STAT318. In Chapter 
4, I found that SOCS3 directly interacts with CD37 and co-localizes at the plasma 
membrane of IL-6-stimulated lymphoma B cells. In mice lacking CD37, SOCS3 could 
not inhibit IL-6 signaling resulting in increased lymphoma B-cell survival. In T cells, 
SOCS1 is reported to be involved in Th1 and Th2 differentiation19. It was shown that 
high IL-4 production by Th2 cells activates SOCS1 which inhibits IFN-γ signaling by 
Th1 cells, and vice versa. Investigating whether CD37 and other tetraspanins directly 
interact with cytokine inhibitory proteins (SHP-1, SOCS proteins) in other immune 
cells, and the intracellular tetraspanin domains involved herein will further increase 
our understanding of tetraspanins in inhibiting cytokine production. My data and 
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these other studies indicate that cytokine production is tightly regulated by the 
interaction between tetraspanins and intracellular signaling proteins.
CD37 is important for myeloid cell migration
Essential for DC migration through the lymphatic system is the interaction between 
CLEC-2 on DCs and podoplanin (PDPN) expressed on lymph node stromal cells 
(LNSCs), like lymphatic endothelial cells (LECs) and fibroblastic reticular cells 
(FRCs)20. Furthermore, this interaction drives elongation of FRCs allowing lymph 
node expansion21,22. Upon activation, CLEC-2 molecules are reorganized into larger 
clusters20,23, but the underlying molecular mechanism has not been elucidated. Since 
Cd37-/- DCs are impaired in adhesion and migration24, we hypothesized that CD37 
controls CLEC-2 membrane organization on DCs. In Chapter 3, I showed that CD37 
was important for local engagement of CLEC-2 on PDPN spots. Furthermore, Cd37-
/- DCs are impaired in making actin protrusions in response to PDPN in a 3D collagen 
matrix, in a similar manner as DCs completely lacking CLEC-2. As described above 
we found a direct molecular interaction between CD37 and CLEC-2, which provides 
further evidence for the model that CD37 directly controls CLEC-2 organization on 
the plasma membrane of DCs upon PDPN binding (Chapter 3). 
 PDPN stimulation of CLEC-2 is reported to change the activity of Rho GTPases20 
including downregulation of RhoA which leads to decreased actomyosin contractility, 
and upregulation of Rac1 which results in activation of actin polymerization and cell 
movement. Interestingly, Cd37-/- DCs stimulated with a small GTPase activating 
toxin were shown to have decreased Rac1 activity and increased activity of Cdc42, 
another Rho GTPase25. Furthermore, CD37 is shown to be important for neutrophil 
transmigration by promoting adhesion to endothelium via integrin β2, which results 
in actin polymerization and cell spreading via downregulation of Rac126. However, 
no co-clustering or direct interaction between CD37 and β2 integrins was found, 
suggesting that CD37 controls the molecular link between β2 integrins and the 
actin cytoskeleton through Rho GTPases. In line with this, other tetraspanins (i.e. 
CD927, CD8128, CD8225,29,30, CD15131,32) were shown to affect Rho GTPase activity and 
cytoskeletal rearrangements, although no direct interactions between tetraspanins 
and Rho GTPases were reported in these studies. Only recently it was shown using co-
immunoprecipitation (co-IP) and “Förster Resonance Energy Transfer – Fluorescence 
Life-time Imaging Microscopy” (FRET-FLIM) experiments that tetraspanin CD81 
directly interacts with Rac1 via its C-terminal intracellular tail33. CD81 controls Rac1 
activity at the leading edge of migrating cells, and lack of CD81 expression results in 
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increased adhesion formation and decreased cell migration. Thus, tetraspanins are 
important for (immune) cell migration by controlling the activity of Rho GTPases. 
FRET-FLIM experiments were also used to investigate the specific translocation of 
PKCβ to CD53 at the plasma membrane upon B cell stimulation [Zuidscherwoude and 
Dunlock et al, Science Signaling, in press], thereby providing dynamic and localized 
information on protein interactions (within ~10nm distance) in living cells in contrast 
to co-IP experiments. Unraveling whether tetraspanins control the activity of Rho 
GTPases via a direct interaction using FRET-FLIM, or whether Rho GTPase activity 
is indirectly facilitated by tetraspanin-enriched microdomains will aid in further 
understanding the role of CD37 and other tetraspanins in controlling (immune) cell 
migration.
CD37 in B-cell lymphoma
Enhanced B-cell survival is a key feature of B-cell lymphoma. CD37 plays an 
important role in B-cell survival by modulating signaling via the AKT survival 
pathway16,34. In the 1980’s, CD37 was found to be highly expressed on malignant B 
cells35 and CD37-targeting was investigated as novel anti-lymphoma therapy36. As 
described in Chapter 6, the promising results of clinical trials with anti-CD20 therapy 
(rituximab) brought CD37 into oblivion as therapeutic target. B-cell lymphoma 
patients treated with immuno-chemotherapy (rituximab combined with different 
chemotherapeutics, abbreviated as R-CHOP) still face disease relapse, which 
is often caused by resistance for anti-CD20 therapy. Therefore, CD37-targeted 
therapies recently regained the interest of the scientific community and clinical 
trials in patients with leukemia and lymphoma are currently ongoing16,37,38. However, 
not all B-cell lymphoma patients will benefit from anti-CD37-targeted therapies, 
since I discovered that 50% of diffuse large B-cell lymphomas (DLBCL) lack CD37 
protein expression (Chapter 4). Patients suffering from CD37-negative DLBCL had 
significantly worse overall and progression-free survival compared to patients with 
CD37-positive DLBCL upon R-CHOP treatment. Furthermore, increased levels of 
components of the IL-6 signaling pathway (IL6 and AKT mRNA, and phosphorylated 
(P-)STAT3) were found in CD37-negative tumors of DLBCL patients. Strikingly, 
mice lacking both CD37 and IL-6 (Cd37-/-xIl6-/-) were fully protected against B cell 
lymphoma development (Chapter 4), indicating that IL-6 plays an important role in 
CD37-negative lymphoma B cell survival. As a direct consequence from my work I 
propose that CD37-negative DLBCL patients may benefit from anti-IL-6 or anti-IL-6 
receptor (IL-6R) therapies (Chapter 6). 
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 Therapeutic blocking of the IL-6R using monoclonal antibodies to prevent IL-6 
binding is already approved for rheumatoid arthritis and tested in clinical trials for 
hematological malignancies, including multiple myeloma and B-cell lymphoma39,40. 
Furthermore, the therapeutic potential of inhibiting IL-6 or its downstream signaling 
proteins (i.e. JAK and STAT3) is investigated in patients with hematological 
malignancies39,41. Therefore, it would be relevant to test the potential of anti-IL-6(R) 
therapy for patients with CD37-negative DLBCL. I propose that different anti-IL-6(R) 
therapies, preferably already used in the clinic, should first be tested for their anti-
tumor effect on DLBCL cell lines by means of inhibition of the IL-6 signaling pathway 
and cell survival in vitro. These experiments are relatively straight-forward, as CD37 
expression on those DLBCL cell lines is already known42, and we are currently 
characterizing them for expression of IL-6R and downstream signaling components. 
Next, the most promising anti-IL-6(R) therapies could be tested in vitro on fresh 
tumor material from DLBCL patients and in vivo in B-cell lymphoma bearing Cd37-/- 
mice.
 Apart from hyperactivation of the IL-6 signaling pathway, loss of CD37 may also 
be beneficial for the tumor in its response to R-CHOP therapy. In the DLBCL cohort 
studied in Chapter 4 all patients received R-CHOP therapy, but patients with CD37-
negative DLBCL showed decreased survival compared to patients with CD37-positive 
DLBCL. This was verified in a larger and independent cohort in collaboration with the 
group of Prof. Ken Young (MD Anderson Cancer Center, Houston, Texas, USA). These 
results confirmed our findings, and excitingly showed that CD37 is an independent 
prognostic factor for R-CHOP therapy outcome in DLBCL42. These studies suggested 
that patients with CD37-negative DLBCL did not sufficiently respond to the anti-
CD20 therapy rituximab and raised the question whether CD37 may modulate CD20 
expression and/or function. Therefore, I investigated membrane expression of CD37 
and CD20 in a range of DLBCL cell lines and found a significant correlation; DLBCL 
cell lines that lacked CD37 expression also did not express CD2042. DLBCL cell lines 
lacking both CD37 and CD20 expression did not show decreased viability in response 
to rituximab treatment in contrast to DLBCL cell lines positive for both CD37 and 
CD20. This was also reflected in the large DLBCL cohort studied by Prof. Ken Young; 
R-CHOP-treated DLBCL patients with high levels of CD20 mRNA showed better 
survival than patients with low levels of CD20 mRNA42. However, the prognostic 
effect of CD37 expression was shown to be independent of CD20 mRNA levels. 
Moreover, in a cohort of DLBCL patients only treated with chemotherapy (CHOP), 
patients with CD37-positive DLBCL still showed significantly better survival outcome 
than patients with CD37-negative DLBCL, although the survival rate was lower than 
in the R-CHOP treated cohort42. Altogether, these data and my results indicate that 
189
7
loss of CD37 is important for B-cell lymphoma progression in at least two ways: 1) 
continuous IL-6 signaling leading to lymphoma B-cell survival, and 2) impaired anti-
tumor response to the anti-CD20 therapy rituximab.
 There are two possible mechanisms underlying the impaired response to 
R-CHOP therapy of patients with CD37-negative DLBCL. First, CD37 might function 
as a trafficking partner for CD20 to the plasma membrane43, and therefore loss of 
CD37 may result in loss of CD20 membrane expression on lymphoma B cells as 
supported by our findings with DLBCL cell lines42. To verify this it would be relevant 
to investigate CD20 protein, rather than mRNA, expression in CD37-negative and 
CD37-positive DLBCLs using immunohistochemistry (tissue micro arrays (TMA)) and 
flow cytometry. Second, CD37 microdomains may facilitate CD20 clustering upon 
rituximab treatment. Rituximab induces clustering of CD20 upon binding which in 
turn activates lymphoma cell death processes44. CD20 clustering upon rituximab 
binding in absence or presence of CD37 can initially be studied on DLBCL cell lines 
using super-resolution microscopy, and later on fresh tumor material from DLBCL 
patients. However, both options are not mutually exclusive, since they both rely on 
a direct interaction between CD20 and CD37. CD20 is known to interact with several 
other tetraspanins (CD53, CD81 and CD82)45, although a direct interaction between 
CD37 and CD20 has so far not been reported. Accordingly, more studies are required 
to determine a direct interaction between CD37 and CD20, and to distinguish 
between the two possibilities explaining the decreased lymphoma cell death in 
R-CHOP-treated patients suffering from CD37-negative DLBCL.
 In Chapter 5, I investigated the underlying mechanism of CD37 protein loss in CD37-
negative DLBCLs. I found somatic mutations in two different patients with CD37-
negative DLBCL (out-of-15) using next-generation sequencing of the coding regions 
of CD37. One was a splice site mutation leading to a frame-shift and a premature 
stop codon, which resulted in a non-functional CD37 protein. The second mutation 
was a missense mutation leading to an amino acid change in exon 3. To investigate 
the functional consequences of this missense mutation, it was cloned into a GFP-
expression vector and the mutated protein was found to be impaired in glycosylation 
and membrane localization. Decreased glycosylation of CD37 may inhibit transport 
of CD37 protein to the plasma membrane as has been reported for other membrane 
proteins46. The finding of CD37 mutations in two patients with CD37-negative DLBCL 
does not explain CD37 protein loss in ~50% of DLBCLs (Chapter 4 and ref. 42). Other 
causes may include aberrations in the CD37 promoter region, including mutations 
affecting transcription factor binding or epigenetic regulation, or alterations in 
expression of microRNAs (miRNAs) affecting mRNA stability47–49. Further studies 
on a larger cohort of CD37-negative DLBCLs are necessary to unravel the molecular 
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cause of CD37 protein loss, and to get more insight in the timing of loss of CD37 
protein expression during B-cell lymphoma development.
Tetraspanin web on antigen-presenting cells versus 
lymphoma cells
 
The cell membrane is a highly-organized structure formed by specialized membrane 
microdomains, including tetraspanin-enriched microdomains (TEMs), that facilitate 
cell-cell interactions and signaling processes (Chapter 1). On immune cells, it is 
evident that these microdomains are important for initiation and activation of 
immune responses. Identifying the multiple different protein interactions in TEMs 
at the cell surface of APCs is essential to understand the molecular basis of immune 
cell function. In this thesis, I unraveled the role of CD37 on APCs by investigating 
DC migration and B-cell lymphoma development. I discovered two new interacting 
partners of CD37: CLEC-2 on DCs (Chapter 3) and SOCS3 on B cells (Chapter 4). 
Furthermore, I found that the α-chain of the IL-6R complex (IL-6Rα) co-localizes with 
CD37 on resting B cells (Chapter 4), but whether this is a direct or indirect interaction 
was not addressed. However, I observed that IL-6Rα or SOCS3 were not co-localizing 
with all CD37 domains at the plasma membrane using confocal microcopy, indicating 
that different CD37 microdomains may exist on a single B cell. To investigate this 
in more detail, super-resolution microscopy studies were performed by our group 
mapping tetraspanin microdomains in relation to each other and their interacting 
proteins50. These studies showed that microdomains of two different tetraspanins do 
not overlap in contrast to microdomains of a tetraspanin and its partner, like CD53 and 
MHC-II. Here, I propose a model for the tetraspanin web on APCs in which different 
microdomains of one tetraspanin species (e.g. CD37, CD53, CD81) are present on the 
plasma membrane in close proximity to their interacting partners (e.g. IL-6R, CLRs, 
MHC-II, integrins) (Figure 1A). This provides APCs with a high level of membrane 
organization that controls membrane protein function and downstream signaling.
 Evidence is accumulating that many different types of cancer cells show aberrant 
tetraspanin expression which can be either a tumor-promoting or tumor-suppressive 
factor51–54. For example, tetraspanin CD151 is upregulated on a diverse range of 
solid tumors (breast, pancreatic, colorectal and non-small-cell lung cancer) and this 
increases their metastatic potential. CD151 promotes tumor cell migration via direct 
interactions with integrins which results in transcription and activation of matrix 
metalloproteases degrading the extracellular matrix51,52. Similarly, Tspan8 promotes 
tumor metastasis via direct interaction with integrins, and furthermore induces 
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7^ Figure 1. Model illustrating the tetraspanin web on antigen-presenting cells versus 
lymphoma cells. (A) On antigen-presenting cells, the tetraspanin web consist of microdomains 
of different tetraspanin types (e.g. CD37, CD53, CD81) that do not overlap (circles). Domains 
of interacting proteins (e.g. IL-6R, MHC-II, integrins; grey) and tetraspanin microdomains do 
overlap, but not all microdomains of the same tetraspanin overlap with the same interacting 
protein. For simplicity only two types of tetraspanin domains (red and blue) and two types of 
interacting protein (grey squares and hexagons) are depicted. Tetraspanins dynamically interact 
with their membrane and intracellular partner proteins within one microdomain and as such 
control homeostatic cell signaling processes. (B) Lymphoma cells have a disturbed tetraspanin 
web (i.e. overexpression of tumor-promoting tetraspanins (e.g. CD151, Tspan8; red circles) and 
downregulation of tumor-suppressing tetraspanins (e.g. CD37, CD82). Loss of tumor-suppressing 
tetraspanins leads to impaired interaction with both membrane and intracellular partner proteins 
leading to increased cell survival signaling in lymphoma cells.
A. Antigen-presenting cell
Homeostatic
cell signaling
CELL SURVIVAL
SIGNALING
B. Lymphoma cell
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tumor angiogenesis51–53. Tetraspanin CD9 has been reported to have either a tumor-
promoting or tumor-suppressive function which is dependent on the interactions with 
its partner molecules on different cancer types. Tumor suppression is mediated by 
the interaction between CD9 and integrins resulting in increased tumor cell adhesion 
and decreased cell motility51,52,54. Similar to my findings with CD37 in lymphoma, low 
expression of CD9 was correlated with worse survival in DLBCL patients55. Another 
well-known metastasis-suppressing tetraspanin is CD82, of which expression is lost 
upon tumor progression and is protective against metastasis of solid tumors51–53. 
CD82 directly interacts with integrins and growth factor receptors and this whole 
complex is internalized upon stimulation resulting in impaired tumor cell motility. 
So far, the role of CD82 in hematological malignancies has not been explored. CD81 
is highly expressed in several non-Hodgkin B-cell lymphomas, but further studies are 
required to unravel its potential as prognostic factor56.
 These studies, together with my results showing loss of CD37 on ~50% of DLBCL 
tumors, indicate that lymphoma cells have a disturbed tetraspanin web. I propose 
that loss or increased expression of one specific tetraspanin (for example CD37) at 
the cell surface of lymphoma cells disrupts the tetraspanin web thereby affecting 
expression of other tetraspanins, their partner proteins, and cell survival signaling 
(Figure 1B). This novel concept will have important implications for understanding 
the biology of lymphoma cells, and for the application and development of 
membrane-targeted therapies for B-cell lymphoma.
In conclusion, I discovered new CD37 interacting partners (CLEC2, SOCS3), which 
gives more insight into the protein interactions within tetraspanin microdomains 
that are critical for immune cell migration and cytokine production. Moreover, 
I discovered that CD37 is lost on ~50% of DLBCLs resulting in decreased patient 
survival. Since CD37-negative tumors have constitutive activation of the IL-6 
signaling survival pathway, patients suffering from CD37-negative DLBCL may 
likely benefit from therapies targeting IL-6(R). This thesis emphasizes the important 
role of membrane organization in immune cell function and reveals novel clinical 
implications for B-cell lymphoma patients.
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Het immuunsysteem
Het immuunsysteem, ook wel afweersysteem genoemd, beschermt ons lichaam 
tegen ongewenste indringers, zoals bacteriën, virussen en schimmels (pathogenen). 
Daarnaast speelt het ook een belangrijke rol in het elimineren van kanker, de 
ziekte die ontstaat wanneer lichaamseigen cellen muteren en zo ongecontroleerd 
kunnen groeien. De immuunreactie bestaat uit twee fasen. In de eerste fase wordt 
het aangeboren (“innate”) immuunsysteem geactiveerd, wat een snelle, maar 
niet specifieke immuunreactie tegen de indringer geeft. In de tweede fase wordt 
het verworven (“adaptieve”) immuunsysteem geactiveerd, wat een langzamere, 
maar zeer specifieke reactie tegen het pathogeen oplevert. In het adaptieve 
immuunsysteem spelen dendritische cellen (DC) een sleutelrol. DCs kunnen 
pathogenen herkennen, kleine stukjes ervan opeten en deze zogenoemde antigenen 
vervolgens presenteren op hun celoppervlak. Immuuncellen met deze eigenschap 
worden antigeen-presenterende cellen genoemd. DCs verplaatsen zich naar de 
lymfeklier, waar ze het antigeen presenteren aan andere immuuncellen, zoals B en T 
cellen (Figuur 1). B en T cellen die het antigeen herkennen, vermenigvuldigen zich en 
kunnen het pathogeen zeer gericht en efficiënt elimineren. Ondertussen activeren 
ze ook andere immuuncellen door bijvoorbeeld het uitscheiden van activerende 
moleculen (cytokinen). Geactiveerde T cellen kunnen virus-geïnfecteerde cellen of 
kankercellen doden. Geactiveerde B cellen produceren antistoffen die pathogenen 
herkennen en ervoor zorgen dat ze opgegeten worden door “opruimcellen” 
(fagocyten).
 Tijdens de activatie van de immuunreactie is goede en efficiënte cel-cel 
communicatie van cruciaal belang. Het celoppervlak, of celmembraan, omsluit de 
cel en is op die manier het doorgeefluik voor signalen van binnen naar buiten de cel 
en vice versa. Dit gebeurt via tal van verschillende eiwitten die aanwezig zijn op de 
celmembraan. Om de signalering specifiek en efficiënt te laten verlopen, worden deze 
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eiwitten georganiseerd in groepjes. Dit is een dynamisch proces, waardoor eiwitten 
en daarbij horende signalen zich aan elke situatie kunnen aanpassen. Membraan-
organiserende eiwitten, zoals tetraspanins, binden specifieke eiwitten en zorgen 
voor groepering van eiwitten en de juiste plaatsing op het celmembraan (Figuur 1). 
In hoofdstuk 1 wordt het belang van de membraanorganisatie in de functie van 
antigeen-presenterende cellen bediscussieerd.
Tetraspanins
In mensen zijn 33 verschillende tetraspanins bekend, die in verschillende 
samenstellingen op elke cel in het lichaam voorkomen. Tetraspanins zitten met 4 
stukken verankerd in de celmembraan, aan de buitenkant van de cel hebben ze een 
kleine en een grote lus en aan de binnenkant twee kleine uiteinden. Met de grote 
lus aan de buitenkant binden ze andere eiwitten aan zich en vormen op die manier 
gespecialiseerde ‘eilandjes’, microdomeinen genoemd, op de celmembraan. Met 
^ Figuur 1. In het menselijk lichaam komen op verschillende plekken lymfeklieren voor, zoals 
bijvoorbeeld in de oksel (links). Door het opnemen van een pathogeen worden dendritische 
cellen (DC, groen) geactiveerd en migreren ze naar de lymfeklier (midden). Hier presenteren 
ze een stukje pathogeen (antigeen) aan B en T cellen (blauw, rechtsboven), die zich vervolgens 
vermenigvuldigen en de infectie te lijf gaan. Tijdens deze cel-cel communicatie is de organisatie 
van de celmembraan erg belangrijk. Membraan-organiserende eiwitten, zoals tetraspanins (eiwit 
uitgebeeld door de dunne zwarte lijn) binden andere eiwitten (grijs, bijvoorbeeld CLEC-2) aan 
zich en vormen zo tetraspanin microdomeinen (rechtsonder). Deze domeinen geven signalen 
van buiten naar binnen de cel door via het binden van activeringseiwitten in de cel (zwart, 
bijvoorbeeld SOCS3).
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de twee uiteinden aan de binnenkant, kunnen ze communicatie naar de binnenkant 
van de cel regelen (signaleringsprocessen) (Figuur 1). Op deze manier vormen 
tetraspanins een brug tussen buiten en binnen de cel en zijn ze belangrijk voor de 
communicatie van een cel met zijn omgeving.
 Tetraspanins CD37 en CD53 zijn de enige twee tetraspanins die alleen maar op 
immuuncellen voorkomen. Uit eerdere studies is bekend dat ze een belangrijke 
rol spelen in het immuunsysteem, maar het was niet precies bekend op welke 
immuuncellen en op welke plek in het lichaam ze voorkomen. In hoofdstuk 2 heb 
ik gevonden dat CD53 veel voorkomt op alle immuuncellen in het bloed, maar CD37 
met name op antigeen-presenterende cellen, zoals B cellen en DCs. Met een speciale 
microscopietechniek genaamd “multispectral imaging” heb ik dunne plakjes van 
verschillende weefsels gekleurd voor tetraspanin CD37 en CD53 en markers om B en T 
cellen te kunnen onderscheiden. Met deze techniek is het mogelijk om tegelijkertijd 
te kijken naar het celtype en de plaats in het weefsel waar CD37 en CD53 voorkomen. 
Dit is belangrijk om meer informatie te krijgen over de functie van CD37 en CD53 op 
verschillende plekken in het immuunsysteem. Ik heb onderzoek gedaan naar twee 
plekken in het lichaam waar veel immuuncellen aanwezig zijn: het beenmerg en de 
lymfeklieren. In het beenmerg, de plek waar nieuwe immuuncellen aangemaakt 
worden, kwam CD37 hoog tot expressie op 80% van de immuuncellen, terwijl 
CD53 met name gevonden werd op T cellen. In de lymfeklieren zijn er verschillende 
gebieden te onderscheiden: er zijn gebieden waar veel B cellen of veel T cellen 
zijn, en gebieden daarbuiten, waar je minder B en T cellen aantreft en meer andere 
immuuncellen, zoals DCs en fagocyten. CD53 kwam tot expressie in alle gebieden, 
maar het hoogste in gebieden met veel B cellen. CD37 kwam met name hoog tot 
expressie in B celgebieden, wat overeenkomt met onze bevindingen in bloed en 
eerdere studies. Onze studie laat zien dat twee verschillende tetraspanins een ander 
expressie patroon hebben in het immuunsysteem. Dit verschil in lokalisatie van deze 
twee tetraspanins suggereert dat ze ook een andere functie in het immuunsysteem 
hebben.
Tetraspanin CD37 in dendritische celmigratie naar de 
lymfeklier
Als DCs stukjes pathogeen hebben opgenomen, activeert dit hun verplaatsing 
(migratie) via de lymfevaten naar de lymfeklier om daar B en T cellen te activeren. 
Tijdens deze migratie beweegt de DC langs de wand van de lymfevaten door middel 
van een verbinding tussen twee eiwitten: CLEC-2 op de DC en podoplanin op de 
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wand van het lymfevat. Eerdere studies hebben aangetoond dat deze verbinding 
essentieel is voor DC migratie en dat er groepjes van CLEC-2 eiwitten worden 
gevormd op de celmembraan van de DCs die een verbinding hebben met podoplanin. 
Echter, het was niet bekend hoe groepering van CLEC-2 op de celmembraan van DCs 
gereguleerd wordt. Omdat DCs zonder CD37 (Cd37-/-) ook een verminderde migratie 
lieten zien in een eerdere studie, heb ik onderzocht of CD37 CLEC-2 kan binden en 
op die manier CLEC-2 groepering en DC migratie reguleert. In hoofdstuk 3 heb ik 
gevonden dat op DCs van Cd37-/- muizen minder CLEC-2 aanwezig is dan op cellen 
van normale (wild-type) muizen. In een modelsysteem van het lymfestelsel waar ik 
DCs en podoplanin in heb gedaan, heb ik gevonden dat de Cd37-/- DCs minder goed 
uitlopers konden maken, die nodig zijn om zichzelf voort te bewegen. Daarnaast 
bleek ook dat Cd37-/- DCs niet in staat waren om CLEC-2 eiwitten te verplaatsen in 
de celmembraan wanneer ze in contact kwamen met podoplanin. Uiteindelijk heb ik 
laten zien dat CD37 en CLEC-2 direct aan elkaar binden. Deze resultaten tonen aan 
dat CD37 belangrijk is voor de juiste plaatsing van CLEC-2 in het celmembraan en op 
die manier DC migratie reguleert. Door deze bevindingen begrijpen we beter hoe 
DCs zich verplaatsen naar de lymfeklier om daar andere immuuncellen te activeren 
om het pathogeen op te ruimen. 
Tetraspanin CD37 in lymfeklierkanker
B cellen in de lymfeklier worden door DCs en T cellen geactiveerd om antistoffen 
te maken. Om deze antistoffen specifiek gericht tegen het pathogeen te maken, 
wordt het DNA van de B cel wat codeert voor de antistoffen aangepast. Tijdens 
deze aanpassingen kunnen er fouten optreden, die we mutaties noemen. Als 
deze mutaties niet gerepareerd worden, gaan de gemuteerde B cellen extra hard 
en ongecontroleerd groeien, waardoor er lymfeklierkanker ontstaat. De meeste 
vormen van lymfeklierkanker worden behandeld met een combinatie van chemo- 
en immunotherapie, zoals beschreven in hoofdstuk 6. Deze immunotherapie 
(rituximab) bindt aan het eiwit CD20 dat zich op alle B cellen, inclusief de kanker 
B cellen, bevindt en veroorzaakt celdood. Wanneer de kanker toch doorgroeit, 
bijvoorbeeld omdat de kanker B cellen zijn veranderd (gemuteerd) om te ontsnappen 
aan de immunotherapie, is de lymfeklierkanker vaak resistent geworden voor 
rituximab. Om deze reden is er behoefte aan nieuwe immunotherapieën. CD37 
staat momenteel in de belangstelling om te gebruiken als target voor nieuwe 
immunotherapieën, omdat het net als CD20 hoog voorkomt op kanker B cellen.
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 Echter, niet alle lymfeklierkankerpatiënten zullen kunnen profiteren van deze 
nieuwe therapie gericht tegen CD37. Ik heb namelijk gevonden dat ongeveer de helft 
van de patiënten met een bepaald type lymfeklierkanker, genaamd diffuus grootcellig 
B cellymfoom, helemaal geen CD37 hebben op de kanker B cellen (hoofdstuk 4) 
(Figuur 2A). In dat geval zal deze nieuwe therapie de kanker B cellen niet kunnen 
herkennen en geen effect hebben. Deze CD37-negatieve kanker B cellen hebben 
daarnaast meer interleukine-6 (IL-6), een oplosbare ontstekingsfactor. Dit zorgt 
voor snellere vermenigvuldiging en verminderde celdood van de kanker B cellen. 
In gewone B cellen en in de CD37-positieve kanker B cellen bindt CD37 aan SOCS3, 
een eiwit dat de IL-6 activatie remt. Dit remmende mechanisme is dus afwezig in de 
CD37-negatieve kanker B cellen (Figuur 2B). Daarnaast bleek dat de patiënten met 
CD37-negatief diffuus grootcellig B cellymfoom verminderde overlevingskansen 
hadden wanneer ze de standaard chemo- en immunotherapie kregen in vergelijking 
met patiënten met CD37-positief diffuus grootcellig B cellymfoom. Op basis van mijn 
bevindingen, veronderstel ik dat patiënten met CD37-negatief diffuus grootcellig B 
cellymfoom gebaat zouden zijn bij een therapie die de verhoogde activatie van IL-6 
remt.
 In hoofdstuk 5 heb ik onderzocht hoe het komt dat de helft van de patiënten 
met diffuus grootcellig B cellymfoom geen CD37 tot expressie brengen op de kanker 
B cellen. We hebben het DNA dat codeert voor CD37 van 15 CD37-negatieve B 
cellymfoom patiënten nauwkeurig onderzocht en in twee van deze patiënten hebben 
we een mutatie in het DNA voor CD37 gevonden. Eén mutatie leidt tot een verkort 
en instabiel CD37 eiwit, waardoor het snel wordt afgebroken binnenin de cel en dus 
niet op de celmembraan terecht komt. De andere mutatie bleek ervoor te zorgen 
dat CD37 niet van binnenin de cel, waar het gemaakt wordt, naar de celmembraan 
getransporteerd kan worden. Deze twee verschillende mutaties kunnen echter niet 
volledig verklaren waarom CD37 afwezig is op de kanker B cellen van de helft van 
de patiënten met diffuus grootcellig B cellymfoom. Om antwoord te vinden op deze 
vraag zal meer onderzoek gedaan moeten worden, waarbij ook andere oorzaken 
dan DNA mutaties uitgezocht moeten worden.
Nieuwe visie op de membraanorganisatie van gezonde 
immuuncellen en kanker B cellen
In hoofdstuk 7 heb ik de resultaten, zoals beschreven in dit proefschrift, samengevat 
en bediscussieerd. In mijn onderzoek naar de rol van CD37 in dendritische celmigratie 
en B cellymfoom ontwikkeling heb ik twee nieuwe interactiepartners van CD37 
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^ Figuur 2. De rol van CD37 in lymfeklierkanker. A. Door het kleuren van dunne plakjes 
lymfeklierkanker weefsel hebben we aangetoond dat de helft van de patiënten met diffuus 
grootcellig B cellymfoom geen expressie van CD37 op de kanker B cellen heeft. Rood = CD37, 
blauw = kanker B cellen. B. Links: op gezonde B cellen is CD37 aanwezig op de celmembraan. 
Wanneer de B cel geactiveerd wordt door interleukine-6 (IL-6) zal binding van SOCS3 aan CD37 
ervoor zorgen dat de B cel niet teveel geactiveerd wordt. Hierdoor kan er een normale celactivatie 
plaatsvinden en zal de B cel productie van antistoffen starten waardoor de immuunreactie in gang 
wordt gezet. Rechts: in patiënten met CD37-negatief diffuus grootcellig B cellymfoom zijn er 
hoge hoeveelheden van IL-6 aanwezig. Omdat CD37 afwezig is op de kanker B cellen, kan SOCS3 
de IL-6 activatie niet remmen. Hierdoor is er verhoogde IL-6 productie en gaan de kanker B cellen 
zich vermenigvuldigen. Ook leidt de afwezigheid van CD37 tot een slechtere respons van de 
patiënt op de standaard chemo- en immunotherapie, wat de noodzaak voor nieuwe therapieën 
voor deze patiënten benadrukt.
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ontdekt: CLEC-2 op de celmembraan van dendritische cellen en SOCS3 binnenin B 
cellen. Deze bevindingen geven meer inzicht in de formatie, samenstelling en functie 
van CD37 microdomeinen op antigeen-presenterende immuuncellen. Op kanker 
B cellen bleek dat CD37 afwezig was in ongeveer de helft van de patiënten met 
diffuus grootcellig B cellymfoom. Dit is in lijn met eerdere studies die laten zien dat 
kankercellen een veranderde aanwezigheid van tetraspanins op hun celmembraan 
hebben. Dit heeft geleid tot een nieuw concept dat de veranderende aanwezigheid 
van één tetraspanin de organisatie van het celmembraan van kanker B cellen 
verstoort. Dit heeft een direct effect heeft op de expressie van andere tetraspanins, 
de samenstelling van gespecialiseerde tetraspanin-microdomeinen en leidt tot 
een veranderende of defecte celfunctie. Dit nieuwe concept is belangrijk voor het 
begrijpen van de ontwikkeling van lymfeklierkanker en voor het ontwikkelen van 
nieuwe immunotherapieën voor deze patiënten.
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